,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,179,1,1,,148014,31593,Inactive,,,,,NCI AIDS Antiviral Assay,Confirmatory,,
1,328,1,1,,148014,31593,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
2,1469,1,1,,29217996,31593,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
3,1471,2,1,,29217996,31593,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
4,1479,1,2,,29217996,31593,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
5,1490,2,1,,29217996,31593,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
6,1511,1,3,,56320744,31593,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
7,1554,1,1,,56320744,31593,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
8,1662,1,2,,56320744,31593,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
9,1663,1,2,,56320744,31593,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
10,1672,1,3,,56320744,31593,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
11,1688,1,1,,29217996,31593,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
12,1766,1,1,,29217996,31593,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
13,1766,1,1,,29217996,31593,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
14,1768,1,1,,29217996,31593,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
15,1768,1,1,,29217996,31593,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
16,1813,1,2,,56320744,31593,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
17,1814,1,2,,56320744,31593,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
18,1832,2,1,,56320744,31593,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
19,1850,2,1,,56320744,31593,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
20,1863,2,1,,56320744,31593,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
21,1875,2,1,,56320744,31593,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
22,1885,2,1,,56320744,31593,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
23,1899,1,3,,56320744,31593,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
24,1903,2,3,,56320744,31593,Inconclusive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
25,1906,1,3,,56320744,31593,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
26,1910,1,2,,56320744,31593,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
27,1947,1,2,,56320744,31593,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
28,1950,1,3,,56320744,31593,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
29,1962,1,2,,56320744,31593,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
30,1974,1,2,,56320744,31593,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
31,1979,1,1,,56320744,31593,Inactive,994798.0,,,,Fluorescence Cell-Based Primary HTS of C.albicans growth in the presence of Fluconazole and compound,Screening,,
32,1987,1,2,,56320744,31593,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
33,1996,2,2,,56323658,31593,Active,,,,,Aqueous Solubility from MLSMR Stock Solutions,Other,,
34,2016,1,3,,56320744,31593,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
35,2023,1,3,,56320744,31593,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
36,2025,1,3,,56320744,31593,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
37,2029,1,3,,56320744,31593,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
38,2052,2,1,,56320744,31593,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
39,2057,1,2,,56320744,31593,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
40,2066,1,4,,56320744,31593,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
41,2094,1,2,,56320744,31593,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
42,2094,1,2,,56320744,31593,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
43,2094,1,2,,56320744,31593,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
44,2097,1,2,,56320744,31593,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
45,2098,1,1,,56320744,31593,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
46,2099,1,1,,56320744,31593,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
47,2101,1,1,,56320744,31593,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
48,2129,1,2,,56320744,31593,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
49,2130,1,3,,56320744,31593,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
50,2156,2,2,,56320744,31593,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
51,2174,1,3,,56320744,31593,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
52,2177,1,3,,56320744,31593,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
53,2216,1,3,,56320744,31593,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
54,2221,1,2,,56320744,31593,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
55,2227,1,2,,56320744,31593,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
56,2234,1,2,,56320744,31593,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
57,2235,1,2,,56320744,31593,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
58,2237,1,2,,56320744,31593,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
59,2239,1,2,,56320744,31593,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
60,2247,1,2,,56320744,31593,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
61,2280,2,3,,56320744,31593,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
62,2300,1,3,,56320744,31593,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
63,2380,1,2,,56320744,31593,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
64,2391,1,1,,56320744,31593,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
65,2435,1,2,,56320744,31593,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
66,2445,1,2,,56320744,31593,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
67,2462,1,1,,56320744,31593,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
68,2462,1,1,,56320744,31593,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
69,2517,2,1,,56320744,31593,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
70,2520,1,4,,56320744,31593,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
71,2521,1,3,,56320744,31593,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
72,2524,1,2,,56320744,31593,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
73,2528,1,2,,29217996,31593,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
74,2540,1,2,,56320744,31593,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
75,2544,1,2,,56320744,31593,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
76,2546,1,1,,29217996,31593,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
77,2550,1,3,,56320744,31593,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
78,2551,1,1,,29217996,31593,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
79,2553,1,2,,56320744,31593,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
80,2557,1,3,,56320744,31593,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
81,2563,1,1,,56320744,31593,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
82,2599,1,2,,56320744,31593,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
83,2606,1,2,,56320744,31593,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
84,2629,1,1,,56320744,31593,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
85,2642,1,2,,56320744,31593,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
86,2648,1,2,,56320744,31593,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
87,2650,2,1,,56320744,31593,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
88,2661,1,1,,56320744,31593,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
89,2662,2,1,,29217996,31593,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
90,2676,1,2,,56320744,31593,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
91,2685,1,1,,56320744,31593,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
92,2690,1,2,,56320744,31593,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
93,2716,1,1,,56320744,31593,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
94,2717,1,2,,56320744,31593,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
95,2718,1,1,,56320744,31593,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
96,2751,2,2,,56320744,31593,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
97,2796,1,4,,56320744,31593,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
98,2797,1,2,,56320744,31593,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
99,2805,2,2,,56320744,31593,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
100,2806,2,2,,56320744,31593,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
101,2825,1,2,,56320744,31593,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
102,3334,8,1,,103178476,31593,Unspecified,,,50.0,ED50,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,Confirmatory,11206479.0,
103,3375,8,1,,103178476,31593,Unspecified,,,50.0,ED50,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,Confirmatory,11405646.0,
104,75731,6,4,,103178476,31593,Unspecified,,,50.0,IC50,In vitro inhibition of rabbit muscle GAPDH.,Confirmatory,11405646.0,
105,100286,5,2,,103178476,31593,Inconclusive,,,,,In vitro inhibitory affect against Leishmania donovani; No data,Other,10866368.0,
106,106020,6,2,,103178476,31593,Unspecified,,,50.0,CC50,In Vitro cytotoxicity on MRC-5 cells,Confirmatory,10893302.0,
107,106021,6,2,,103178476,31593,Unspecified,,,50.0,CC50,Tested for cytotoxicity towards human MRC-5 cells,Confirmatory,12443785.0,
108,155965,5,2,,103178476,31593,Inconclusive,,,,,Cytotoxicity against peritoneal macrophages of female CD1 mice culturing amastigote stages of Leishmania donovani; no data,Other,10866368.0,
109,155967,5,2,,103178476,31593,Inconclusive,,,,,Cytotoxicity against peritoneal macrophages of female CD1 mice culturing amastigote stages of Trypanosoma cruzi; no data,Other,10866368.0,
110,213632,8,1,,103178476,31593,Active,,,3.31,ED50,Evaluated in vitro for antitrypanosomal activity against Trypanosoma cruzi,Confirmatory,12443785.0,
111,213635,8,1,,103178476,31593,Active,,,0.5,ED50,Effective concentration required to inhibit the growth of mammalian stage of Trypanosoma cruzi grown in murine 3T3 fibroblasts,Confirmatory,11405646.0,
112,213636,8,1,,103178476,31593,Active,,,0.6,ED50,Effective dose required against Trypanosoma cruzi in bloodstream,Confirmatory,11206479.0,
113,213640,5,1,,103178476,31593,Unspecified,,,,,In vitro inhibitory affect against Trypanosoma cruzi; (32.7 mM Sb),Other,10866368.0,
114,213643,10,1,,103178476,31593,Unspecified,,,,ED50,The compound was evaluated for its inhibitory activity against Trypanosoma cruzi,Confirmatory,10866389.0,
115,213650,3,4,,103178476,31593,Unspecified,,,,,"Percent inhibition of growth against Trypanosoma cruzi epimastigotes, Y strain at concentration 4 ug/ml (13-17 uM)",Other,,
116,213664,6,3,,103178476,31593,Active,,,8.95,IC50,"In vitro antitrypanosomal activity against Trypanosoma cruzi epimastigote, CL strain",Confirmatory,,
117,213665,6,3,,103178476,31593,Active,,,8.97,IC50,"In vitro for antitrypanosomal activity against Trypanosoma cruzi epimastigote, SC-28 strain",Confirmatory,,
118,213666,6,3,,103178476,31593,Active,,,8.05,IC50,"In vitro for antitrypanosomal activity against Trypanosoma cruzi epimastigote, Ystrain",Confirmatory,,
119,213667,6,2,,103178476,31593,Active,,,2.58,IC50,In vitro growth inhibition of amastigotes of Trypanosoma cruzi,Confirmatory,15177472.0,
120,213669,6,2,,103178476,31593,Active,,,2.2,IC50,In vitro growth inhibition of epimastigotes of Trypanosoma cruzi,Confirmatory,15177472.0,
121,213672,6,2,,103178476,31593,Active,,,1.27,IC50,Inhibitory activity against Trypanosoma cruzi,Confirmatory,12781196.0,
122,213787,9,1,,103178476,31593,Unspecified,,,,IC50,Inhibitory concentration against Epimastigotes (Tulahuen strain) of Trypanosoma cruzi,Confirmatory,11591517.0,
123,214326,4,3,,103178476,31593,Active,,,3.13,IC50,In Vitro inhibition concentration against Trypomastigote form of Trypanosoma cruzi,Confirmatory,10893302.0,
124,214467,4,3,,103178476,31593,Active,,,0.0035,IC50,Compound was evaluated for anti-parasitic activity against Trypanosoma cruzi,Confirmatory,11300872.0,
125,214501,6,7,,103178476,31593,Inconclusive,136620.0,,,,The compound was evaluated for its in vitro inhibitory affect against trypanothione reductase; No data,Other,10866368.0,
126,214976,8,1,,103178476,31593,Active,,,7.1,ED50,In vitro Trypanosoma cruzi (TC),Confirmatory,11459645.0,
127,215337,5,2,,103178476,31593,Inconclusive,,,,,In vitro inhibitory affect against Trypanosoma brucei; No data,Other,10866368.0,
128,229349,4,3,,103178476,31593,Unspecified,,,,,Ratio of inhibitory concentration to that of reference drug was determined,Other,11591517.0,
129,247798,6,2,,103178476,31593,Active,,,0.8,IC50,Trypanocidal activity against amastigote forms of Y strain of Trypanosoma cruzi,Confirmatory,15603944.0,
130,249624,3,4,,103178476,31593,Unspecified,,,,,Percentage delyse against amastigote forms of Y strain of Trypanosoma cruzi at 2 uM,Other,15603944.0,
131,249625,3,4,,103178476,31593,Unspecified,,,,,Percentage delyse against amastigote forms of Y strain of Trypanosoma cruzi at 8 uM,Other,15603944.0,
132,249626,3,4,,103178476,31593,Unspecified,,,,,Percentage delyse against amastigote forms of Y strain of Trypanosoma cruzi at 32 uM,Other,15603944.0,
133,249627,3,4,,103178476,31593,Unspecified,,,,,Percentage delyse against amastigote forms of Y strain of Trypanosoma cruzi at 0.5 uM,Other,15603944.0,
134,251290,6,1,,103178476,31593,Unspecified,,,,,"In vivo activity at a dose of 45 mg/kg, p.o., for 5 doses in in rodent model with Trypanosoma brucei brucei STIB 795 strain, measured as survival days (control 13 days)",Other,16107157.0,
135,252103,3,5,,103178476,31593,Unspecified,,,,,"In vivo percent inhibition of compound at a dose of 45 mg/kg, p.o., for 5 doses in rodent model with Trypanosoma brucei brucei STIB 795 strain [ND = not determined]",Other,16107157.0,
136,253512,6,2,,103178476,31593,Unspecified,,,116.3,IC50,Inhibitory concentration against wild-type (427) Trypanosoma brucei,Confirmatory,16107157.0,
137,253513,6,2,,103178476,31593,Unspecified,,,114.2,IC50,Inhibitory concentration against wild-type (427) with NAC Trypanosoma brucei,Confirmatory,16107157.0,
138,263376,4,3,,103178476,31593,Inconclusive,,,,,Antitrypanosomal activity against Trypanosoma cruzi epimastigotes at 100 ug/ml,Other,16455249.0,
139,263377,4,3,,103178476,31593,Inconclusive,,,,,Antitrypanosomal activity against Trypanosoma cruzi epimastigotes at 10 ug/ml,Other,16455249.0,
140,263378,4,3,,103178476,31593,Inconclusive,,,,,Antitrypanosomal activity against Trypanosoma cruzi epimastigotes at 1 ug/ml,Other,16455249.0,
141,263379,4,4,,103178476,31593,Unspecified,,,,,Unspecific cytotoxicity against murine J774 macrophages at 100 ug/ml,Other,16455249.0,
142,263380,4,4,,103178476,31593,Unspecified,,,,,Unspecific cytotoxicity against murine J774 macrophages at 10 ug/ml,Other,16455249.0,
143,263381,4,4,,103178476,31593,Unspecified,,,,,Unspecific cytotoxicity against murine J774 macrophages at 1 ug/ml,Other,16455249.0,
144,263382,4,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi amastigotes at 100 ug/ml,Other,16455249.0,
145,263383,4,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi amastigotes at 10 ug/ml,Other,16455249.0,
146,263384,4,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi amastigotes at 1 ug/ml,Other,16455249.0,
147,265553,3,3,,103178476,31593,Unspecified,,,,,Antitrypanosomatid activity against Trypanosoma cruzi Tulahuen 2 epimastigote form at 25 uM,Other,16722639.0,
148,265555,6,2,,103178476,31593,Active,,,8.5,IC50,Antitrypanosomatid activity against Trypanosoma cruzi Tulahuen 2 epimastigote form,Confirmatory,16722639.0,
149,265556,6,2,,103178476,31593,Active,,,3.4,IC50,Antitrypanosomatid activity against Trypanosoma cruzi CL Brener epimastigote form,Confirmatory,16722639.0,
150,265557,6,2,,103178476,31593,Active,,,3.8,IC50,Antitrypanosomatid activity against Trypanosoma cruzi Y epimastigote form,Confirmatory,16722639.0,
151,266614,6,2,,103178476,31593,Active,,,1.04,IC50,Antitrypanosomal activity against Trypanosoma cruzi,Confirmatory,16677813.0,
152,272980,8,1,,103178476,31593,Active,,,1.0,ED50,Antitrypanosomal activity against Trypanosoma cruzi trypomastigotes in CD1 mouse macrophage,Confirmatory,17004723.0,
153,274746,6,2,,103178476,31593,Unspecified,,,,,Antiprotozoal activity against Trypanosoma cruzi Tulahuen C2C4 trypomastigotes in L6 cells,Other,17253841.0,
154,282993,8,1,,103178476,31593,Active,,,28.9,ED50,Antiparasitic activity against Leishmania donovani MHOM/ET/67/HU3 intracellular amastigotes,Confirmatory,16279799.0,
155,282994,10,1,,103178476,31593,Active,,,0.0001,ED50,Antiparasitic activity against Trypanosoma brucei rhodesiense STIB900 blood stream form,Confirmatory,16279799.0,
156,282995,8,1,,103178476,31593,Active,,,4.2,ED50,Antiparasitic activity against Trypanosoma cruzi MHOM/CL/00/Tulahuan-LacZ intracellular amastigotes,Confirmatory,16279799.0,
157,284136,3,3,,103178476,31593,Unspecified,,,,,"Trypanocidal activity in Swiss albino mouse inoculated with Trypanosoma cruzi Y blood trypomastigotes assessed as parasitaemia reduction administered after 7th day of inoculation at 250 mg/kg, po after 4 hrs relative to control",Other,17055730.0,
158,284137,3,3,,103178476,31593,Unspecified,,,,,"Trypanocidal activity in Swiss albino mouse inoculated with Trypanosoma cruzi Y blood trypomastigotes assessed as parasitaemia reduction administered after 7th day of inoculation at 250 mg/kg, po after 6 hrs relative to control",Other,17055730.0,
159,285207,3,3,,103178476,31593,Unspecified,,,,,"Mortality rate in Trypanosoma cruzi Y infected wild type C57BL/6 mouse Chagas disease model at 100 mg/kg, po after 20 days",Other,17220408.0,
160,285208,3,4,,103178476,31593,Unspecified,,,,,"Mortality rate in Trypanosoma cruzi Y infected IFN-gamma knock out C57BL/6 mouse Chagas disease model at 100 mg/kg, po after 20 days",Other,17220408.0,
161,285209,3,3,,103178476,31593,Unspecified,,,,,"Mortality rate in Trypanosoma cruzi Y infected IL12 knock out C57BL/6 mouse Chagas disease model at 100 mg/kg, po after 20 days",Other,17220408.0,
162,285210,6,1,,103178476,31593,Unspecified,,,,,"Effect on survival in Trypanosoma cruzi Y infected C57BL/6 mouse Chagas disease model assessed as mean survival time at 100 mg/kg, po after 20 days",Other,17220408.0,
163,285211,6,1,,103178476,31593,Unspecified,,,,,"Effect on survival in Trypanosoma cruzi Y infected IFN-gamma knock out C57BL/6 mouse Chagas disease model assessed as mean survival time at 100 mg/kg, po after 20 days",Other,17220408.0,
164,285212,6,1,,103178476,31593,Unspecified,,,,,"Effect on survival in Trypanosoma cruzi Y infected IL12 knock out C57BL/6 mouse Chagas disease model assessed as mean survival time at 100 mg/kg, po after 20 days",Other,17220408.0,
165,285213,3,3,,103178476,31593,Unspecified,,,,,"Antimicrobial activity against Trypanosoma cruzi Y infected wild type C57BL/6 mouse Chagas disease model assessed as percent of cured mouse at 100 mg/kg, po after 20 days",Other,17220408.0,
166,285214,3,4,,103178476,31593,Unspecified,,,,,"Antimicrobial activity against Trypanosoma cruzi Y infected IFN-gamma knock out C57BL/6 mouse Chagas disease model assessed as percent of cured mouse at 100 mg/kg, po after 20 days",Other,17220408.0,
167,285215,3,3,,103178476,31593,Unspecified,,,,,"Antimicrobial activity against Trypanosoma cruzi Y infected IL12 knock out C57BL/6 mouse Chagas disease model assessed as percent of cured mouse at 100 mg/kg, po after 20 days",Other,17220408.0,
168,287513,6,2,,103178476,31593,Unspecified,,,,,Inhibition of Trypanosoma cruzi Maracay epimastigotes after 72 hrs,Other,17222558.0,
169,287514,6,2,,103178476,31593,Unspecified,,,,,Toxicity against Vero cells after 72 hrs,Other,17222558.0,
170,287713,6,2,,103178476,31593,Active,,,7.4,IC50,Antitrypanosomatid activity against Trypanosoma cruzi Tulahuen 2 epimastigotes assessed as reduction of growth after 5 days,Confirmatory,17287123.0,
171,287714,6,2,,103178476,31593,Active,,,4.5,IC50,Antitrypanosomatid activity against Trypanosoma cruzi CL Brener epimastigotes assessed as reduction of growth after 5 days,Confirmatory,17287123.0,
172,287715,6,2,,103178476,31593,Active,,,3.8,IC50,Antitrypanosomatid activity against Trypanosoma cruzi Y epimastigotes assessed as reduction of growth after 5 days,Confirmatory,17287123.0,
173,299531,6,2,,103178476,31593,Active,,,8.7,IC50,Inhibition of Trypanosoma cruzi,Confirmatory,17532634.0,
174,302064,6,2,,103178476,31593,Active,,,14.58,IC50,Antiprotozoal activity against Trypanosoma cruzi Y in vero cells,Confirmatory,17889546.0,
175,302065,6,2,,103178476,31593,Unspecified,,,1000.0,CC50,Cytotoxicity against Vero cells by MTT assay,Confirmatory,17889546.0,
176,302066,4,3,,103178476,31593,Inconclusive,,,,,Reduction of Leishmania amazonensis 575 infection in mouse peritoneal macrophage at 25 uM after 48 hrs,Other,17889546.0,
177,302069,4,4,,103178476,31593,Unspecified,,,,,Reduction of Trypanosoma cruzi Y amastigotes infection in Vero cells at 25 uM after 48 hrs,Other,17889546.0,
178,303263,6,2,,103178476,31593,Active,,,2.13,IC50,Antiparasitic activity against Trypanosoma cruzi Tulahuen T4 in amastigotes stage,Confirmatory,17949068.0,
179,303378,6,2,,103178476,31593,Active,,,7.4,IC50,Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2,Confirmatory,17960923.0,
180,303379,6,2,,103178476,31593,Active,,,4.5,IC50,Antitrypanosomal activity against Trypanosoma cruzi CL Brener,Confirmatory,17960923.0,
181,303380,6,2,,103178476,31593,Active,,,3.8,IC50,Antitrypanosomal activity against Trypanosoma cruzi Y,Confirmatory,17960923.0,
182,303387,3,3,,103178476,31593,Unspecified,,,,,"Toxicity in Trypanosoma cruzi Tulahuen 2 infected Swiss mouse model of Chagas disease at 100 mg/kg, po",Other,17960923.0,
183,309301,6,2,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi after 72 hrs,Other,17765547.0,
184,311644,6,2,,103178476,31593,Active,,,2.4,IC50,Antiparasitic activity against Trypanosoma cruzi,Confirmatory,17922552.0,
185,313539,6,2,,103178476,31593,Unspecified,,,74.0,IC50,Antitrypanosomal activity against Trypanosoma cruzi Tulahuen epimastigotes after 72 hrs,Confirmatory,18024033.0,
186,315106,6,2,,103178476,31593,Active,,,1.7,IC50,Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C4 amastigotes by microplate assay,Confirmatory,18353643.0,
187,317066,6,2,,103178476,31593,Active,,,15.8,IC50,Antiparasitic activity against Trypanosoma cruzi epimastigotes after 72 hrs,Confirmatory,18293910.0,
188,317067,6,2,,103178476,31593,Active,,,13.6,IC50,Toxicity in african green monkey Vero cells after 72 hrs,Confirmatory,18293910.0,
189,323757,6,2,,103178476,31593,Active,,,2.21,IC50,Antiparasitic activity against Trypanosoma cruzi Y epimastigote,Confirmatory,18226906.0,
190,323758,6,2,,103178476,31593,Active,,,6.61,IC50,Antiparasitic activity against Trypanosoma cruzi Y trypomastigotes,Confirmatory,18226906.0,
191,323759,6,2,,103178476,31593,Active,,,2.51,IC50,Antiparasitic activity against Trypanosoma cruzi Y amastigotes,Confirmatory,18226906.0,
192,324605,6,2,,103178476,31593,Active,,,20.6,IC50,Growth inhibition of Trypanosoma cruzi Tulahuen epimastigotes assessed as drug level causing decrease in growth constant,Confirmatory,18029184.0,
193,324607,3,3,,103178476,31593,Unspecified,,,,,Effect on oxygen uptake per mg of protein in Trypanosoma cruzi Tulahuen epimastigotes relative to control,Other,18029184.0,
194,324608,3,3,,103178476,31593,Unspecified,,,,,Effect on oxygen redox cycling in Trypanosoma cruzi Tulahuen assessed as oxygen consumption per mg of protein relative to control,Other,18029184.0,
195,327492,7,2,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi Y infected in human LLC-MK2 cells after 24 hrs by MTT assay,Other,18177008.0,
196,333757,6,2,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi,Other,15620251.0,
197,335403,6,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi Tulahuen,Other,,
198,335550,7,2,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi Tulahuen strain C2C4 containing galactosidase gene in rat L6 cells after 4 days,Other,12193010.0,
199,337130,4,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi Tulahuen after 48 hrs,Other,1919589.0,
200,337132,4,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi 27R27CL1 after 48 hrs,Other,1919589.0,
201,337134,4,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi Z1 after 48 hrs,Other,1919589.0,
202,337135,4,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi Z2 after 48 hrs,Other,1919589.0,
203,337136,4,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi Z2CL4 after 48 hrs,Other,1919589.0,
204,337137,4,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi 13379 CL3 after 48 hrs,Other,1919589.0,
205,337138,4,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi 13379 CL5 after 48 hrs,Other,1919589.0,
206,337139,4,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi 13379 CL6 after 48 hrs,Other,1919589.0,
207,337140,4,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi 13379 CL8 after 48 hrs,Other,1919589.0,
208,337141,4,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi C8 CL1 after 48 hrs,Other,1919589.0,
209,337142,4,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi A98CL5 after 48 hrs,Other,1919589.0,
210,337143,4,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi MIL4CL10 after 48 hrs,Other,1919589.0,
211,337144,4,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi M6241CL6 after 48 hrs,Other,1919589.0,
212,337145,4,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi 9280CL1 after 48 hrs,Other,1919589.0,
213,337146,4,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi CL after 48 hrs,Other,1919589.0,
214,337147,4,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi Y after 48 hrs,Other,1919589.0,
215,337148,4,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi A99CL7 after 48 hrs,Other,1919589.0,
216,337149,4,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi R107 after 48 hrs,Other,1919589.0,
217,337150,4,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi TeCL2 after 48 hrs,Other,1919589.0,
218,337151,4,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi 31R16CL1 after 48 hrs,Other,1919589.0,
219,341599,7,2,,103178476,31593,Inconclusive,,,,,Antiplasmodial activity against Plasmodium falciparum K1,Other,17562801.0,
220,341600,7,2,,103178476,31593,Inconclusive,,,,,Antiplasmodial activity against Plasmodium falciparum NF54,Other,17562801.0,
221,341601,7,2,,103178476,31593,Inconclusive,,,,,Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900,Other,17562801.0,
222,341602,7,2,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C4,Other,17562801.0,
223,341603,7,2,,103178476,31593,Inconclusive,,,,,Antileishmanial activity against Leishmania donovani MHOM-ET-67/L82 amastigotes by axenic assay,Other,17562801.0,
224,341604,7,2,,103178476,31593,Inconclusive,,,,,Antimicrobial activity against Giardia duodenalis WB,Other,17562801.0,
225,341605,7,2,,103178476,31593,Inconclusive,,,,,Antimicrobial activity against Giardia duodenalis G1,Other,17562801.0,
226,341606,7,2,,103178476,31593,Inconclusive,,,,,Antimicrobial activity against Babesia divergens 1903B,Other,17562801.0,
227,341607,7,2,,103178476,31593,Inconclusive,,,,,Antimicrobial activity against Babesia divergens 4201,Other,17562801.0,
228,343556,3,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi Tulahuen 2 at 25 uM relative to control,Other,18547811.0,
229,343557,6,2,,103178476,31593,Active,,,7.4,IC50,Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi Tulahuen 2,Confirmatory,18547811.0,
230,343558,6,2,,103178476,31593,Active,,,4.5,IC50,Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi CL Brener,Confirmatory,18547811.0,
231,344424,6,2,,103178476,31593,Unspecified,,,1000.0,IC50,Antitrypanosomal activity against bloodstream trypomastigote of Trypanosoma cruzi Y assessed as number of motile forms after 1 hr by hemocytometer,Confirmatory,18570370.0,
232,344425,6,2,,103178476,31593,Unspecified,,,2000.0,IC50,Cytotoxicity against chinese hamster V79 cells,Confirmatory,18570370.0,
233,344427,3,3,,103178476,31593,Unspecified,,,,,Antiproliferative activity against Trypanosoma cruzi Y epimastigotes assessed as number of motile forms at 0.1 mM after 1 hr by hemocytometer,Other,18570370.0,
234,344428,3,3,,103178476,31593,Unspecified,,,,,Antiproliferative activity against Trypanosoma cruzi Y epimastigotes assessed as number of motile forms at 0.5 mM after 1 hr by hemocytometer,Other,18570370.0,
235,344429,3,3,,103178476,31593,Unspecified,,,,,Antiproliferative activity against Trypanosoma cruzi Y epimastigotes assessed as number of motile forms at 1 mM after 1 hr by hemocytometer,Other,18570370.0,
236,344430,3,3,,103178476,31593,Unspecified,,,,,Antiproliferative activity against Trypanosoma cruzi Y epimastigotes assessed as number of motile forms at 0.1 mM after 4 hrs by hemocytometer,Other,18570370.0,
237,344431,3,3,,103178476,31593,Unspecified,,,,,Antiproliferative activity against Trypanosoma cruzi Y epimastigotes assessed as number of motile forms at 0.5 mM after 4 hrs by hemocytometer,Other,18570370.0,
238,344432,3,3,,103178476,31593,Unspecified,,,,,Antiproliferative activity against Trypanosoma cruzi Y epimastigotes assessed as number of motile forms at 1 mM after 4 hrs by hemocytometer,Other,18570370.0,
239,344433,3,3,,103178476,31593,Unspecified,,,,,Antiproliferative activity against Trypanosoma cruzi Y epimastigotes assessed as number of motile forms at 0.1 mM after 24 hrs by hemocytometer,Other,18570370.0,
240,344434,3,3,,103178476,31593,Unspecified,,,,,Antiproliferative activity against Trypanosoma cruzi Y epimastigotes assessed as number of motile forms at 0.5 mM after 24 hrs by hemocytometer,Other,18570370.0,
241,344435,3,3,,103178476,31593,Unspecified,,,,,Antiproliferative activity against Trypanosoma cruzi Y epimastigotes assessed as number of motile forms at 1 mM after 24 hrs by hemocytometer,Other,18570370.0,
242,344436,6,2,,103178476,31593,Unspecified,,,1000.0,IC50,Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes assessed as number of motile forms after 24 hrs by hemocytometer,Confirmatory,18570370.0,
243,344437,3,3,,103178476,31593,Inactive,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in Swiss mouse assessed as survivality at 100 nmol/kg, ip after 15 consecutive days",Other,18570370.0,
244,344438,3,3,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in Swiss mouse assessed as decrease in parasitemia at 385 umol/kg, po after 15 consecutive days",Other,18570370.0,
245,344439,3,4,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in Swiss mouse assessed as survivality at 385 umol/kg, po for 1 day after 15 days",Other,18570370.0,
246,344440,5,2,,103178476,31593,Unspecified,,,,,Aqueous solubility at pH 6.5,Other,18570370.0,
247,344441,3,4,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in Swiss mouse assessed as survivality at 385 umol/kg, po after 15 consecutive days",Other,18570370.0,
248,356388,6,2,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi,Other,14510589.0,
249,362661,6,2,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi Tulahuen,Other,18712933.0,
250,362800,6,2,,103178476,31593,Unspecified,,,,,Antiprotozoal activity against Trypanosoma cruzi Tulahuen C4 in rat L6 cells,Other,18683985.0,
251,362866,3,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 at 25 uM after 5 days,Other,17709156.0,
252,362867,8,1,,103178476,31593,Active,,,7.4,ID50,Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 after 5 days,Confirmatory,17709156.0,
253,362868,8,1,,103178476,31593,Unspecified,,,300.0,ID50,Cytotoxicity against human THP1 cells after 48 hrs,Confirmatory,17709156.0,
254,362869,3,3,,103178476,31593,Unspecified,,,,,"Therapeutic index, ID50 for human THP1 cells to ID50 for Trypanosoma cruzi",Other,17709156.0,
255,364956,8,1,,103178476,31593,Active,,,4.5,ID50,Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 assessed as inhibition of epimastigotes growth after 5 days by MTT assay relative to control,Confirmatory,18706821.0,
256,364961,8,1,,103178476,31593,Active,,,3.8,ID50,Antileishmanial activity against Leishmania pifanoi MHOM/VE/57/LV135 assessed as parasite viability after 5 days by MTT assay,Confirmatory,18706821.0,
257,367083,6,2,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Tulahuen C2C4 containing lacZ gene in rat L6 cells after 4 days,Other,19095449.0,
258,371470,6,2,,103178476,31593,Unspecified,,,103.6,IC50,Antitrypanosomal activity against Trypanosoma cruzi Y trypomastigotes after 1 day,Confirmatory,18045742.0,
259,373279,3,4,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi bloodstream trypomastigote infected in BALB/c mouse assessed as parasitemia at 50 mg/kg, po after 60 days by colorimetric method",Other,18706738.0,
260,373281,3,5,,103178476,31593,Unspecified,,,,,"Toxicity in BALB/c mouse assessed as survival fraction at 50 mg/kg, po after 9 weeks",Other,18706738.0,
261,373283,3,4,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi bloodstream trypomastigote infected in BALB/c mouse assessed as antibodies at 50 mg/kg, po after 30 days by colorimetric method",Other,18706738.0,
262,373285,3,4,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi bloodstream trypomastigote infected in BALB/c mouse assessed as antibodies at 50 mg/kg, po after 60 days by colorimetric method",Other,18706738.0,
263,378199,6,2,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against galactosidase gene containing Trypanosoma cruzi Tulahuen C2C4 trypomastigotes in rat L6 cells after 4 days,Other,11087584.0,
264,378742,3,3,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y trypomastigotes infected in Swiss albino mouse assessed as reduction in parasitaemia at 500 mg/kg, po after 6 hrs",Other,10075791.0,
265,378743,3,3,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y trypomastigotes infected in Swiss albino mouse assessed as mortality rate at 100 mg/kg, po daily for 4 days assessed after 6 to 9 days",Other,10075791.0,
266,382236,6,2,,103178476,31593,Unspecified,,,103.6,IC50,Trypanocidal activity against Trypanosoma cruzi Y blood stream trypomastigotes after 24 hrs,Confirmatory,18378461.0,
267,382467,6,2,,103178476,31593,Unspecified,,,,,Antiplasmodial activity against Plasmodium falciparum K1 infected human erythrocytes after 48 hrs as [3H]hypoxanthine uptake,Other,17475370.0,
268,382468,3,4,,103178476,31593,Unspecified,,,,,"Therapeutic index, ratio of IC50 for rat L6 cells to IC50 for Plasmodium falciparum K1",Other,17475370.0,
269,392005,3,3,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Colombiana infected Swiss mouse assessed as reduction in circulating trypomastigotes antibody level at 120 mg/kg/day, po after 44 days postinfection",Other,18255195.0,
270,392009,3,3,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 infected Swiss mouse assessed as reduction in circulating trypomastigotes antibody level at 200 mg/kg/day, po after 60 days postinfection",Other,18255195.0,
271,392010,3,3,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 infected Swiss mouse assessed as reduction in circulating trypomastigotes antibody level at 200 mg/kg/day, po after 90 days postinfection",Other,18255195.0,
272,392014,3,3,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 infected Swiss mouse assessed as prevention of heart inflammatory infiltrates at 200 mg/kg/day, po",Other,18255195.0,
273,392015,3,4,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 infected Swiss mouse assessed as prevention of muscle inflammatory infiltrates at 200 mg/kg/day, po",Other,18255195.0,
274,392018,3,3,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 infected Swiss mouse assessed as prevention of liver congestion at 200 mg/kg/day, po",Other,18255195.0,
275,392020,3,3,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Colombiana infected Swiss mouse assessed as prevention of heart inflammatory infiltrates at 120 mg/kg/day, po",Other,18255195.0,
276,392021,3,4,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Colombiana infected Swiss mouse assessed as prevention of skeletal muscle inflammatory infiltrates at 120 mg/kg/day, po",Other,18255195.0,
277,392022,3,3,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Colombiana infected Swiss mouse assessed as prevention of liver congestion at 120 mg/kg/day, po",Other,18255195.0,
278,392023,3,3,,103178476,31593,Unspecified,,,,,"Toxicity against Trypanosoma cruzi Colombiana infected Swiss mouse assessed as mouse survival at 120 mg/kg/day, po after 25 days",Other,18255195.0,
279,396003,3,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against Trypanosoma cruzi infected in BALB/c mouse assessed as parasitemia remaining in fresh blood,Other,17638698.0,
280,396004,3,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against Trypanosoma cruzi infected in BALB/c mouse assessed as parasitemia remaining in hemoculture,Other,17638698.0,
281,396005,3,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against Trypanosoma cruzi genotype 19 and genotype 39 dually infected in BALB/c mouse assessed as cure rate,Other,17638698.0,
282,396006,3,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against Trypanosoma cruzi infected in BALB/c mouse assessed as parasitemia remaining by PCR method,Other,17638698.0,
283,396007,3,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against Trypanosoma cruzi infected in BALB/c mouse assessed as parasitemia remaining by ELISA,Other,17638698.0,
284,396008,3,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against Trypanosoma cruzi genotype 19 and genotype 32 dually infected in BALB/c mouse assessed as cure rate,Other,17638698.0,
285,396009,3,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against Trypanosoma cruzi infected in BALB/c mouse assessed as parasitemia remaining by FC-ALTA,Other,17638698.0,
286,396010,3,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against Trypanosoma cruzi 1 infected in BALB/c mouse assessed as cure rate,Other,17638698.0,
287,396011,3,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against Trypanosoma cruzi infected in BALB/c mouse assessed as cure rate,Other,17638698.0,
288,396012,3,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against Trypanosoma cruzi 2 infected in BALB/c mouse assessed as cure rate,Other,17638698.0,
289,396013,3,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against Trypanosoma cruzi and Trypanosoma cruzi 2 dually infected in BALB/c mouse assessed as cure rate,Other,17638698.0,
290,396014,3,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against Trypanosoma cruzi 1 and Trypanosoma cruzi 2 dually infected in BALB/c mouse assessed as cure rate,Other,17638698.0,
291,396015,3,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against Trypanosoma cruzi 1 and Trypanosoma cruzi dually infected in BALB/c mouse assessed as cure rate,Other,17638698.0,
292,396016,3,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against Trypanosoma cruzi 1 dually infected in BALB/c mouse assessed as cure rate,Other,17638698.0,
293,396017,3,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against Trypanosoma cruzi genotype 20 infected in BALB/c mouse assessed as cure rate,Other,17638698.0,
294,396018,3,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against Trypanosoma cruzi genotype 19 infected in BALB/c mouse assessed as cure rate,Other,17638698.0,
295,396019,3,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against Trypanosoma cruzi genotype 32 infected in BALB/c mouse assessed as cure rate,Other,17638698.0,
296,396020,3,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against Trypanosoma cruzi genotype 39 infected in BALB/c mouse assessed as cure rate,Other,17638698.0,
297,396021,3,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against Trypanosoma cruzi genotype 20 and genotype 19 dually infected in BALB/c mouse assessed as cure rate,Other,17638698.0,
298,396022,3,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against Trypanosoma cruzi genotype 39 and genotype 32 dually infected in BALB/c mouse assessed as cure rate,Other,17638698.0,
299,396023,3,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against Trypanosoma cruzi OPS21 cl11 and Trypanosoma cruzi MAS cl11 dually infected in BALB/c mouse assessed as cure rate,Other,17638698.0,
300,396024,3,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against Trypanosoma cruzi Bug2148 cl1 and Trypanosoma cruzi MAS cl11 dually infected in BALB/c mouse assessed as cure rate,Other,17638698.0,
301,396580,6,2,,103178476,31593,Active,,,7.4,IC50,Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 epimastigotes,Confirmatory,18068272.0,
302,396581,6,2,,103178476,31593,Active,,,4.5,IC50,Antitrypanosomal activity against Trypanosoma cruzi CL Brener epimastigotes,Confirmatory,18068272.0,
303,396582,6,2,,103178476,31593,Active,,,3.8,IC50,Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes,Confirmatory,18068272.0,
304,396587,6,2,,103178476,31593,Unspecified,,,54.7,IC50,Trypanocidal activity against Trypanosoma cruzi CL-B5 clone epimastigotes expressing lacZ gene after 72 hrs at 28 degC,Confirmatory,18192088.0,
305,396589,6,2,,103178476,31593,Unspecified,,,192.1,IC50,Antitrypanosomal activity against Trypanosoma cruzi CL-B5 amastigotes infected in mouse NCTC-929 fibroblast after 7 days by colorimetric method,Confirmatory,18192088.0,
306,401526,6,2,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi,Other,15165131.0,
307,401638,9,1,,103178476,31593,Unspecified,,,,IC50,Antitrypanosomal activity against Trypanosoma cruzi,Confirmatory,15921407.0,
308,401651,6,2,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi in rat L6 cells,Other,15921410.0,
309,404373,6,2,,103178476,31593,Active,,,0.086,IC50,Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C2C4,Confirmatory,18476684.0,
310,414762,3,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes assessed as parasite growth at 10 ug/ml after 24 hrs,Other,19303308.0,
311,414763,3,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes assessed as parasite growth at 20 ug/ml after 24 hrs,Other,19303308.0,
312,419679,6,2,,103178476,31593,Active,,,1.48,IC50,Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in rat L6 cells,Confirmatory,19414258.0,
313,426304,6,2,,103178476,31593,Active,,,18.62,IC50,Antiparasitic activity against Trichomonas vaginalis GT3 trophozoites after 48 hrs by Hill culture method,Confirmatory,19208443.0,
314,426309,6,2,,103178476,31593,Active,,,22.58,IC50,Antiparasitic activity against Giardia intestinalis IMSS:0696 trophozoites after 48 hrs by Hill culture method,Confirmatory,19208443.0,
315,426310,6,2,,103178476,31593,Active,,,4.27,IC50,Antiamnesic activity against Entamoeba histolytica HM-1:IMSS trophozoites after 48 hrs by Hill culture method,Confirmatory,19208443.0,
316,434955,1,2,,56320744,31593,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
317,434962,1,2,,56320744,31593,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
318,434973,1,3,,56320744,31593,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
319,434989,1,1,,56320744,31593,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
320,435003,1,3,,56320744,31593,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
321,435005,1,1,,56320744,31593,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
322,435022,2,2,,56320744,31593,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
323,435030,1,2,,56320744,31593,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
324,435030,1,2,,56320744,31593,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
325,439776,5,2,,103178476,31593,Unspecified,,,103.6,IC50,Antitrypanosomal activity against Trypanosoma cruzi trypomastigotes,Confirmatory,19606868.0,
326,439873,5,2,,103178476,31593,Active,,,0.521,IC50,Antimicrobial activity against Trypanosoma cruzi Tulahuen C2C4 amastigote forms infected in rat L6 cells,Confirmatory,19817445.0,
327,445550,5,2,,103178476,31593,Active,,,7.4,IC50,Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 epimastigotes assessed as parasite growth inhibition after 5 days,Confirmatory,19837489.0,
328,445551,5,2,,103178476,31593,Active,,,4.5,IC50,Antitrypanosomal activity against Trypanosoma cruzi CL Brener epimastigotes assessed as parasite viability after 5 days by MTT assay,Confirmatory,19837489.0,
329,447812,5,2,,103178476,31593,Active,,,5.0,IC50,Antitrypanosomal activity against Trypanosoma cruzi Y trypomastigote form after 24 hrs by Trypan blue exclusion method,Confirmatory,19539479.0,
330,447813,5,2,,103178476,31593,Active,,,6.6,IC50,Antitrypanosomal activity against Trypanosoma cruzi Y epimastigote form after 11 days by Trypan blue exclusion method,Confirmatory,19539479.0,
331,447814,5,1,,103178476,31593,Unspecified,,,,,Cytotoxicity against BALB/c mouse splenocytes after 24 hrs by [3H]thymidine incorporation assay,Other,19539479.0,
332,449369,7,1,,103178476,31593,Active,,,7.4,ID50,Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 epimastigotes assessed as inhibition of parasite growth after 5 days,Confirmatory,19616875.0,
333,449387,3,3,,103178476,31593,Active,,,,,Inhibition of Mitochondrial dehydrogenase in Trypanosoma cruzi Y epimastigotes at 20 uM after 30 to 240 mins by MTT dye reduction assay in relative to control,Other,19616875.0,
334,449728,1,2,,56320744,31593,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
335,449762,1,2,,56320744,31593,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
336,449763,1,3,,56320744,31593,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
337,450067,8,1,,103178476,31593,Active,,,5.0,IC50,Antitrypanosomal activity against Trypanosoma cruzi epimastigote Y strain after 24 hrs by trypan blue exclusion assay,Confirmatory,19683450.0,
338,450068,5,2,,103178476,31593,Active,,,6.6,IC50,Antitrypanosomal activity against Trypanosoma cruzi trypomastigote Y strain after 24 hrs by trypan blue exclusion assay,Confirmatory,19683450.0,
339,450069,7,1,,103178476,31593,Unspecified,,,,,Cytotoxicity against BALB/c mouse splenocyte assessed as [3H]thymidine incorporation by beta-counting,Other,19683450.0,
340,453255,5,2,,103178476,31593,Active,,,1.25,IC50,Antitrypanosomal activity against Trypanosoma cruzi,Confirmatory,19781948.0,
341,453258,5,2,,103178476,31593,Unspecified,,,90.0,IC50,Toxicity against rat L6 cells,Confirmatory,19781948.0,
342,456260,5,2,,103178476,31593,Active,,,1.54,IC50,Antitrypanosomal activity against Trypanosoma cruzi infected in rat L6 cells,Confirmatory,19942439.0,
343,463079,1,2,,56320744,31593,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
344,463082,1,1,,56320744,31593,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
345,463104,1,2,,56320744,31593,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
346,463111,1,1,,56320744,31593,Active,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
347,463141,1,2,,56320744,31593,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
348,463165,1,1,,56320744,31593,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
349,463190,1,2,,56320744,31593,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
350,463195,1,2,,56320744,31593,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
351,463210,1,2,,56320744,31593,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
352,463212,1,1,,56320744,31593,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
353,463254,1,1,,56320744,31593,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
354,464871,5,2,,103178476,31593,Active,,,1.8,EC50,Antiparasitic activity against Trypanosoma cruzi Tulahuen C2C4 amastigotes,Confirmatory,20185305.0,
355,472780,3,4,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi tulahuen C4 trypomastigotes infected mouse assessed as decrease in parasite replication at 20 mg/kg/day, ip on days 6 to 11 days post infection after 6 days",Other,20356752.0,
356,485270,1,1,,56320744,31593,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
357,485272,1,1,,56320744,31593,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
358,485273,2,1,,56320744,31593,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
359,485275,1,3,,56320744,31593,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
360,485290,1,1,,29217996,31593,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
361,485294,1,1,,56320744,31593,Inconclusive,119389684.0,,5.6234,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
362,485297,1,1,,56320744,31593,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
363,485298,1,1,,56320744,31593,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
364,485313,1,2,,56320744,31593,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
365,485317,1,2,,56320744,31593,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
366,485341,1,1,,56320744,31593,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
367,485344,1,1,,56320744,31593,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
368,485346,1,1,,56320744,31593,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
369,485346,1,1,,56320744,31593,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
370,485347,1,2,,56320744,31593,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
371,485349,1,1,,56320744,31593,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
372,485358,1,1,,56320744,31593,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
373,485360,1,1,,56320744,31593,Inactive,117938328.0,26013.0,,Potency,qHTS Assay for the Inhibitors of L3MBTL1,Confirmatory,,
374,485364,1,1,,56320744,31593,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
375,485367,1,2,,56320744,31593,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
376,488837,1,1,,56320744,31593,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
377,488839,1,1,,56320744,31593,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
378,488839,1,1,,56320744,31593,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
379,488847,1,3,,56320744,31593,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
380,488862,1,1,,56320744,31593,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
381,488890,1,2,,56320744,31593,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
382,488895,1,2,,56320744,31593,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
383,488896,1,1,,56320744,31593,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
384,488899,1,1,,56320744,31593,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
385,488922,1,2,,56320744,31593,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
386,488965,1,2,,56320744,31593,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
387,488966,1,1,,56320744,31593,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
388,488975,1,2,,56320744,31593,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
389,488977,1,2,,56320744,31593,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
390,489030,2,1,,56320744,31593,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
391,489031,2,1,,56320744,31593,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
392,492947,1,1,,56320744,31593,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
393,492953,1,1,,56320744,31593,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
394,492956,1,1,,56320744,31593,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
395,492961,1,1,,29217996,31593,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
396,492972,1,1,,56320744,31593,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
397,493005,1,1,,56320744,31593,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
398,493008,1,1,,56320744,31593,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
399,493008,1,1,,56320744,31593,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
400,493008,1,1,,56320744,31593,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
401,493008,1,1,,56320744,31593,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
402,493011,1,1,,56320744,31593,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
403,493012,1,1,,56320744,31593,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
404,493014,1,1,,56320744,31593,Inactive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
405,493036,1,2,,56320744,31593,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
406,493056,1,1,,56320744,31593,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
407,493084,1,1,,56320744,31593,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
408,493087,1,1,,56320744,31593,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
409,493091,1,1,,56320744,31593,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
410,493098,1,1,,56320744,31593,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
411,493131,1,1,,56320744,31593,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
412,493160,1,1,,56320744,31593,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
413,493187,1,2,,56320744,31593,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
414,493244,1,1,,56320744,31593,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
415,493244,1,1,,56320744,31593,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
416,493244,1,1,,56320744,31593,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
417,493244,1,1,,56320744,31593,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
418,496817,4,2,,103178476,31593,Active,,,3.0,IC50,Antimicrobial activity against Trypanosoma cruzi,Confirmatory,20185316.0,
419,497467,4,2,,103178476,31593,Active,,,2.64,IC50,Trypanocidal activity against trypomastigote form of Trypanosoma cruzi Tulahuen infected in rat L6 cells after 96 hrs,Confirmatory,20614907.0,
420,502042,4,2,,103178476,31593,Active,,,34.38,IC50,Antimicrobial activity against epimastigotes form of Trypanosoma cruzi MHOM/MX/1994/Ninoa after 72 hrs,Confirmatory,20674375.0,
421,504326,1,2,,56320744,31593,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
422,504326,1,2,,56320744,31593,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
423,504327,1,1,,29217996,31593,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
424,504327,1,1,,56320744,31593,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
425,504329,1,1,,56320744,31593,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
426,504332,1,1,,29217996,31593,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
427,504332,1,1,,56320744,31593,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
428,504333,1,1,,56320744,31593,Inactive,6683500.0,29994.0,,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
429,504339,1,1,,56320744,31593,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
430,504357,1,1,,56320744,31593,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
431,504357,1,1,,56320744,31593,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
432,504406,1,1,,56320744,31593,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
433,504408,2,1,,56320744,31593,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
434,504411,1,1,,56320744,31593,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
435,504414,1,1,,56320744,31593,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
436,504414,1,1,,56320744,31593,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
437,504423,1,1,,56320744,31593,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
438,504441,1,1,,56320744,31593,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
439,504444,1,1,,56320744,31593,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
440,504454,1,3,,56320744,31593,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
441,504462,1,1,,56320744,31593,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
442,504466,1,1,,56320744,31593,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
443,504467,1,1,,56320744,31593,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
444,504490,1,2,,56320744,31593,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
445,504523,1,1,,56320744,31593,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
446,504523,1,1,,56320744,31593,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
447,504558,1,1,,56320744,31593,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
448,504577,2,2,,56320744,31593,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
449,504582,2,1,,56320744,31593,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
450,504621,1,1,,56320744,31593,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
451,504634,1,1,,56320744,31593,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
452,504648,1,1,,56320744,31593,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
453,504651,1,1,,56320744,31593,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
454,504652,1,1,,56320744,31593,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
455,504660,1,1,,56320744,31593,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
456,504690,1,3,,56320744,31593,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
457,504692,2,2,,56320744,31593,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
458,504700,1,1,,56320744,31593,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
459,504700,1,1,,56320744,31593,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
460,504706,1,1,,56320744,31593,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
461,504707,1,1,,56320744,31593,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
462,504707,1,1,,56320744,31593,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
463,504720,1,1,,56320744,31593,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
464,504734,1,1,,56320744,31593,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
465,504749,1,3,,29217996,31593,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
466,504749,1,3,1.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
467,504749,1,3,2.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
468,504749,1,3,3.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
469,504749,1,3,4.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
470,504749,1,3,5.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
471,504749,1,3,6.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
472,504749,1,3,7.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
473,504749,1,3,8.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
474,504749,1,3,9.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
475,504749,1,3,10.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
476,504749,1,3,11.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
477,504749,1,3,12.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
478,504749,1,3,13.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
479,504749,1,3,14.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
480,504749,1,3,15.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
481,504749,1,3,16.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
482,504749,1,3,17.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
483,504749,1,3,18.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
484,504749,1,3,19.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
485,504749,1,3,20.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
486,504749,1,3,21.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
487,504749,1,3,22.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
488,504749,1,3,23.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
489,504749,1,3,24.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
490,504749,1,3,25.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
491,504749,1,3,26.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
492,504749,1,3,27.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
493,504749,1,3,28.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
494,504749,1,3,29.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
495,504749,1,3,30.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
496,504749,1,3,31.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
497,504749,1,3,32.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
498,504749,1,3,33.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
499,504749,1,3,34.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
500,504749,1,3,35.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
501,504749,1,3,36.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
502,504749,1,3,37.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
503,504749,1,3,38.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
504,504749,1,3,39.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
505,504749,1,3,40.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
506,504749,1,3,41.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
507,504749,1,3,42.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
508,504749,1,3,43.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
509,504749,1,3,44.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
510,504749,1,3,45.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
511,504749,1,3,46.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
512,504749,1,3,47.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
513,504749,1,3,48.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
514,504749,1,3,49.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
515,504749,1,3,50.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
516,504749,1,3,51.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
517,504749,1,3,52.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
518,504749,1,3,53.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
519,504749,1,3,54.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
520,504749,1,3,55.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
521,504749,1,3,56.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
522,504749,1,3,57.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
523,504749,1,3,58.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
524,504749,1,3,59.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
525,504749,1,3,60.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
526,504749,1,3,61.0,29217996,31593,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
527,504766,2,1,,56320744,31593,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
528,504775,1,1,,56320744,31593,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
529,504803,1,1,,56320744,31593,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
530,504810,1,2,,56320744,31593,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
531,504812,1,2,,56320744,31593,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
532,504832,1,1,,29217996,31593,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
533,504832,1,1,,56320744,31593,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
534,504834,1,1,,29217996,31593,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
535,504834,1,1,,56320744,31593,Inactive,,,13.1154,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
536,504842,1,1,,56320744,31593,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
537,504845,1,1,,56320744,31593,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
538,504847,1,1,,29217996,31593,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
539,504847,1,1,,56320744,31593,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
540,504865,1,1,,29217996,31593,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
541,504884,1,2,,56320744,31593,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
542,504891,1,1,,56320744,31593,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
543,504894,1,1,,56320744,31593,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
544,504937,1,2,,56320744,31593,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
545,509508,2,3,,103178476,31593,Unspecified,,,,,Antiprotozoal activity against Trypanosoma cruzi Tulahuen C2C4 infected in rat skeletal myoblast at 4.8 ug/ml after 48 hrs,Other,20573426.0,
546,527277,5,2,,103178476,31593,Unspecified,,,,,Trypanocidal activity against intracellular amastigotes of Trypanosoma cruzi Tulahuen C2C4 expressing LacZ gene infected in rat L6 cells after 96 hrs,Other,20855214.0,
547,536024,3,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi Y assessed as viability at 40 uM after 11 days by trypan blue exclusion assay,Other,20961766.0,
548,536025,4,2,,103178476,31593,Active,,,6.6,IC50,Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi Y assessed as viability after 11 days by trypan blue exclusion assay,Confirmatory,20961766.0,
549,536026,4,2,,103178476,31593,Active,,,5.0,IC50,Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Y assessed as viability after 24 hrs by trypan blue exclusion assay,Confirmatory,20961766.0,
550,536027,4,1,,103178476,31593,Unspecified,,,,,Cytotoxicity against BALB/c mouse Splenocyte assessed as non-cytotoxic concentration after 24 hrs by [3H]-thymidine incorporation assay relative to control,Other,20961766.0,
551,536028,3,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi Y assessed as viability at 40 uM after 15 hrs by trypan blue exclusion assay,Other,20961766.0,
552,536029,3,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi Y assessed as viability at 40 uM after 7 days by trypan blue exclusion assay,Other,20961766.0,
553,536030,2,3,,103178476,31593,Unspecified,,,,,"Toxicity in Swiss mouse assessed as mortality at 100 mg/kg, ip after 72 hrs",Other,20961766.0,
554,536809,4,2,,103178476,31593,Active,,,1.979,IC50,Antitrypanosomal activity against clone C4 Trypanosoma cruzi Tulahuen expressing LacZ,Confirmatory,20850207.0,
555,537130,4,2,,103178476,31593,Inconclusive,,,,IC50,Antileishmanial activity against promastigotes of Leishmania chagasi MHOM/BR/1972/LD after 18 hrs by MTT assay,Confirmatory,20934347.0,
556,537131,4,2,,103178476,31593,Inconclusive,,,,IC50,Antileishmanial activity against amastigotes of Leishmania chagasi MHOM/BR/1972/LD after 24 hrs by MTT assay,Confirmatory,20934347.0,
557,537132,4,2,,103178476,31593,Inconclusive,,,,IC50,Antileishmanial activity against promastigotes of Leishmania amazonensis WHO/BR/00/LT0016 after 18 hrs by MTT assay,Confirmatory,20934347.0,
558,537133,4,2,,103178476,31593,Inconclusive,,,,IC50,Antileishmanial activity against promastigotes of Leishmania major MHOM/1L/80/Fredlin after 18 hrs by MTT assay,Confirmatory,20934347.0,
559,537134,4,2,,103178476,31593,Inconclusive,,,,IC50,Antileishmanial activity against promastigotes of Leishmania braziliensis MHO/BR/75/M2903 after 18 hrs by MTT assay,Confirmatory,20934347.0,
560,537135,4,2,,103178476,31593,Unspecified,,,172.37,IC50,Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi infected in rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay,Confirmatory,20934347.0,
561,537136,4,2,,103178476,31593,Unspecified,,,1366.0,IC50,Cytotoxicity against rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay,Confirmatory,20934347.0,
562,537139,2,5,,103178476,31593,Unspecified,,,,,Cytotoxicity in BALB/c mouse erythrocytes assessed as hemolysis at 50 uM after 3 hrs,Other,20934347.0,
563,540253,1,1,,56320744,31593,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
564,540253,1,1,,56320744,31593,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
565,540253,1,1,,56320744,31593,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
566,540263,1,1,,56320744,31593,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
567,540263,1,1,,56320744,31593,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
568,540267,1,1,,56320744,31593,Active,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
569,540275,1,1,,56320744,31593,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
570,540277,1,1,,56320744,31593,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
571,540295,1,1,,56320744,31593,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
572,540303,1,1,,56320744,31593,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
573,540303,1,1,,56320744,31593,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
574,540303,1,1,,56320744,31593,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
575,540308,1,1,,56320744,31593,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
576,540317,1,1,,56320744,31593,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
577,540336,1,1,,56320744,31593,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
578,540336,1,1,,56320744,31593,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
579,540364,1,2,,56320744,31593,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
580,547245,2,3,,103178476,31593,Unspecified,,,,,"Toxicity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as weight loss at 12 mg/kg, po BID for 90 days started 12 to 22 days postinfection measured after 1 day",Other,20404124.0,
581,547246,2,3,,103178476,31593,Unspecified,,,,,"Toxicity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as weight loss at 7 mg/kg, po BID for 90 days started 12 to 22 days postinfection measured after 1 day",Other,20404124.0,
582,547247,2,3,,103178476,31593,Unspecified,,,,,"Toxicity in mongrel dog infected with Trypanosoma cruzi Y assessed as weight loss at 12 mg/kg, po BID for 90 days started 12 to 22 days postinfection measured after 6 months",Other,20404124.0,
583,547248,2,3,,103178476,31593,Unspecified,,,,,"Toxicity in mongrel dog infected with Trypanosoma cruzi Y assessed as weight loss at 7 mg/kg, po BID for 90 days started 12 to 22 days postinfection measured after 6 months",Other,20404124.0,
584,547249,2,3,,103178476,31593,Unspecified,,,,,"Toxicity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as weight loss at 12 mg/kg, po BID for 90 days started 12 to 22 days postinfection measured after 6 months",Other,20404124.0,
585,547250,2,3,,103178476,31593,Unspecified,,,,,"Toxicity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as weight loss at 7 mg/kg, po BID for 90 days started 12 to 22 days postinfection measured after 6 months",Other,20404124.0,
586,547251,2,3,,103178476,31593,Unspecified,,,,,"Antimicrobial activity against Trypanosoma cruzi Y infected in mongrel dog assessed as suppression of microbial proliferation at 12 mg/kg, po BID started 12 to 22 days postinfection measured after 1 day",Other,20404124.0,
587,547252,2,3,,103178476,31593,Unspecified,,,,,"Antimicrobial activity against Trypanosoma cruzi Berenice-78 infected in mongrel dog assessed as suppression of microbial proliferation at 12 mg/kg, po BID started 12 to 22 days postinfection measured after 1 day",Other,20404124.0,
588,547253,2,3,,103178476,31593,Unspecified,,,,,"Antimicrobial activity against Trypanosoma cruzi Y infected in mongrel dog assessed as suppression of microbial proliferation at 7 mg/kg, po BID started 12 to 22 days postinfection measured after 1 day",Other,20404124.0,
589,547254,2,3,,103178476,31593,Unspecified,,,,,"Antimicrobial activity against Trypanosoma cruzi Berenice-78 infected in mongrel dog assessed as suppression of microbial proliferation at 7 mg/kg, po BID started 12 to 22 days postinfection measured after 1 day",Other,20404124.0,
590,547255,2,3,,103178476,31593,Unspecified,,,,,"Antimicrobial activity against Trypanosoma cruzi Y infected in mongrel dog assessed as survival of dog at 12 mg/kg, po BID started 12 to 22 days postinfection measured after 1 day",Other,20404124.0,
591,547256,2,3,,103178476,31593,Unspecified,,,,,"Antimicrobial activity against Trypanosoma cruzi Berenice-78 infected in mongrel dog assessed as survival of dog at 12 mg/kg, po BID started 12 to 22 days postinfection measured after 1 day",Other,20404124.0,
592,547257,2,3,,103178476,31593,Unspecified,,,,,"Antimicrobial activity against Trypanosoma cruzi Y infected in mongrel dog assessed as survival of dog at 7 mg/kg, po BID started 12 to 22 days postinfection measured after 1 day",Other,20404124.0,
593,547258,2,3,,103178476,31593,Unspecified,,,,,"Antimicrobial activity against Trypanosoma cruzi Berenice-78 infected in mongrel dog assessed as survival of dog at 7 mg/kg, po BID started 12 to 22 days postinfection measured after 1 day",Other,20404124.0,
594,547263,2,4,,103178476,31593,Unspecified,,,,,"Antimicrobial activity against Trypanosoma cruzi Y infected in mongrel dog assessed as parasite level in blood of dog at 7 mg/kg, po BID started 12 to 22 days postinfection measured after 30 days by PCR analysis",Other,20404124.0,
595,547264,2,4,,103178476,31593,Unspecified,,,,,"Antimicrobial activity against Trypanosoma cruzi Berenice-78 infected in mongrel dog assessed as parasite level in blood of dog at 7 mg/kg, po BID started 12 to 22 days postinfection measured after 30 days by PCR analysis",Other,20404124.0,
596,547269,2,3,,103178476,31593,Active,,,,,"Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as production of antibody IgG at 12 mg/kg, po BID for 90 days measured up to 30 days by ELISA",Other,20404124.0,
597,547270,2,3,,103178476,31593,Active,,,,,"Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as production of antibody IgG2 at 12 mg/kg, po BID for 90 days measured up to 30 days by ELISA",Other,20404124.0,
598,547271,2,3,,103178476,31593,Active,,,,,"Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as production of antibody IgG at 7 mg/kg, po BID for 90 days measured up to 30 days by ELISA",Other,20404124.0,
599,547272,2,3,,103178476,31593,Active,,,,,"Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as production of antibody IgG2 at 7 mg/kg, po BID for 90 days measured up to 30 days by ELISA",Other,20404124.0,
600,547273,2,3,,103178476,31593,Active,,,,,"Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as production of antibody IgG at 7 mg/kg, po BID for 90 days measured after 6 months by ELISA",Other,20404124.0,
601,547274,2,3,,103178476,31593,Active,,,,,"Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as production of antibody IgG2 at 7 mg/kg, po BID for 90 days measured after 6 months by ELISA",Other,20404124.0,
602,547275,2,3,,103178476,31593,Active,,,,,"Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Y assessed as production of antibody IgG at 7 mg/kg, po BID for 90 days measured after 6 months by ELISA",Other,20404124.0,
603,547276,2,3,,103178476,31593,Active,,,,,"Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Y assessed as production of antibody IgG2 at 7 mg/kg, po BID for 90 days measured after 6 months by ELISA",Other,20404124.0,
604,547277,2,4,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in mongrel dog assessed as reduction in INFgamma production in right atrium at 12 mg/kg, po BID after 180 days by semiquantitative RT-PCR",Other,20404124.0,
605,547278,2,4,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in mongrel dog assessed as reduction in IL10 production in right atrium at 12 mg/kg, po BID after 180 days by semiquantitative RT-PCR",Other,20404124.0,
606,547279,2,4,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in mongrel dog assessed as reduction in INFgamma production in right atrium at 7 mg/kg, po BID after 180 days by semiquantitative RT-PCR",Other,20404124.0,
607,547280,2,4,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in mongrel dog assessed as reduction in IL10 production in right atrium at 7 mg/kg, po BID after 180 days by semiquantitative RT-PCR",Other,20404124.0,
608,547508,2,3,,103178476,31593,Active,,,,,"Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as production of antibody IgG at 12 mg/kg, po BID for 90 days measured after 6 months by ELISA",Other,20404124.0,
609,547509,2,3,,103178476,31593,Active,,,,,"Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as production of antibody IgG2 at 12 mg/kg, po BID for 90 days measured after 6 months by ELISA",Other,20404124.0,
610,547510,2,3,,103178476,31593,Active,,,,,"Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Y assessed as production of antibody IgG at 12 mg/kg, po BID for 90 days measured after 6 months by ELISA",Other,20404124.0,
611,547511,2,3,,103178476,31593,Active,,,,,"Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Y assessed as production of antibody IgG2 at 12 mg/kg, po BID for 90 days measured after 6 months by ELISA",Other,20404124.0,
612,548108,1,3,,103178476,31593,Unspecified,,,,,Selectivity for Trypanosoma cruzi triosephosphate isomerase over human triosephosphate isomerase,Other,20889239.0,
613,548109,6,1,,103178476,31593,Active,,,7.4,ID50,Antiparasitic activity against Trypanosoma cruzi T2 epimastigotes assessed as growth inhibition,Confirmatory,20889239.0,
614,548110,2,3,,103178476,31593,Active,,,,,Antiparasitic activity against Trypanosoma cruzi T2 epimastigotes assessed as growth inhibition at 25 uM after 5 days,Other,20889239.0,
615,548112,3,8,,103178476,31593,Inconclusive,1730005.0,,,,Inhibition of Trypanosoma cruzi triosephosphate isomerase at 100 uM after 2 hrs,Other,20889239.0,
616,548113,2,9,,103178476,31593,Unspecified,1730005.0,,,,Inhibition of Trypanosoma cruzi triosephosphate isomerase at 400 uM after 2 hrs,Other,20889239.0,
617,548280,6,1,,103178476,31593,Active,,,30.0,EC50,Antimicrobial activity against Trypanosoma brucei,Confirmatory,20439607.0,
618,548281,5,2,,103178476,31593,Unspecified,,,154.0,EC50,Antimicrobial activity against Trypanosoma brucei NfxR1,Confirmatory,20439607.0,
619,548282,7,1,,103178476,31593,Unspecified,,,155.0,EC50,Antimicrobial activity against Trypanosoma brucei NfxR2,Confirmatory,20439607.0,
620,548283,2,3,,103178476,31593,Unspecified,,,,,Selectivity ratio of EC50 for Trypanosoma brucei NfxR1 to EC50 for Trypanosoma brucei,Other,20439607.0,
621,548284,2,3,,103178476,31593,Unspecified,,,,,Selectivity ratio of EC50 for Trypanosoma brucei NfxR2 to EC50 for Trypanosoma brucei,Other,20439607.0,
622,558399,6,1,,103178476,31593,Active,,,0.0018,IC50,Antiprotozoal activity against Trypanosoma cruzi Tulahuen C2C4 amastigotes,Confirmatory,19364854.0,
623,563555,2,3,,103178476,31593,Unspecified,,,,,"Toxicity in CH3/He(H-2k) mouse assessed as effect on creatine kinase level at 100 mg/kg/day, po",Other,20457822.0,
624,563559,2,3,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in Swiss-Webster mouse assessed as decrease in parasite-induced weight loss at 100 mg/kg/day, ip administered 5 days post-infection for 10 consecutive days measured on day 120",Other,20457822.0,
625,563560,2,4,,103178476,31593,Unspecified,,,,,"Cardiotoxicity in CH3/He(H-2k) mouse assessed as effect on heart rate level at 100 mg/kg/day, po",Other,20457822.0,
626,563562,2,3,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y bloodstream forms infected in Swiss-Webster mouse assessed as decrease in parasite load at 100 mg/kg/day, po administered 5 days postinfection for 10 alternate days measured after 31 days",Other,20457822.0,
627,563565,2,3,,103178476,31593,Unspecified,,,,,Cytotoxicity against Swiss-Webster mouse assessed as effect on creatine kinase at 100 mg/kg/day measured after 14 days postinfection,Other,20457822.0,
628,563566,2,3,,103178476,31593,Unspecified,,,,,Hepatotoxicity against Swiss-Webster mouse assessed as GPT at 100 mg/kg/day measured after 14 days postinfection,Other,20457822.0,
629,563570,2,3,,103178476,31593,Unspecified,,,,,"Toxicity in CH3/He(H-2k) mouse assessed as mortality at cumulative dose of 100 mg/kg, po measured after 48 hrs",Other,20457822.0,
630,564076,5,2,,103178476,31593,Active,,,7.65,IC50,Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes after 24 hrs by light microscopy,Confirmatory,20457822.0,
631,564077,5,2,,103178476,31593,Inconclusive,,,,IC50,Antitrypanosomal activity against Trypanosoma cruzi 762 epimastigotes after 24 hrs by light microscopy,Confirmatory,20457822.0,
632,564078,5,2,,103178476,31593,Active,,,12.57,IC50,Antitrypanosomal activity against Trypanosoma cruzi 855 epimastigotes after 24 hrs by light microscopy,Confirmatory,20457822.0,
633,564079,5,2,,103178476,31593,Active,,,7.9,IC50,Antitrypanosomal activity against Trypanosoma cruzi 875 epimastigotes after 24 hrs by light microscopy,Confirmatory,20457822.0,
634,564080,5,2,,103178476,31593,Active,,,3.96,IC50,Antitrypanosomal activity against Trypanosoma cruzi 956 epimastigotes after 24 hrs by light microscopy,Confirmatory,20457822.0,
635,564081,5,2,,103178476,31593,Active,,,13.7,IC50,Antitrypanosomal activity against Trypanosoma cruzi 958 epimastigotes after 24 hrs by light microscopy,Confirmatory,20457822.0,
636,564733,5,2,,103178476,31593,Active,,,6.44,IC50,Antitrypanosomal activity against Trypanosoma cruzi 960 epimastigotes after 24 hrs by light microscopy,Confirmatory,20457822.0,
637,564734,5,2,,103178476,31593,Active,,,5.3,IC50,Antitrypanosomal activity against Trypanosoma cruzi MS1523 epimastigotes after 24 hrs by light microscopy,Confirmatory,20457822.0,
638,564735,5,2,,103178476,31593,Active,,,5.06,IC50,Antitrypanosomal activity against Trypanosoma cruzi RBVIII epimastigotes after 24 hrs by light microscopy,Confirmatory,20457822.0,
639,564744,2,3,,103178476,31593,Unspecified,,,,,"Toxicity in CH3/He(H-2k) mouse assessed as mortality at cumulative dose of 200 mg/kg, ip measured after 48 hrs",Other,20457822.0,
640,564745,2,3,,103178476,31593,Unspecified,,,,,"Toxicity in female Swiss-Webster mouse assessed as mortality at cumulative dose of 200 mg/kg, ip measured after 48 hrs",Other,20457822.0,
641,564746,2,3,,103178476,31593,Unspecified,,,,,"Toxicity in male Swiss-Webster mouse assessed as mortality at cumulative dose of 200 mg/kg, ip measured after 48 hrs",Other,20457822.0,
642,564747,2,3,,103178476,31593,Unspecified,,,,,"Toxicity in male Swiss-Webster mouse assessed as weight loss at cumulative dose of 200 mg/kg, ip measured after 48 hrs",Other,20457822.0,
643,564756,2,3,,103178476,31593,Inactive,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y bloodstream forms infected in Swiss-Webster mouse assessed as decrease in parasite load at 100 mg/kg/day, po administered 8 days postinfection measured on day 2",Other,20457822.0,
644,564757,2,3,,103178476,31593,Inactive,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y bloodstream forms infected in Swiss-Webster mouse assessed as survival of mouse at 100 mg/kg/day, ip administered 8 days postinfection measured on day 120",Other,20457822.0,
645,564764,2,3,,103178476,31593,Inactive,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Columbian bloodstream forms infected in C3H mouse assessed as decrease in parasite load at 100 mg/kg/day, ip administered 21 days postinfection measured on day 46",Other,20457822.0,
646,564765,2,3,,103178476,31593,Unspecified,,,,,"Hepatotoxicity in Swiss-Webster mouse assessed as effect on GPT level at 25 mg/kg/day, ip administered 21 days postinfection measured on day 120",Other,20457822.0,
647,564766,2,3,,103178476,31593,Unspecified,,,,,"Hepatotoxicity in Swiss-Webster mouse assessed as effect on GPT level at 50 mg/kg/day, ip administered 21 days postinfection measured on day 120",Other,20457822.0,
648,564767,2,3,,103178476,31593,Unspecified,,,,,"Hepatotoxicity in Swiss-Webster mouse assessed as increased GPT level at 100 mg/kg/day, ip administered 21 days postinfection measured on day 120",Other,20457822.0,
649,564777,2,3,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Columbian bloodstream forms infected in C3H mouse assessed as survival of mouse at 100 mg/kg/day, po administered 5 days postinfection for 10 consecutive days measured after 31 days",Other,20457822.0,
650,564778,2,3,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Columbian bloodstream forms infected in C3H mouse assessed as decrease in parasite load at 100 mg/kg/day, ip administered 5 days postinfection for 10 consecutive days measured after 31 days",Other,20457822.0,
651,564779,2,3,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Columbian bloodstream forms infected in C3H mouse assessed as survival of mouse at 100 mg/kg/day, ip administered 5 days postinfection for 10 consecutive days measured after 31 days",Other,20457822.0,
652,575180,4,2,,103178476,31593,Active,,,3.7,IC50,Antimicrobial activity against Trypanosoma cruzi infected in rat L6E9 myoblasts assessed as inhibition of [3H]uracil incorporation by giemsa staining,Confirmatory,20625148.0,
653,575883,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of hypersensitivity on day 7 to 10,Other,20823286.0,
654,575884,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of dermatitis with cutaneous eruptions on day 7 to 10,Other,20823286.0,
655,575885,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of myalgias,Other,20823286.0,
656,575886,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of arthralgias,Other,20823286.0,
657,575887,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of lymphadenopathy,Other,20823286.0,
658,575888,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of polyneuropathy on 4th week of treatment,Other,20823286.0,
659,575889,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of paresthesias on 4th week of treatment,Other,20823286.0,
660,575890,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of polyneuritis on 4th week of treatment,Other,20823286.0,
661,575891,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of thrombopenic purpura after 2nd week of treatment,Other,20823286.0,
662,576077,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of agranulocytosis after 2nd week of treatment,Other,20823286.0,
663,576078,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Headache at 5 mg/kg/day for 60 days,Other,20823286.0,
664,576079,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Dermatological disorder at 5 mg/kg/day for 60 days,Other,20823286.0,
665,576080,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Urticaria at 5 mg/kg/day for 60 days,Other,20823286.0,
666,576081,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Petechial rash at 5 mg/kg/day for 60 days,Other,20823286.0,
667,576082,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Itching at 5 mg/kg/day for 60 days,Other,20823286.0,
668,576083,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Palmar-plantar rash at 5 mg/kg/day for 60 days,Other,20823286.0,
669,576084,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Edema at 5 mg/kg/day for 60 days,Other,20823286.0,
670,576085,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Dyshidrosis at 5 mg/kg/day for 60 days,Other,20823286.0,
671,576086,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Hyperpigmentation at 5 mg/kg/day for 60 days,Other,20823286.0,
672,576087,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Erythema nodosum at 5 mg/kg/day for 60 days,Other,20823286.0,
673,576088,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Mucositis at 5 mg/kg/day for 60 days,Other,20823286.0,
674,576089,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Anorexia at 5 mg/kg/day for 60 days,Other,20823286.0,
675,576090,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Weakness at 5 mg/kg/day for 60 days,Other,20823286.0,
676,576091,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Fever at 5 mg/kg/day for 60 days,Other,20823286.0,
677,576092,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Articular involvement at 5 mg/kg/day for 60 days,Other,20823286.0,
678,576093,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Arthromyalgia at 5 mg/kg/day for 60 days,Other,20823286.0,
679,576094,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Arthritis at 5 mg/kg/day for 60 days,Other,20823286.0,
680,576095,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Paresthesia at 5 mg/kg/day for 60 days,Other,20823286.0,
681,576096,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Gastrointestinal disorders at 5 mg/kg/day for 60 days,Other,20823286.0,
682,576097,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Epigastralgia at 5 mg/kg/day for 60 days,Other,20823286.0,
683,576098,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Nausea at 5 mg/kg/day for 60 days,Other,20823286.0,
684,576099,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Dysphagia at 5 mg/kg/day for 60 days,Other,20823286.0,
685,576100,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Abdominal bloating at 5 mg/kg/day for 60 days,Other,20823286.0,
686,576101,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Heartburn at 5 mg/kg/day for 60 days,Other,20823286.0,
687,576102,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Vomiting at 5 mg/kg/day for 60 days,Other,20823286.0,
688,576103,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Diarrhea at 5 mg/kg/day for 60 days,Other,20823286.0,
689,576104,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Aphthous stomatitis at 5 mg/kg/day for 60 days,Other,20823286.0,
690,576105,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Hearing impairment at 5 mg/kg/day for 60 days,Other,20823286.0,
691,576106,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of cardiac disorders at 5 mg/kg/day for 60 days,Other,20823286.0,
692,576107,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of degree 1 esophagopathy at 5 mg/kg/day for 60 days,Other,20823286.0,
693,576108,1,3,,103178476,31593,Unspecified,,,,,Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of dolichocolon at 5 mg/kg/day for 60 days,Other,20823286.0,
694,576828,4,2,,103178476,31593,Active,,,15.83,IC50,Antitrypanosomal activity against epimastigote of Trypanosoma cruzi Maracay after 72 hrs,Confirmatory,21229977.0,
695,576829,4,2,,103178476,31593,Active,,,13.56,IC50,Cytotoxicity against african green monkey Vero cells after 72 hrs by trypan blue assay,Confirmatory,21229977.0,
696,576830,1,5,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for epimastigote of Trypanosoma cruzi Maracay",Other,21229977.0,
697,576831,1,4,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi infected in african green monkey Vero cells assessed as reduction of parasite infection rate at IC25 after 10 days,Other,21229977.0,
698,576832,1,4,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi infected in african green monkey Vero cells assessed as reduction of amastigote number per infected cell at IC25 after 10 days relative to control,Other,21229977.0,
699,576833,1,4,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi infected in african green monkey Vero cells assessed as reduction of trypomastigote number per infected cell at IC25 after 10 days relative to control,Other,21229977.0,
700,576835,1,3,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against trypomastigote of Trypanosoma cruzi infected in BALB/c mouse assessed as increase of host survival at 1 mg/kg, ip for 5 days administered 7 days after infection",Other,21229977.0,
701,576837,1,3,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against trypomastigote of Trypanosoma cruzi infected in BALB/c mouse assessed as reduction of anti-Trypanosoma cruzi antibody level at 1 mg/kg, ip qd for 5 days measured after 120 days postinfection by ELISA",Other,21229977.0,
702,576939,2,3,,103178476,31593,Unspecified,,,,,"Antimicrobial activity against Trypanosoma cruzi Tulahuen infected in Swiss mouse assessed as mouse mortality at 60 mg/kg/day, po for 6 days per week until completion of 60 compound doses administered 5 days post infection",Other,20566772.0,
703,576940,2,3,,103178476,31593,Unspecified,,,,,"Antimicrobial activity against Trypanosoma cruzi Tulahuen infected in Swiss mouse assessed as parasite DNA level at 60 mg/kg/day, po for 6 days per week until completion of 60 compound doses administered 5 days post infection measured 30 days post dose by PCR amplification method",Other,20566772.0,
704,576942,2,3,,103178476,31593,Unspecified,,,,,"Antimicrobial activity against Trypanosoma cruzi Tulahuen infected in Swiss mouse assessed as parasite DNA level at 60 mg/kg/day, po for 6 days per week until completion of 60 compound doses administered 5 days post infection measured 180 days post dose by PCR amplification method",Other,20566772.0,
705,576947,2,4,,103178476,31593,Active,,,,,"Antimicrobial activity against Trypanosoma cruzi Tulahuen infected in Swiss mouse assessed as reduction in blood parasite load at 60 mg/kg/day, po for 6 days per week until completion of 60 compound doses administered 5 days post infection",Other,20566772.0,
706,576949,2,3,,103178476,31593,Active,,,,,"Antimicrobial activity against Trypanosoma cruzi Tulahuen infected in Swiss mouse assessed as reduction in parasite specific antibodies at 60 mg/kg/day, po for 6 days per week until completion of 60 compound doses administered 5 days post infection measured 45 days post dose by ELISA based serological study",Other,20566772.0,
707,576951,2,3,,103178476,31593,Unspecified,,,,,"Antimicrobial activity against Trypanosoma cruzi Tulahuen infected in Swiss mouse assessed as reduction in parasite specific antibodies at 60 mg/kg/day, po for 6 days per week until completion of 60 compound doses administered 5 days post infection measured 180 days post dose by ELISA based serological study",Other,20566772.0,
708,577156,2,3,,103178476,31593,Active,,,,,"Antimicrobial activity against Trypanosoma cruzi Tulahuen infected in Swiss mouse assessed as reduction in reduction in parasite induced histopathological changes in skeletal muscle at 60 mg/kg/day, po for 6 days per week until completion of 60 compound doses administered 5 days post infection by hematoxylin-eosin staining",Other,20566772.0,
709,577157,2,4,,103178476,31593,Active,,,,,"Antimicrobial activity against Trypanosoma cruzi Tulahuen infected in Swiss mouse assessed as reduction in reduction in parasite induced histopathological changes in liver at 60 mg/kg/day, po for 6 days per week until completion of 60 compound doses administered 5 days post infection by hematoxylin-eosin staining",Other,20566772.0,
710,577160,2,4,,103178476,31593,Unspecified,,,,,"Toxicity in Trypanosoma cruzi Tulahuen infected in Swiss mouse assessed as changes in liver SGOT enzyme levels at 60 mg/kg/day, po for 6 days per week until completion of 60 compound doses administered 5 days post infection by hematoxylin-eosin staining",Other,20566772.0,
711,580575,2,3,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in C57BL/6 mouse assessed as increase in survival of mouse at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection",Other,19001113.0,
712,580576,2,3,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in C57BL/6 mouse assessed as mean survival time at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection",Other,19001113.0,
713,580577,2,3,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in C57BL/6 mouse assessed as cure rate in mouse at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection",Other,19001113.0,
714,580581,2,3,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD4+ T-lymphocyte knockout C57BL/6 mouse assessed as increase in survival of mouse at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection",Other,19001113.0,
715,580582,2,3,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD4+ T-lymphocyte knockout C57BL/6 mouse assessed as mean survival time at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection",Other,19001113.0,
716,580583,2,3,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD4+ T-lymphocyte knockout C57BL/6 mouse assessed as cure rate in mouse at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection",Other,19001113.0,
717,580587,2,3,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD8+ T-lymphocyte knockout C57BL/6 mouse assessed as increase in survival of mouse at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection",Other,19001113.0,
718,580588,2,3,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD8+ T-lymphocyte knockout C57BL/6 mouse assessed as mean survival time at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection",Other,19001113.0,
719,580589,2,3,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD8+ T-lymphocyte knockout C57BL/6 mouse assessed as cure rate in mouse at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection",Other,19001113.0,
720,580593,2,3,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in B-lymphocyte knockout C57BL/6 mouse assessed as increase in survival of mouse at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection",Other,19001113.0,
721,580594,2,3,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in B-lymphocyte knockout C57BL/6 mouse assessed as mean survival time at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection",Other,19001113.0,
722,580595,2,3,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in B-lymphocyte knockout C57BL/6 mouse assessed as cure rate in mouse at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection",Other,19001113.0,
723,580599,2,3,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD4+ T-lymphocyte knockout C57BL/6 mouse assessed as occurrence of subpatent parasitemia level in mouse at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 4 to 24 days post infection",Other,19001113.0,
724,580600,2,3,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD4+ T-lymphocyte knockout C57BL/6 mouse assessed as occurrence of subpatent parasitemia level in mouse at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 4 to 24 days post infection",Other,19001113.0,
725,580602,2,3,,103178476,31593,Inactive,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD4+ T-lymphocyte knockout C57BL/6 mouse assessed as reactivation of parasite in mouse at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 11 days post infection",Other,19001113.0,
726,580603,2,3,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD8+ T-lymphocyte knockout C57BL/6 mouse assessed as occurrence of subpatent level of parasitemia at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection",Other,19001113.0,
727,580660,2,3,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD8+ T-lymphocyte knockout C57BL/6 mouse assessed as occurrence of subpatent level of parasitemia at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post infection",Other,19001113.0,
728,580661,2,3,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD8+ T-lymphocyte knockout C57BL/6 mouse assessed as occurrence of low level of circulating parasites at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 15 days post infection",Other,19001113.0,
729,580663,2,3,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD8+ T-lymphocyte knockout C57BL/6 mouse assessed as number of mouse with reactivated parasite at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection",Other,19001113.0,
730,580665,2,3,,103178476,31593,Inactive,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in B-lymphocyte knockout C57BL/6 mouse assessed as number of mouse with reactivation of infection at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 22 days post infection",Other,19001113.0,
731,580667,2,3,,103178476,31593,Inactive,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD4+ T-lymphocyte knockout C57BL/6 mouse assessed as reactivation of parasite in mouse at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post infection",Other,19001113.0,
732,580668,2,3,,103178476,31593,Inactive,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD4+ T-lymphocyte knockout C57BL/6 mouse assessed as reactivation of parasite in mouse at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection",Other,19001113.0,
733,582595,4,2,,103178476,31593,Active,,,1.97,IC50,Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C2C4 trypomastigote after 48 hrs,Confirmatory,19564359.0,
734,588334,1,1,,56320744,31593,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
735,588335,1,1,,56320744,31593,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
736,588342,1,1,,56320744,31593,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
737,588352,1,2,,56320744,31593,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
738,588354,1,1,,56320744,31593,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
739,588358,1,2,,56320744,31593,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
740,588382,1,2,,56320744,31593,Inconclusive,,,9.2683,Potency,qHTS of small molecules that selectively kill Giardia lamblia: Hit Validation in HepG2 cytotox,Confirmatory,,
741,588391,1,1,,56320744,31593,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
742,588397,1,1,,56320744,31593,Active,,,1.2964,Potency,qHTS of small molecules that selectively kill Giardia lamblia: Hit Validation.,Confirmatory,,
743,588405,1,1,,56320744,31593,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
744,588413,1,2,,56320744,31593,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
745,588436,1,1,,56320744,31593,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
746,588453,1,1,,56320744,31593,Inconclusive,8659577.0,58819.0,79.4328,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
747,588456,1,1,,56320744,31593,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
748,588458,1,1,,56320744,31593,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
749,588473,1,1,,56320744,31593,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
750,588473,1,1,,56320744,31593,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
751,588475,1,2,,56320744,31593,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
752,588475,1,2,,56320744,31593,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
753,588478,1,2,,124800483,31593,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
754,588489,1,1,,56320744,31593,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
755,588492,1,1,,56320744,31593,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
756,588493,1,2,,56320744,31593,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
757,588497,1,2,,56320744,31593,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
758,588497,1,2,,56320744,31593,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
759,588497,1,2,,56320744,31593,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
760,588499,1,3,,56320744,31593,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
761,588499,1,3,,56320744,31593,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
762,588499,1,3,,56320744,31593,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
763,588501,1,2,,56320744,31593,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
764,588501,1,2,,56320744,31593,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
765,588501,1,2,,56320744,31593,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
766,588511,1,2,,56320744,31593,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
767,588549,1,1,,56320744,31593,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
768,588579,1,1,,29217996,31593,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
769,588579,1,1,,56320744,31593,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
770,588590,1,1,,56320744,31593,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
771,588591,1,1,,56320744,31593,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
772,588621,1,1,,56320744,31593,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
773,588627,1,1,,56320744,31593,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
774,588664,1,2,,56320744,31593,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
775,588664,1,2,,56320744,31593,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
776,588674,1,2,,56320744,31593,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
777,588675,1,1,,56320744,31593,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
778,588676,1,1,,56320744,31593,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
779,588689,1,1,,56320744,31593,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
780,588692,2,1,,56320744,31593,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
781,588726,1,2,,56320744,31593,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
782,588727,1,1,,56320744,31593,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
783,588795,1,1,,56320744,31593,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
784,588814,1,3,,56320744,31593,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
785,588819,1,4,,56320744,31593,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
786,588834,2,1,,144205917,31593,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
787,588850,1,1,,56320744,31593,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
788,588852,1,3,,56320744,31593,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
789,588855,1,1,,56320744,31593,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
790,588856,1,1,,56320744,31593,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
791,593266,3,2,,103178476,31593,Active,,,2.7680000000000002,IC50,Antiparasitic activity against Trypanosoma cruzi amastigotes infected in gamma-irradiated vero cells assessed as growth inhibition by fluorescence assay,Confirmatory,21419634.0,
792,595452,3,2,,103178476,31593,Active,,,1.35,IC50,Antiparasitic activity against intracellular amastigotes of Trypanosoma cruzi Tulahuen C2C4 expressing LacZ gene infected in rat L6 cells after 96 hrs by photometrically,Confirmatory,21348447.0,
793,596493,3,2,,103178476,31593,Active,,,1.95,IC50,Antiparasitic activity against Trypanosoma cruzi Tulahuen C4 amastigotes,Confirmatory,21456549.0,
794,596806,3,2,,103178476,31593,Active,,,15.8,IC50,Antitrypanosomal activity against epimastigote form of Trypanosoma cruzi assessed as inhibition of parasite growth,Confirmatory,21466157.0,
795,596807,3,2,,103178476,31593,Active,,,13.6,IC50,Cytotoxicity against african green monkey Vero cells assessed as cell viability after 72 hrs by FACS analysis,Confirmatory,21466157.0,
796,596808,1,4,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for epimastigote form of Trypanosoma cruzi",Other,21466157.0,
797,596809,1,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against metacyclic forms of Trypanosoma cruzi infected in vero cells assessed as inhibition of infection at IC25 concentration after 12 hrs,Other,21466157.0,
798,596810,1,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against metacyclic forms of Trypanosoma cruzi infected in vero cells assessed as decrease in trypomastigotes at IC25 concentration after 12 hrs,Other,21466157.0,
799,596811,1,3,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against blood trypomastigote forms of Trypanosoma cruzi infected in BALB/c mouse assessed as mouse survival rate at 1 mg/kg, ip administered 7 days postinfection once daily for 5 days",Other,21466157.0,
800,597234,1,6,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi CL Brener clone infected in Swiss albino mouse assessed as increase of mouse survival days at 50 mg/kg/day, po relative to control",Other,21506600.0,
801,597236,1,3,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in Swiss albino mouse assessed as increase of mouse survival days at 50 mg/kg/day, po relative to control",Other,21506600.0,
802,597239,1,6,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi CL Brener clone infected in BALB/c mouse assessed as increase of mouse survival days at 50 mg/kg/day, po relative to control",Other,21506600.0,
803,597246,1,3,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Y infected in Swiss albino mouse assessed as reduction of microbial antibody level at 50 mg/kg/day, po by Wilconxon test",Other,21506600.0,
804,597248,1,6,,103178476,31593,Inactive,,,,,"Antitrypanosomal activity against Trypanosoma cruzi CL Brener clone infected in BALB/c mouse assessed as reduction of microbial antibody level at 50 mg/kg/day, po after 90 days by Wilconxon test",Other,21506600.0,
805,598281,3,2,,103178476,31593,Active,,,22.58,IC50,Antiprotozoan activity against Giardia intestinalis IMSS:0696:1 trophozoites after 48 hrs,Confirmatory,21397502.0,
806,598282,3,2,,103178476,31593,Active,,,18.62,IC50,Antiprotozoan activity against Trichomonas vaginalis GT3 trophozoites after 48 hrs,Confirmatory,21397502.0,
807,598283,3,2,,103178476,31593,Active,,,4.27,IC50,Antiprotozoan activity against Entamoeba histolytica HM1-IMSS trophozoites after 48 hrs,Confirmatory,21397502.0,
808,598284,3,2,,103178476,31593,Unspecified,,,50.0,IC50,Antileishmanial activity against Leishmania mexicana MHOM/MX/ISETGS promastigotes after 72 hrs by neubauer chamber,Confirmatory,21397502.0,
809,598285,3,2,,103178476,31593,Active,,,34.38,IC50,Antitrypanosomal activity against Trypanosoma cruzi MHOM/MX/1994/Ninoa epimastigotes after 72 hrs by neubauer chamber,Confirmatory,21397502.0,
810,598286,3,2,,103178476,31593,Active,,,4.07,IC50,Antimalarial activity against Plasmodium berghei schizonts isolated from parasitized erythrocytes infected Wistar rat measured 16 hrs post compound exposure,Confirmatory,21397502.0,
811,598287,3,2,,103178476,31593,Active,,,14.0,CC50,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay,Confirmatory,21397502.0,
812,601812,3,2,,103178476,31593,Active,,,37.3,IC50,Trypanocidal activity against Trypanosoma cruzi Y epimastigotes after 72 hrs by MTT assay,Confirmatory,21506530.0,
813,602123,1,1,,56320744,31593,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
814,602141,1,1,,56320744,31593,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
815,602162,1,1,,56320744,31593,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
816,602163,1,1,,56320744,31593,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
817,602179,1,2,,56320744,31593,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
818,602229,1,1,,56320744,31593,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
819,602233,1,1,,56320744,31593,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
820,602244,1,2,,56320744,31593,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
821,602247,1,2,,56320744,31593,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
822,602248,1,2,,56320744,31593,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
823,602250,1,2,,56320744,31593,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
824,602252,1,1,,56320744,31593,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
825,602252,1,1,,56320744,31593,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
826,602261,1,1,,56320744,31593,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
827,602274,1,2,,56320744,31593,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
828,602281,1,1,,56320744,31593,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
829,602281,1,1,,56320744,31593,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
830,602310,1,2,,56320744,31593,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
831,602313,1,1,,56320744,31593,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
832,602329,1,1,,56320744,31593,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
833,602332,1,1,,29217996,31593,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
834,602332,1,1,,56320744,31593,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
835,602340,1,2,,56320744,31593,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
836,602342,2,1,,56320744,31593,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
837,602346,1,1,,56320744,31593,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
838,602363,1,1,,56320744,31593,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
839,602393,1,1,,56320744,31593,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
840,602396,1,2,,56320744,31593,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
841,602399,1,2,,56320744,31593,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
842,602405,1,1,,56320744,31593,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
843,602410,1,1,,56320744,31593,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
844,602429,1,1,,56320744,31593,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
845,602438,1,1,,56320744,31593,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
846,602440,1,1,,56320744,31593,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
847,602449,1,2,,56320744,31593,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
848,602481,1,1,,56320744,31593,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
849,603333,3,2,,103178476,31593,Unspecified,,,103.6,IC50,Antitrypanosomal activity against bloodstream trypomastigote form of Trypanosoma cruzi Y isolated from albino mouse blood after 24 hrs,Confirmatory,21450374.0,
850,613444,3,2,,103178476,31593,Active,,,5.8,IC50,Trypanocidal activity against epimastigote form of Trypanosoma cruzi assessed as [3H]thymidine uptake after 72 hrs by liquid scintillation counter,Confirmatory,21664012.0,
851,613445,3,2,,103178476,31593,Active,,,34.1,IC50,Trypanocidal activity against bloodstream trypomastigote form of Trypanosoma cruzi after 24 hrs,Confirmatory,21664012.0,
852,613446,3,2,,103178476,31593,Active,,,3.6,IC50,Trypanocidal activity against intracellular amastigotes form of Trypanosoma cruzi expressing beta-galactosidase infected in mouse J774 cells on day 7,Confirmatory,21664012.0,
853,613447,3,3,,103178476,31593,Unspecified,,,706.0,CC50,Cytotoxicity against african green monkey COS7 cells after 24 hrs by MTT assay,Confirmatory,21664012.0,
854,613448,1,3,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of CC50 for african green monkey COS7 cells to IC50 for bloodstream trypomastigote form of Trypanosoma cruzi",Other,21664012.0,
855,613449,1,4,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of CC50 for african green monkey COS7 cells to IC50 for intracellular amastigotes form of Trypanosoma cruzi",Other,21664012.0,
856,616289,3,2,,103178476,31593,Active,,,1.8,IC50,Antiparasitic activity against Trypanosoma cruzi Tulahuen C4 amastigotes stage forms incubated for 96 hrs by beta-galactosidase reporter gene assay,Confirmatory,21846091.0,
857,621152,3,2,,103178476,31593,Active,,,0.8859999999999999,IC50,Antiprotozoal activity against Trypanosoma cruzi Tulahuen C4 at pH 7.4 by microplate assay,Confirmatory,21868222.0,
858,621157,1,4,,103178476,31593,Inconclusive,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma cruzi Tulahuen C4",Other,21868222.0,
859,623721,3,2,,103178476,31593,Active,,,3.8,IC50,Trypanocidal activity against intracellular amastigote form of Trypanosoma cruzi Tulahuen expressing beta-galactosidase infected in mouse L929 cells after 7 days by microplate reader analysis,Confirmatory,21940071.0,
860,623870,1,1,,56320744,31593,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
861,623870,1,1,,56320744,31593,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
862,623877,1,1,,56320744,31593,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
863,623901,1,1,,56320744,31593,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
864,624030,1,2,,29217996,31593,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
865,624031,1,2,,29217996,31593,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
866,624032,1,2,,29217996,31593,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
867,624037,1,3,,56320744,31593,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
868,624038,1,3,,56320744,31593,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
869,624040,1,3,,56320744,31593,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
870,624044,1,2,,29217996,31593,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
871,624125,1,4,,56320744,31593,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
872,624126,1,3,,56320744,31593,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
873,624127,1,2,,56320744,31593,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
874,624168,1,1,,56320744,31593,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
875,624169,1,1,,56320744,31593,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
876,624170,1,1,,29217996,31593,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
877,624170,1,1,,56320744,31593,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
878,624171,1,1,,56320744,31593,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
879,624172,1,1,,29217996,31593,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
880,624172,1,1,,56320744,31593,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
881,624173,1,3,,29217996,31593,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
882,624173,1,3,,56320744,31593,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
883,624178,1,1,,56320744,31593,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
884,624202,1,1,,56320744,31593,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
885,624204,1,2,,56320744,31593,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
886,624246,1,1,,56320744,31593,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
887,624256,1,2,,56320744,31593,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
888,624263,1,1,,56320744,31593,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
889,624263,1,1,,56320744,31593,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
890,624267,1,2,,56320744,31593,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
891,624267,1,2,,56320744,31593,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
892,624268,1,3,,56320744,31593,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
893,624288,1,1,,56320744,31593,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
894,624296,1,1,,29217996,31593,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
895,624296,1,1,,56320744,31593,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
896,624297,1,1,,29217996,31593,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
897,624297,1,1,,56320744,31593,Inactive,7705682.0,51053.0,17.7828,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
898,624304,1,2,,56320744,31593,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
899,624330,1,2,,56320744,31593,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
900,624352,1,1,,56320744,31593,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
901,624354,1,1,,56320744,31593,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
902,624377,1,1,,56323658,31593,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
903,624414,1,1,,56320744,31593,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
904,624415,1,2,,56320744,31593,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
905,624416,1,1,,56323658,31593,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
906,624417,1,1,,56320744,31593,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
907,624418,1,1,,56320744,31593,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
908,624463,1,1,,56320744,31593,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
909,624464,1,1,,56320744,31593,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
910,624465,1,1,,56320744,31593,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
911,624466,1,3,,56323658,31593,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
912,624467,1,1,,56323658,31593,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
913,624483,1,1,,56320744,31593,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
914,626316,3,2,,103178476,31593,Active,,,2.55,IC50,Antiparasitic activity against trypomastigotes of Trypanosoma cruzi Tulahuen C2C4 expressing LacZ gene infected in rat L6 cells after 96 hrs,Confirmatory,21937228.0,
915,626321,1,4,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma cruzi Tulahuen C2C4 trypomastigotes",Other,21937228.0,
916,630656,3,2,,103178476,31593,Active,,,20.84,IC50,Antitrypanosomal activity against epimastigote form of Trypanosoma cruzi Y after 5 days by spectrophotometer analysis,Confirmatory,21962987.0,
917,632297,3,2,,103178476,31593,Active,,,1.32,IC50,Antitrypanosomal activity against blood stream form of Trypanosoma cruzi Tulahuen C4 infected in rat L6 cells after 72 hrs by alamar blue assay,Confirmatory,22023653.0,
918,632303,1,4,,103178476,31593,Unspecified,,,,,Ratio of benznidazole IC50 to compound IC50 for Trypanosoma cruzi Tulahuen C4 infected in rat L6 cells after 72 hrs by alamar blue assay,Other,22023653.0,
919,634123,3,2,,103178476,31593,Unspecified,,,125.0,IC50,Antitrypanosomal activity against Trypanosoma cruzi Tulaheun infected in monkey LLC-MK2 cells after 4 days by beta-galactosidase reporter gene assay,Confirmatory,22154559.0,
920,635853,3,3,,103178476,31593,Active,,,1.1340000000000001,IC50,Antitrypanosomal activity against trypomastigote form of Trypanosoma cruzi Tulahuen C2C4 expressing Lac Z infected in rat L6 cells after 96 hrs by spectrophotometry,Confirmatory,22061825.0,
921,637700,3,2,,103178476,31593,Unspecified,,,,,Trypanocidal activity against trypomastigote Trypanosoma cruzi Tulahuen C2C4 infected in L6 cells after 96 hrs by beta-galactosidase reporter gene assay,Other,22217867.0,
922,644366,3,3,,103178476,31593,Active,,,1.4,IC50,Antiprotozoal activity against Trypanosoma cruzi Tulahuen C2C4 amastigotes infected in rat L6 myoblasts after 96 hrs by CPRG/Nonidet-based spectrophotometry,Confirmatory,22285027.0,
923,651550,1,1,,56320744,31593,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
924,651560,1,1,,56320744,31593,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
925,651572,1,2,,56323658,31593,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
926,651582,1,1,,56320744,31593,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
927,651602,1,1,,56323658,31593,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
928,651602,1,1,,56323658,31593,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
929,651602,1,1,,56323658,31593,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
930,651610,2,1,,56323658,31593,Inactive,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
931,651631,4,1,,144205917,31593,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
932,651632,4,1,,144205917,31593,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
933,651633,4,1,,144205917,31593,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
934,651634,4,1,,144205917,31593,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
935,651635,1,3,,56320744,31593,Inconclusive,171543895.0,6311.0,39.8107,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
936,651636,1,1,,56320744,31593,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
937,651640,1,1,,56323658,31593,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
938,651644,1,1,,56320744,31593,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
939,651647,1,1,,56320744,31593,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
940,651654,1,1,,56320744,31593,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
941,651658,1,1,,56323658,31593,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
942,651661,2,1,,56323658,31593,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
943,651687,1,1,,56320744,31593,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
944,651699,1,1,,56320744,31593,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
945,651699,1,1,,56320744,31593,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
946,651702,1,2,,56320744,31593,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
947,651704,2,1,,56323658,31593,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
948,651710,1,1,,56323658,31593,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
949,651711,2,1,,56323658,31593,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
950,651718,1,2,,56323658,31593,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
951,651723,1,1,,56320744,31593,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
952,651724,1,1,,56320744,31593,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
953,651725,1,1,,56320744,31593,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
954,651768,1,2,,56320744,31593,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
955,651800,1,1,,56323658,31593,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
956,651819,1,1,,56320744,31593,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
957,651820,1,1,,56320744,31593,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
958,651821,2,4,,56323658,31593,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
959,651869,1,2,,124360168,31593,Active,,,,,Cidal vs. static assay: inhibition of T. cruzi (CAI/72) after prolonged treatment and treatment withdrawal Measured in Cell-Based System Using Imaging - 2138-08_Inhibitor_SinglePoint_DryPowder_Activity_Set2,Other,,
960,651877,1,2,,124360168,31593,Active,,,,,Cidal vs. static assay: inhibition of T. cruzi (CAI/72) after prolonged treatment and treatment withdrawal Measured in Cell-Based System Using Imaging - 2138-08_Inhibitor_SinglePoint_DryPowder_Activity,Other,,
961,651957,1,1,,56323658,31593,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
962,651958,1,1,,56323658,31593,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
963,651965,1,1,,56320744,31593,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
964,651999,1,1,,56320744,31593,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
965,652010,1,1,,56323658,31593,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
966,652017,1,1,,56323658,31593,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
967,652025,1,1,,56320744,31593,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
968,652039,1,1,,56323658,31593,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
969,652048,1,2,,56320744,31593,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
970,652048,1,2,,144205917,31593,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
971,652051,1,1,,56320744,31593,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
972,652051,1,1,,144205917,31593,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
973,652054,1,1,,56320744,31593,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
974,652067,1,4,,56323658,31593,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
975,652104,1,1,,56320744,31593,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
976,652105,1,1,,56320744,31593,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
977,652106,1,1,,56320744,31593,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
978,652115,1,1,,56323658,31593,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
979,652126,1,3,,56323658,31593,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
980,652154,1,1,,56323658,31593,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
981,652162,2,1,,56323658,31593,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
982,652163,1,1,,56323658,31593,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
983,652197,1,1,,56323658,31593,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
984,652257,1,1,,56323658,31593,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
985,652275,1,2,,124360168,31593,Active,,,0.153,AC50_uM,Inhibition of T.cruzi proliferation in culture Measured in Cell-Based System Using Plate Reader - 2138-01_Inhibitor_Dose_DryPowder_Activity_Set2,Confirmatory,,
986,652280,1,2,,124360168,31593,Inactive,,,,AC50_uM,NIH/3T3 (mouse embryonic fibroblast) toxicity Measured in Cell-Based System Using Plate Reader - 2138-02_Inhibitor_Dose_DryPowder_Activity_Set2,Confirmatory,,
987,656214,2,2,,103178476,31593,Active,,,2.1,IC50,Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 infected in african green monkey Vero cells expressing red fluorescent protein after 3 days by fluorescence analysis,Confirmatory,22414614.0,
988,656215,1,3,,103178476,31593,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells at 25 uM after 3 days,Other,22414614.0,
989,656216,1,3,,103178476,31593,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells at 12.5 uM after 3 days,Other,22414614.0,
990,656217,1,3,,103178476,31593,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells at 6.25 uM after 3 days,Other,22414614.0,
991,656218,2,2,,103178476,31593,Active,,,2.1,IC50,Cytotoxicity against african green monkey Vero cells after 3 days,Confirmatory,22414614.0,
992,660266,2,2,,103178476,31593,Unspecified,,,103.6,IC50,Trypanocidal activity against bloodstream form of Trypanosoma cruzi Y isolated from albino mouse blood after 24 hrs by neubauer chamber analysis,Confirmatory,22483633.0,
993,664488,2,2,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against intracellular amastigote stage of Trypanosoma cruzi Tulahuen C2C4 infected in rat L6 cells after 96 hrs by spectrophotometric analysis,Other,22352841.0,
994,666682,2,2,,103178476,31593,Active,,,0.122,IC50,Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C2C4 intracellular amastigotes infected in rat L6 cells after 4 days by photometry,Confirmatory,22727447.0,
995,666683,2,2,,103178476,31593,Active,,,10.8,IC50,Antitrypanosomal activity against bloodstream form of Trypanosoma cruzi Y trypomastigotes infected in Swiss mouse,Confirmatory,22727447.0,
996,666684,2,2,,103178476,31593,Unspecified,,,3840.7,IC50,Cytotoxicity against mouse J774 cells after 18 hrs by MTT assay,Confirmatory,22727447.0,
997,666686,1,3,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse J774 cells to IC50 for bloodstream form of Trypanosoma cruzi trypomastigote",Other,22727447.0,
998,669297,2,2,,103178476,31593,Active,,,6.5,IC50,Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes after 96 hrs by neubauer chamber,Confirmatory,22440015.0,
999,669298,2,2,,103178476,31593,Active,,,34.5,EC50,Antitrypanosomal activity against Trypanosoma cruzi Y trymastigotes infected in monkey LLC-MK2 cells after 24 hrs by Brenner counter method,Confirmatory,22440015.0,
1000,669299,2,2,,103178476,31593,Active,,,19.2,IC50,Antitrypanosomal activity against Trypanosoma cruzi Y amastigotes infected in monkey LLC-MK2 cells after 96 hrs by Geimsa staining method,Confirmatory,22440015.0,
1001,669300,2,2,,103178476,31593,Unspecified,,,614.7,CC50,Cytotoxicity against monkey LLC-MK2 cells after 96 hrs by sulforhodamine B assay,Confirmatory,22440015.0,
1002,669301,1,2,,103178476,31593,Unspecified,,,,,Toxicity in human RBC assessed as hemolysis after 3 hrs,Other,22440015.0,
1003,669302,1,3,,103178476,31593,Unspecified,,,,,Selectivity ratio of CC50 for monkey LLC-MK2 cells to IC50 for Trypanosoma cruzi Y amastigotes,Other,22440015.0,
1004,669304,1,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi Y trymastigotes infected in monkey LLC-MK2 cells after 24 hrs by Brenner counter method in presence of copalic,Other,22440015.0,
1005,669305,1,3,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi Y trymastigotes infected in monkey LLC-MK2 cells after 24 hrs by Brenner counter method in presence of beta-hydroxycopalic,Other,22440015.0,
1006,669380,2,2,,103178476,31593,Inconclusive,,,,IC50,Antileishmanial activity against Leishmania amazonensis MPRO/BR/1972/M1841-LV-79 after 72 hrs by MTT assay,Confirmatory,22559947.0,
1007,669381,2,2,,103178476,31593,Inconclusive,,,,IC50,Antileishmanial activity against Leishmania chagasi MHOM/BR/1974/PP75 after 72 hrs by MTT assay,Confirmatory,22559947.0,
1008,669382,2,2,,103178476,31593,Active,,,42.7,IC50,Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi after 72 hrs by MTT assay,Confirmatory,22559947.0,
1009,669383,2,2,,103178476,31593,Unspecified,,,1141.0,IC50,Cytotoxicity against Balb/c mouse peritoneal macrophages after 24 hrs by MTT assay,Confirmatory,22559947.0,
1010,669384,1,3,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for Balb/c mouse peritoneal macrophages to IC50 for epimastigotes of Trypanosoma cruzi",Other,22559947.0,
1011,671572,1,3,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Tulahuen infected in Swiss mouse model of chagas disease assessed as decrease in parasite level in blood at 100 mg/kg, po administered 8 day after post infection qd for 20 days",Other,22536986.0,
1012,671573,1,2,,103178476,31593,Active,,,,,"Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Tulahuen infected in Swiss mouse model of chagas disease assessed as increase in host survival at 100 mg/kg, po administered 8 day after post infection qd for 20 days",Other,22536986.0,
1013,671575,1,3,,103178476,31593,Active,,,,,"Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Tulahuen infected immunosuppressed Swiss mouse assessed as level of parasite in blood at 20 mg/kg, po administered 8 day after post infection qd for 20 days measured after 3 cycles of immunosuppression",Other,22536986.0,
1014,671576,1,3,,103178476,31593,Active,,,,,"Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Tulahuen infected immunosuppressed Swiss mouse assessed as level of parasite in blood at 100 mg/kg, po administered 8 day after post infection qd for 20 days measured after 3 cycles of immunosuppression",Other,22536986.0,
1015,672965,1,2,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes assessed as cell death at 50 uM after 72 hrs by propidium iodide staining-based flow cytometric analysis,Other,22795899.0,
1016,672966,2,2,,103178476,31593,Active,,,11.5,IC50,Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes after 72 hrs by Neubauer counter-based microscopic analysis,Confirmatory,22795899.0,
1017,672967,2,2,,103178476,31593,Active,,,48.0,CC50,Cytotoxicity against african green monkey Vero cells after 72 hrs by spectrophotometric analysis,Confirmatory,22795899.0,
1018,675025,2,2,,103178476,31593,Active,,,5.39,IC50,Trypanocidal activity against epimastigotes of Trypanosoma cruzi Tulahuen 2 assessed as inhibition of parasite growth after 4 days by trypan blue staining,Confirmatory,22840495.0,
1019,675026,2,2,,103178476,31593,Active,,,30.26,IC50,Trypanocidal activity against bloodstream trypomastigotes of Trypanosoma cruzi infected in mouse blood assessed as lytic effect after 24 hrs,Confirmatory,22840495.0,
1020,675029,2,2,,103178476,31593,Unspecified,,,82.79,CC50,Cytotoxicity against african green monkey Vero cells after 24 hrs by MTT assay,Confirmatory,22840495.0,
1021,677205,2,2,,103178476,31593,Active,,,15.9,IC50,Trypanosomicidal activity against Trypanosoma cruzi SN3 epimastigote after 72 hrs by hemocytometric analysis,Confirmatory,22443115.0,
1022,677206,2,2,,103178476,31593,Active,,,18.9,IC50,Trypanosomicidal activity against Trypanosoma cruzi SN3 anexic amastigote after 48 hrs by hemocytometric analysis,Confirmatory,22443115.0,
1023,677207,2,2,,103178476,31593,Active,,,23.3,IC50,Trypanosomicidal activity against Trypanosoma cruzi SN3 amastigote infected in Vero cells after 72 hrs by Giemsa staining method,Confirmatory,22443115.0,
1024,677208,2,2,,103178476,31593,Active,,,13.6,IC50,Cytotoxicity against African green monkey Vero cells assessed as cell viability after 72 hrs by flow cytometric analysis,Confirmatory,22443115.0,
1025,677209,1,3,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for Vero cells to IC50 for Trypanosoma cruzi epimastigote",Other,22443115.0,
1026,677210,1,3,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for Vero cells to IC50 for Trypanosoma cruzi anexic amastigote",Other,22443115.0,
1027,677211,1,3,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for Vero cells to IC50 for Trypanosoma cruzi intracellular amastigote infected in Vero cells",Other,22443115.0,
1028,677212,1,3,,103178476,31593,Unspecified,,,,,Trypanosomicidal activity against Trypanosoma cruzi infected in Vero cells assessed as reduction in rate of infection after 10 days by Giemsa staining method,Other,22443115.0,
1029,677213,1,3,,103178476,31593,Unspecified,,,,,Trypanosomicidal activity against Trypanosoma cruzi infected in Vero cells assessed as reduction in amastigotes per infected Vero cells after 6 days by Giemsa staining method,Other,22443115.0,
1030,677214,1,3,,103178476,31593,Unspecified,,,,,Trypanosomicidal activity against Trypanosoma cruzi infected in Vero cells assessed as reduction in trypomastigotes in culture medium after 10 days by Giemsa staining method,Other,22443115.0,
1031,677287,1,2,,103178476,31593,Unspecified,,,,,"Toxicity in BALB/c mouse liver infected with Trypanosoma cruzi assessed as granulomas with limphocitic infiltration at 5 mg/kg, ip after 120 days postinfection by Histopathological analysis",Other,22443115.0,
1032,677288,1,2,,103178476,31593,Unspecified,,,,,"Toxicity in BALB/c mouse liver infected with Trypanosoma cruzi assessed as delocalized hepatic destruction at 5 mg/kg, ip after 120 days postinfection by Histopathological analysis",Other,22443115.0,
1033,677289,1,2,,103178476,31593,Unspecified,,,,,"Toxicity in BALB/c mouse liver infected with Trypanosoma cruzi assessed as blood vessels with thickened walls at 5 mg/kg, ip after 120 days postinfection by Histopathological analysis",Other,22443115.0,
1034,677290,1,2,,103178476,31593,Unspecified,,,,,"Toxicity in BALB/c mouse liver infected with Trypanosoma cruzi assessed as lymphocytic infiltrations in portal tracts at 5 mg/kg, ip after 120 days postinfection Histopathological analysis",Other,22443115.0,
1035,677291,1,2,,103178476,31593,Unspecified,,,,,"Toxicity in BALB/c mouse liver infected with Trypanosoma cruzi assessed as intestinal hemorrhage at 5 mg/kg, ip after 120 days postinfection by Histopathological analysis",Other,22443115.0,
1036,677292,1,2,,103178476,31593,Unspecified,,,,,"Toxicity in BALB/c mouse liver infected with Trypanosoma cruzi assessed as hepatic destruction in portal tracts at 5 mg/kg, ip after 120 days postinfection by Histopathological analysis",Other,22443115.0,
1037,677293,1,2,,103178476,31593,Unspecified,,,,,"Toxicity in BALB/c mouse liver infected with Trypanosoma cruzi assessed as necrotic cells in portal tracts at 5 mg/kg, ip after 120 days postinfection by Histopathological analysis",Other,22443115.0,
1038,677303,1,2,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi infected in BALB/c mouse assessed as reduction in parasitemia at 1 mg/kg, ip dosed for 5 days measured on day 30 post infection",Other,22443115.0,
1039,677305,1,2,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi infected in BALB/c mouse assessed as reduction in anti-organism antibody at 1 mg/kg, ip dosed for 5 days measured on day 40 to 120 post infection",Other,22443115.0,
1040,677307,1,2,,103178476,31593,Unspecified,,,,,Trypanosomicidal activity against Trypanosoma cruzi epimastigotes assessed as inhibition of acetate metabolite excretion after 96 hrs by NMR analysis,Other,22443115.0,
1041,677309,1,2,,103178476,31593,Active,,,,,Trypanosomicidal activity against Trypanosoma cruzi epimastigotes assessed as change in L-alanine metabolite excretion after 96 hrs by NMR analysis,Other,22443115.0,
1042,677310,1,2,,103178476,31593,Active,,,,,Trypanosomicidal activity against Trypanosoma cruzi epimastigotes assessed as change in ethanol metabolite excretion after 96 hrs by NMR analysis,Other,22443115.0,
1043,677311,1,2,,103178476,31593,Active,,,,,Trypanosomicidal activity against Trypanosoma cruzi epimastigotes assessed as change in succinate metabolite excretion after 96 hrs by NMR analysis,Other,22443115.0,
1044,677312,1,2,,103178476,31593,Active,,,,,Trypanosomicidal activity against Trypanosoma cruzi epimastigotes assessed as change in L-lactate metabolite excretion after 96 hrs by NMR analysis,Other,22443115.0,
1045,677313,1,2,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi infected in BALB/c mouse assessed as survival rate at 1 mg/kg, ip dosed for 5 days",Other,22443115.0,
1046,677564,2,2,,103178476,31593,Active,,,1.5619999999999998,IC50,Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C4 amastigotes,Confirmatory,22550999.0,
1047,677571,2,2,,103178476,31593,Active,,,21.8,IC50,Antitrypanosomal activity against bloodstream form of Trypanosoma brucei brucei Lister 427 clone 221a overexpressing tet-inducible NTR in presence of tetracycline after 3 days,Confirmatory,22550999.0,
1048,677572,2,2,,103178476,31593,Active,,,2.2,IC50,Antitrypanosomal activity against bloodstream form of Trypanosoma brucei brucei Lister 427 clone 221a overexpressing tet-inducible NTR in absence of tetracycline after 3 days,Confirmatory,22550999.0,
1049,677575,1,3,,103178476,31593,Unspecified,,,,,Selectivity ratio of IC50 for Trypanosoma brucei brucei Lister 427 clone 221a overexpressing tet-inducible NTR in presence of tetracycline to IC50 for Trypanosoma brucei brucei overexpressing tet-inducible NTR in absence of tetracyclin,Other,22550999.0,
1050,686940,1,1,,56323658,31593,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
1051,686964,1,1,,56323658,31593,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
1052,686970,1,2,,56320744,31593,Inactive,49168486.0,3417.0,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
1053,686971,1,2,,56320744,31593,Inactive,,,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
1054,686978,1,1,,56320744,31593,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1055,686978,1,1,,144205917,31593,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1056,686979,1,1,,56320744,31593,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1057,686979,1,1,,144205917,31593,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1058,686992,2,1,,56323658,31593,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
1059,686996,1,1,,56323658,31593,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1060,687014,1,1,,56323658,31593,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
1061,687016,1,1,,56323658,31593,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
1062,690544,2,2,,103178476,31593,Active,,,1.47,IC50,Antiprotozoal activity against intracellular Trypanosoma cruzi amastigotes in rat L6 cells,Confirmatory,22932312.0,
1063,693340,1,2,,103178476,31593,Unspecified,,,,,Growth inhibition of epimastigote form of Trypanosoma cruzi CL-B5 at 128 uM after 72 hrs by lacZ reporter gene assay,Other,23124218.0,
1064,693341,1,2,,103178476,31593,Unspecified,,,,,Growth inhibition of mouse J774 cells at 256 uM after 24 hrs by resazurin reduction assay,Other,23124218.0,
1065,693342,1,2,,103178476,31593,Unspecified,,,,,Growth inhibition of epimastigote form of Trypanosoma cruzi CL-B5 at 256 uM after 72 hrs by lacZ reporter gene assay,Other,23124218.0,
1066,693343,1,2,,103178476,31593,Unspecified,,,,,Growth inhibition of mouse J774 cells at 128 uM after 24 hrs by resazurin reduction assay,Other,23124218.0,
1067,693344,1,2,,103178476,31593,Unspecified,,,,,Growth inhibition of epimastigote form of Trypanosoma cruzi CL-B5 at 64 uM after 72 hrs by lacZ reporter gene assay,Other,23124218.0,
1068,693345,1,2,,103178476,31593,Unspecified,,,,,Growth inhibition of mouse J774 cells at 64 uM after 24 hrs by resazurin reduction assay,Other,23124218.0,
1069,693360,2,2,,103178476,31593,Active,,,27.32,IC50,Growth inhibition of epimastigote form of Trypanosoma cruzi CL-B5 after 72 hrs by lacZ reporter gene assay,Confirmatory,23124218.0,
1070,694793,1,3,,103178476,31593,Active,,,,,"Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Y infected in BALB/c mouse assessed as reduction of parasite level in blood at 100 mg/kg, po administered after 5 days of postinfection qd for 5 days",Other,23006639.0,
1071,694953,2,2,,103178476,31593,Active,,,7.5,IC50,Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi Y after 5 days,Confirmatory,23006639.0,
1072,694955,2,2,,103178476,31593,Active,,,11.3,IC50,Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Y infected in rhesus monkey LLC-MK2 cells assessed parasite viability after 24 hrs,Confirmatory,23006639.0,
1073,706518,2,2,,103178476,31593,Active,,,18.9,IC50,Antitrypanosomal activity against Trypanosoma cruzi IRHOD/VO/2008/SN3 axenic amastigotes infected in african green monkey Vero cells incubated for 72 hrs,Confirmatory,23043291.0,
1074,706519,2,2,,103178476,31593,Active,,,15.9,IC50,Antitrypanosomal activity against Trypanosoma cruzi IRHOD/VO/2008/SN3 epimastigotes infected in african green monkey Vero cells incubated for 72 hrs,Confirmatory,23043291.0,
1075,707762,1,2,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi IRHOD/VO/2008/SN3 metacyclic forms infected in BALB/c mouse model of chronic Chagas disease subjected to 3 cycles of immunosuppression with 50 mg/kg cyclophosphamide monohydrate for 3 consecutive weeks assessed as parasitemia reactivation level at 5 mg/kg/day, ip administered for 5 consecutive days starting on day 7 post infection until day 12 post infection and measured on day 150 post infection",Other,23043291.0,
1076,707764,1,2,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi IRHOD/VO/2008/SN3 metacyclic forms infected in BALB/c mouse model of acute Chagas disease assessed as reduction parasitemia at 5 mg/kg/day, ip administered for 5 consecutive days starting on day 7 post infection until day 12 post infection and measured on day 25 post infection",Other,23043291.0,
1077,707766,1,2,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi IRHOD/VO/2008/SN3 metacyclic forms infected in BALB/c mouse model of acute Chagas disease assessed as reduction parasitemia at 5 mg/kg/day, ip administered for 5 consecutive days starting on day 7 post infection until day 12 post infection and measured on day 40 post infection",Other,23043291.0,
1078,707767,1,2,,103178476,31593,Unspecified,,,,,"Toxicity in Trypanosoma cruzi IRHOD/VO/2008/SN3 metacyclic forms infected BALB/c mouse model of acute Chagas disease assessed as mortality incidence at 5 mg/kg/day, ip administered for 5 consecutive days starting on day 7 post infection until day 12 post infection and measured 40 days post infection",Other,23043291.0,
1079,707768,1,2,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi IRHOD/VO/2008/SN3 metacyclic forms infected in BALB/c mouse model of acute Chagas disease assessed as reduction parasitemia at 5 mg/kg/day, ip administered for 5 consecutive days starting on day 7 post infection until day 12 post infection and measured on day 15 to 20 post infection",Other,23043291.0,
1080,707773,1,2,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi IRHOD/VO/2008/SN3 metacyclic forms infected in african green monkey Vero cells assessed as inhibition of trypomastigotes level at IC25 level 0.5 to 10 days,Other,23043291.0,
1081,707774,1,2,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi IRHOD/VO/2008/SN3 metacyclic forms infected in african green monkey Vero cells assessed as inhibition of intracellular amastigotes replication at IC25 level 0.5 to 10 days,Other,23043291.0,
1082,707775,1,2,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi IRHOD/VO/2008/SN3 metacyclic forms infected in african green monkey Vero cells assessed as inhibition of infection rate at IC25 level 0.5 to 10 days,Other,23043291.0,
1083,707776,1,2,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for Trypanosoma cruzi IRHOD/VO/2008/SN3 blood trypomastigotes",Other,23043291.0,
1084,707777,1,2,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for Trypanosoma cruzi IRHOD/VO/2008/SN3 intracellular amastigotes",Other,23043291.0,
1085,707778,1,2,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for Trypanosoma cruzi IRHOD/VO/2008/SN3 axenic amastigotes",Other,23043291.0,
1086,707779,1,2,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for Trypanosoma cruzi IRHOD/VO/2008/SN3 epimastigotes",Other,23043291.0,
1087,707780,2,2,,103178476,31593,Active,,,13.6,IC50,Toxicity against african green monkey Vero cells,Confirmatory,23043291.0,
1088,707781,2,2,,103178476,31593,Active,,,16.4,IC50,Antitrypanosomal activity against Trypanosoma cruzi IRHOD/VO/2008/SN3 isolated from mouse blood trypomastigotes incubated for 24 hrs,Confirmatory,23043291.0,
1089,707782,2,2,,103178476,31593,Active,,,23.3,IC50,Antitrypanosomal activity against Trypanosoma cruzi IRHOD/VO/2008/SN3 intracellular amastigotes infected in african green monkey Vero cells incubated for 72 hrs,Confirmatory,23043291.0,
1090,710590,1,2,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for intracellular amastigote form of Trypanosoma cruzi Tulahuen strain C2C4",Other,23153330.0,
1091,710592,2,2,,103178476,31593,Unspecified,,,384.0,IC50,Cytotoxicity against rat L6 cells assessed as growth inhibition after 72 hrs by inverted microscopy,Confirmatory,23153330.0,
1092,710595,2,2,,103178476,31593,Active,,,1.7,IC50,Antitrypanosomal activity against intracellular amastigote form of Trypanosoma cruzi Tulahuen C2C4 infected in rat L6 cells assessed as growth inhibition after 92 hrs by inverted microscopy,Confirmatory,23153330.0,
1093,710861,1,2,,103178476,31593,Active,,,,,Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Y infected in mouse peritoneal macrophages assessed as reduction of intracellular parasite level at 10 uM after 4 days,Other,23167554.0,
1094,710864,2,2,,103178476,31593,Active,,,13.9,IC50,Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Y infected in mouse peritoneal macrophages assessed as reduction of intracellular parasite level after 4 days,Confirmatory,23167554.0,
1095,710877,4,1,,103178476,31593,Unspecified,,,,IC50,Cytotoxicity against BALB/c mouse splenocytes assessed as highest nontoxic concentration by measuring [3H]-thymidine incorporation after 24 hrs by beta-radiation counting,Confirmatory,23167554.0,
1096,710878,2,2,,103178476,31593,Active,,,6.6,IC50,Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi Y infected in LLC-MK2 cells assessed as parasite motility after 11 days,Confirmatory,23167554.0,
1097,710879,2,2,,103178476,31593,Active,,,6.2,IC50,Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Y infected in LLC-MK2 cells assessed as parasite motility after 24 hrs,Confirmatory,23167554.0,
1098,710881,1,2,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Y infected in BALB/c mouse assessed as reduction of blood parasite level at 250 umol/kg, po qd for 5 days",Other,23167554.0,
1099,714975,1,2,,103178476,31593,Active,,,,,Antitrypanosomal activity against bloodstream trypomastigote form of Trypanosoma cruzi NINOA isolated from infected mouse at the peak of parasitemia assessed as reduction in parasite motility at 5 to 50 ug/ml after 24 hrs,Other,22436391.0,
1100,720504,1,1,,56320744,31593,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
1101,720508,1,1,,56323658,31593,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1102,720509,1,1,,56323658,31593,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1103,720511,1,1,,56323658,31593,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
1104,720516,2,1,,144205917,31593,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1105,720532,1,1,,144205917,31593,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1106,720533,1,1,,144205917,31593,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1107,720542,1,2,,56320744,31593,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
1108,720543,1,1,,56323658,31593,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
1109,720551,1,2,,56320744,31593,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
1110,720552,2,1,,144205917,31593,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1111,720553,1,2,,56320744,31593,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
1112,720579,2,1,,56320744,31593,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
1113,720580,1,1,,56320744,31593,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
1114,720582,1,1,,56323658,31593,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
1115,720596,1,1,,56323658,31593,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
1116,720634,2,1,,144205917,31593,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1117,720635,2,1,,144205917,31593,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1118,720637,2,1,,144205917,31593,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1119,720647,1,2,,56323658,31593,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
1120,720648,1,1,,56323658,31593,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
1121,720674,2,2,,144205917,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1122,720675,2,2,,144205917,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1123,720678,2,1,,144205917,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1124,720679,2,1,,144205917,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1125,720680,2,1,,144205917,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1126,720681,2,1,,144205917,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1127,720682,2,1,,144205917,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1128,720683,2,1,,144205917,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1129,720684,2,1,,144205917,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1130,720685,2,1,,144205917,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1131,720686,2,1,,144205917,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1132,720687,2,2,,144205917,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1133,720691,4,1,,144205917,31593,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1134,720692,3,1,,144205917,31593,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1135,720693,3,1,,144205917,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1136,720700,1,4,,56323658,31593,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
1137,720702,1,1,,56323658,31593,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
1138,720704,1,4,,56323658,31593,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
1139,720706,1,2,,56323658,31593,Inactive,,,,,HTS for Bacterial rRNA inhibitors Measured in Microorganism-Based System Using Plate Reader - 7056-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1140,720707,1,2,,56320744,31593,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1141,720708,1,2,,56320744,31593,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
1142,720709,1,2,,56320744,31593,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1143,720711,1,2,,56320744,31593,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
1144,720719,2,1,,144205917,31593,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1145,720725,2,1,,144205917,31593,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1146,725217,1,2,,103178476,31593,Active,,,1.8,IC50,Antiprotozoal activity against Trypanosoma cruzi Tulahuen C4 amastigotes after 96 hrs,Confirmatory,23265884.0,
1147,726224,1,2,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes at 8 uM incubated for 48 hrs by resazurin dye reduction based ELISA method,Other,23391336.0,
1148,726225,1,2,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes at 16 uM incubated for 48 hrs by resazurin dye reduction based ELISA method,Other,23391336.0,
1149,726226,1,2,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes at 32 uM incubated for 48 hrs by resazurin dye reduction based ELISA method,Other,23391336.0,
1150,726227,1,2,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes at 64 uM incubated for 48 hrs by resazurin dye reduction based ELISA method,Other,23391336.0,
1151,726228,1,2,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes at 128 uM incubated for 48 hrs by resazurin dye reduction based ELISA method,Other,23391336.0,
1152,726229,1,2,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes at 256 uM incubated for 48 hrs by resazurin dye reduction based ELISA method,Other,23391336.0,
1153,726231,1,2,,103178476,31593,Inconclusive,,,,,Antitrypanosomal activity against Trypanosoma cruzi DM28 epimastigotes at 256 uM incubated for 48 hrs by resazurin dye reduction based ELISA method,Other,23391336.0,
1154,726232,1,2,,103178476,31593,Inactive,,,,Ki,Inhibition of Trypanosoma cruzi CL Brener recombinant alpha-carbonic anhydrase expressed in insect Sf9 cell Baculovirus system by stopped flow CO2 hydration assay,Confirmatory,23391336.0,
1155,726608,2,1,,103178476,31593,Inconclusive,,,,ED50,Antiparasitic activity against Toxoplasma gondii tachyzoite expressing red fluorescence protein assessed as growth inhibition by fluorescence plate reader,Confirmatory,23318904.0,
1156,726609,2,5,,103178476,31593,Inconclusive,122107391.0,,,IC50,Inhibition of Toxoplasma gondii farnesyl diphosphate synthase assessed as incorporation of [4-14C]IPP measured at 37 degC,Confirmatory,23318904.0,
1157,726610,2,1,,103178476,31593,Active,,,1.7,ED50,Antiparasitic activity against Trypanosoma cruzi amastigotes infected in gamma-irradiated vero cells assessed as growth inhibition measured after 3 days by fluorescence assay,Confirmatory,23318904.0,
1158,726611,2,5,,103178476,31593,Inconclusive,74844344.0,,,IC50,Inhibition of Trypanosoma cruzi farnesyl diphosphate synthase assessed as incorporation of [4-14C]IPP measured at 37 degC,Confirmatory,23318904.0,
1159,727320,1,3,,103178476,31593,Active,,,1.6059999999999999,IC50,Antiparasitic activity against Trypanosoma cruzi Tulahuen C2C4 expressing beta-galactosidase infected in rat L6 cells after 96 hrs,Confirmatory,23360309.0,
1160,728164,1,2,,103178476,31593,Active,,,,,Antitrypanosomal activity against Trypanosoma cruzi trypomastigote infected in mouse NIH/3T3 cells at 9.5 uM incubated for 3 days post infection by DAPI-staining based immunofluorescence assay,Other,23448316.0,
1161,728165,1,2,,103178476,31593,Active,,,,,Antitrypanosomal activity against Trypanosoma cruzi Y infected in monkey LLC-MK2 cells after 48 to 72 hrs by luciferase reporter gene assay,Other,23448316.0,
1162,728167,1,2,,103178476,31593,Active,,,,,Antitrypanosomal activity against Trypanosoma cruzi Tulahuen infected in monkey LLC-MK2 cells after 48 to 72 hrs by beta-galactosidase reporter gene assay,Other,23448316.0,
1163,728170,1,2,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of EC50 for mouse NIH/3T3 cells to EC50 for Trypanosoma cruzi trypomastigote",Other,23448316.0,
1164,728171,1,4,,103178476,31593,Unspecified,,,50.0,EC50,Cytotoxicity against mouse NIH/3T3 cells,Confirmatory,23448316.0,
1165,728172,3,1,,103178476,31593,Active,,,1.9,EC50,Antitrypanosomal activity against Trypanosoma cruzi trypomastigote infected in monkey LLC-MK2 cells after 96 hrs by luciferase reporter gene assay,Confirmatory,23448316.0,
1166,730419,1,2,,103178476,31593,Unspecified,,,100.0,IC50,Cytotoxicity against rat L6 cells after 72 hrs by Alamar Blue assay,Confirmatory,23462713.0,
1167,730420,1,2,,103178476,31593,Active,,,1.15,IC50,Antitrypanosomal activity against Trypanosoma cruzi Tulahuen TcVI extracellular trypomastigotes forms transfected with beta-galactosidase gene infected in rat L6 cells assessed as inhibition of parasite growth after 4 days,Confirmatory,23462713.0,
1168,736792,1,2,,103178476,31593,Unspecified,,,440.7,GI50,Antitrypanosomal activity against Trypanosoma cruzi trypomastigotes after 24 hrs by MTT assay,Confirmatory,23266185.0,
1169,738320,1,2,,103178476,31593,Active,,,,,Antitrypanosomal activity against amastigote form of Trypanosoma cruzi Tulahuen infected in african green monkey Vero cells assessed as decrease in number of intracellular parasites at 0.06 to 0.5 mM treated after removal of parasite on cell supernatant following 12 hrs of infection measured after 24 hrs by Giemsa staining based optical microscopy,Other,23415086.0,
1170,738323,1,2,,103178476,31593,Active,,,30.0,IC50,Antitrypanosomal activity against trypomastigote form of Trypanosoma cruzi Tulahuen expressing beta galactosidase infected in rhesus monkey LLC-MK2 cells assessed as inhibition of parasite viability treated at 24 hrs post-infection measured after 4 days by CPRG based colorimetric assay,Confirmatory,23415086.0,
1171,743012,3,1,,144205917,31593,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1172,743014,3,1,,144205917,31593,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1173,743015,3,1,,144205917,31593,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1174,743033,3,1,,144205917,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1175,743035,2,1,,144205917,31593,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1176,743036,2,1,,144205917,31593,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1177,743040,3,1,,144205917,31593,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1178,743041,3,1,,144205917,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1179,743042,3,1,,144205917,31593,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1180,743053,2,1,,144205917,31593,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1181,743054,2,1,,144205917,31593,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1182,743063,2,1,,144205917,31593,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1183,743064,3,1,,144205917,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1184,743065,3,1,,144205917,31593,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1185,743066,3,1,,144205917,31593,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1186,743067,2,1,,144205917,31593,Inconclusive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1187,743069,2,1,,144205917,31593,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1188,743074,2,1,,144205917,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1189,743075,2,1,,144205917,31593,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1190,743077,2,1,,144205917,31593,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1191,743078,2,1,,144205917,31593,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1192,743079,3,1,,144205917,31593,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1193,743080,3,1,,144205917,31593,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1194,743081,3,1,,144205917,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1195,743083,3,1,,144205917,31593,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1196,743084,3,1,,144205917,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1197,743085,3,1,,144205917,31593,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1198,743086,3,1,,144205917,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1199,743091,2,1,,144205917,31593,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1200,743094,3,1,,144205917,31593,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1201,743122,2,1,,144205917,31593,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1202,743126,1,1,,56323658,31593,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
1203,743139,2,1,,144205917,31593,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1204,743140,2,1,,144205917,31593,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1205,743191,3,1,,170466539,31593,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1206,743194,3,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
1207,743199,2,1,,170466539,31593,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1208,743202,4,1,,170466539,31593,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1209,743203,3,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
1210,743209,3,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
1211,743210,4,1,,170466539,31593,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
1212,743211,3,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1213,743212,3,1,,170466539,31593,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1214,743213,3,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1215,743215,3,1,,170466539,31593,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1216,743217,3,1,,170466539,31593,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1217,743218,3,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1218,743219,3,1,,170466539,31593,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
1219,743220,3,1,,170466539,31593,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1220,743221,3,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1221,743222,3,1,,170466539,31593,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1222,743223,3,1,,170466539,31593,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1223,743224,3,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1224,743225,3,1,,170466539,31593,Inconclusive,,,0.0038,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1225,743226,2,1,,170466539,31593,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1226,743227,2,1,,170466539,31593,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1227,743228,3,1,,170466539,31593,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
1228,743238,1,1,,56323658,31593,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
1229,743239,2,1,,170466539,31593,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1230,743240,2,1,,170466539,31593,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1231,743241,2,1,,170466539,31593,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1232,743242,2,1,,170466539,31593,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1233,743244,1,1,,144205917,31593,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
1234,743247,1,2,,56323658,31593,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1235,743255,1,1,,56320744,31593,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
1236,743266,1,2,,56320744,31593,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
1237,743269,1,1,,56323658,31593,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1238,743269,1,1,,56323658,31593,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1239,743279,1,2,,56320744,31593,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
1240,743287,1,1,,56323658,31593,Inactive,,,,,Luminescent GLuc Reporter Gene Assay Primary HTS to Identify Small Molecule Activator of Glucose Dependent Insulin Secretion Measured in Cell-Based System Using Plate Reader - 7055-01_Activator_SinglePoint_HTS_Activity,Screening,,
1241,743397,1,1,,56323658,31593,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1242,743398,1,1,,56323658,31593,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
1243,744593,1,1,,103178476,31593,Active,,,3.66,IC50,"Antiprotozoal activity against trypomastigote form of Trypanosoma cruzi Colombian infected in BALB/c mouse assessed as decrease in parasitemia at 100 mg/kg, po administered for 1 week followed by weekly administration measured after 8 months",Confirmatory,23518280.0,
1244,748436,1,2,,103178476,31593,Active,,,1.671,IC50,Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C2C4 amastigotes infected in rat L6 cells after 96 hrs by photometric analysis,Confirmatory,24900706.0,
1245,753034,1,1,,103178476,31593,Unspecified,,,200.0,IC50,Cytotoxicity against human fibroblasts assessed as growth inhibition after 24 hrs by MTT assay,Confirmatory,23644203.0,
1246,753035,1,1,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for human fibroblasts to GI50 for epimastigote stage of Trypanosoma cruzi Y",Other,23644203.0,
1247,753036,1,1,,103178476,31593,Active,,,22.69,GI50,Antitrypanosomal activity against epimastigote stage of Trypanosoma cruzi Y assessed as parasite growth inhibition after 5 days by spectrophotometric analysis,Confirmatory,23644203.0,
1248,753401,1,1,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi Y trypomastigotes",Other,23659860.0,
1249,753403,1,1,,103178476,31593,Inconclusive,,,,CC50,Cytotoxicity against peritoneal macrophage after 24 hrs by resazurin assay,Confirmatory,23659860.0,
1250,753404,1,1,,103178476,31593,Inconclusive,,,,CC50,Cytotoxicity against African green monkey Vero cells after 24 hrs by resazurin assay,Confirmatory,23659860.0,
1251,753405,1,1,,103178476,31593,Inconclusive,,,,CC50,Cytotoxicity against human HeLa cells after 24 hrs by resazurin assay,Confirmatory,23659860.0,
1252,753406,1,3,,103178476,31593,Inconclusive,,,,IC50,Trypanocidal activity against Trypanosoma cruzi strain CL trypomastigotes infected in human HeLa cells at 37 degC after 18 hrs by resazurin assay,Confirmatory,23659860.0,
1253,753407,1,1,,103178476,31593,Inconclusive,,,,IC50,Trypanocidal activity against Trypanosoma cruzi H510 trypomastigotes infected in human HeLa cells at 37 degC after 18 hrs by resazurin assay,Confirmatory,23659860.0,
1254,753408,1,1,,103178476,31593,Active,,,25.6,IC50,Trypanocidal activity against Trypanosoma cruzi Y trypomastigotes infected in human HeLa cells at 37 degC after 18 hrs by resazurin assay,Confirmatory,23659860.0,
1255,753409,1,1,,103178476,31593,Unspecified,,,500.0,IC50,Trypanocidal activity against Trypanosoma cruzi Y trypomastigotes infected in human HeLa cells at 4 degC after 18 hrs by hemocytometric analysis,Confirmatory,23659860.0,
1256,756886,1,2,,103178476,31593,Unspecified,,,150.0,IC50,Cytotoxicity against rat L6 cells after 72 hrs by Alamar Blue assay,Confirmatory,23795673.0,
1257,756892,1,2,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma cruzi Tulahuen C2C4",Other,23795673.0,
1258,756893,1,2,,103178476,31593,Active,,,1.3,IC50,Antiprotozoal activity against intracellular amastigote form of Trypanosoma cruzi Tulahuen C2C4 expressing LacZ infected in rat L6 cells after 48 hrs,Confirmatory,23795673.0,
1259,762346,1,1,,103178476,31593,Active,,,,IC50,Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C2C4 amastigotes infected in rat L6 cells after 96 hrs by beta-galactosidase reporter gene assay,Confirmatory,23831695.0,
1260,762752,1,2,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of C57BL/6 mouse spleen cells to trypomastigotes forms of Trypanosoma cruzi Tulahuen infected in monkey LLC-MK2 cells",Other,23850203.0,
1261,762753,1,1,,103178476,31593,Unspecified,,,,,Trypanocidal activity against trypomastigotes forms of Trypanosoma cruzi Tulahuen infected in monkey LLC-MK2 cells after 24 hrs by beta-galactosidase reporter assay,Other,23850203.0,
1262,762754,1,3,,103178476,31593,Unspecified,,,,,Cytotoxicity against C57BL/6 mouse spleen cells after 24 hrs using propidium iodide by flow cytometry,Other,23850203.0,
1263,762758,1,2,,103178476,31593,Inconclusive,,,,IC50,Cytotoxicity against Balb-c mouse 3T3 cells by MTT assay,Confirmatory,23850203.0,
1264,764117,1,1,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for human FN1 fibroblasts to IC50 for epimastigotes of Trypanosoma cruzi Y",Other,23816040.0,
1265,764118,1,1,,103178476,31593,Unspecified,,,200.0,IC50,Cytotoxicity against human FN1 fibroblasts after 24 hrs by MTT assay,Confirmatory,23816040.0,
1266,764119,1,1,,103178476,31593,Unspecified,,,400.0,IC50,Cytotoxicity against mouse J774 cells after 48 hrs by MTT assay,Confirmatory,23816040.0,
1267,764120,1,1,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse J774 cells to IC50 for epimastigotes of Trypanosoma cruzi Y",Other,23816040.0,
1268,764122,1,1,,103178476,31593,Active,,,22.69,IC50,Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi Y assessed as parasite growth inhibition after 5 days by spectrophotometric analysis,Confirmatory,23816040.0,
1269,766415,1,3,,103178476,31593,Unspecified,,,,,Antiparasitic activity against amastigotes of Trypanosoma cruzi CL Brener expressing Escherichia coli lacZ gene infected in mouse NCTC-929 cells assessed as parasite growth inhibition at 1 uM after 7 days by colorimetric assay,Other,23899616.0,
1270,766416,1,3,,103178476,31593,Unspecified,,,,,Antiparasitic activity against amastigotes of Trypanosoma cruzi CL Brener expressing Escherichia coli lacZ gene infected in mouse NCTC-929 cells assessed as parasite growth inhibition at 0.5 uM after 7 days by colorimetric assay,Other,23899616.0,
1271,766417,1,3,,103178476,31593,Active,,,0.8,IC50,Antiparasitic activity against amastigotes of Trypanosoma cruzi CL Brener expressing Escherichia coli lacZ gene infected in mouse NCTC-929 cells assessed as parasite growth inhibition after 7 days by colorimetric assay,Confirmatory,23899616.0,
1272,766418,1,1,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of LC50 for mouse NCTC-929 cells to IC50 for amastigotes of Trypanosoma cruzi CL Brener",Other,23899616.0,
1273,766419,1,3,,103178476,31593,Unspecified,,,,,Antiparasitic activity against epimastigotes of Trypanosoma cruzi CL Brener expressing Escherichia coli lacZ gene infected in mouse NCTC-929 cells assessed as parasite growth inhibition at 32 uM after 72 hrs by colorimetric assay,Other,23899616.0,
1274,766420,1,3,,103178476,31593,Active,,,27.12,IC50,Antiparasitic activity against epimastigotes of Trypanosoma cruzi CL Brener expressing Escherichia coli lacZ gene infected in mouse NCTC-929 cells assessed as parasite growth inhibition after 72 hrs by colorimetric assay,Confirmatory,23899616.0,
1275,766421,1,2,,103178476,31593,Unspecified,,,,,Cytotoxicity against mouse NCTC-929 cells at 256 uM after 48 hrs by resazurin based fluorescence assay,Other,23899616.0,
1276,766422,1,2,,103178476,31593,Unspecified,,,256.0,LC50,Cytotoxicity against mouse NCTC-929 cells after 48 hrs by resazurin based fluorescence assay,Confirmatory,23899616.0,
1277,766423,1,1,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of LC50 for mouse NCTC-929 cells to IC50 for epimastigotes of Trypanosoma cruzi CL Brener",Other,23899616.0,
1278,766424,1,3,,103178476,31593,Unspecified,,,,,Antiparasitic activity against amastigotes of Trypanosoma cruzi CL Brener expressing Escherichia coli lacZ gene infected in mouse NCTC-929 cells assessed as parasite growth inhibition at 32 uM after 7 days by colorimetric assay,Other,23899616.0,
1279,766425,1,3,,103178476,31593,Unspecified,,,,,Antiparasitic activity against amastigotes of Trypanosoma cruzi CL Brener expressing Escherichia coli lacZ gene infected in mouse NCTC-929 cells assessed as parasite growth inhibition at 16 uM after 7 days by colorimetric assay,Other,23899616.0,
1280,766426,1,3,,103178476,31593,Unspecified,,,,,Antiparasitic activity against amastigotes of Trypanosoma cruzi CL Brener expressing Escherichia coli lacZ gene infected in mouse NCTC-929 cells assessed as parasite growth inhibition at 8 uM after 7 days by colorimetric assay,Other,23899616.0,
1281,766427,1,3,,103178476,31593,Unspecified,,,,,Antiparasitic activity against amastigotes of Trypanosoma cruzi CL Brener expressing Escherichia coli lacZ gene infected in mouse NCTC-929 cells assessed as parasite growth inhibition at 4 uM after 7 days by colorimetric assay,Other,23899616.0,
1282,766428,1,3,,103178476,31593,Unspecified,,,,,Antiparasitic activity against amastigotes of Trypanosoma cruzi CL Brener expressing Escherichia coli lacZ gene infected in mouse NCTC-929 cells assessed as parasite growth inhibition at 2 uM after 7 days by colorimetric assay,Other,23899616.0,
1283,766605,1,1,,103178476,31593,Unspecified,,,,,Antiparasitic activity against epimastigotes of Trypanosoma cruzi assessed as inhibition of parasite proliferation,Other,23910983.0,
1284,768692,1,5,,103178476,31593,Inconclusive,118157.0,,,,Inhibition of Trypanosoma cruzi cruzain expressed in Escherichia coli DH5-alpha using Bz-Phe-Arg-AMC as substrate at 10 uM preincubated for 5 mins followed by substrate addition measured for 5 mins by spectrofluorimetric analysis relative to control,Other,23851115.0,
1285,768695,1,1,,103178476,31593,Unspecified,,,,,Mutagenicity in Swiss albino mouse at 100 mg/kg after 30 hrs by micronucleus test,Other,23851115.0,
1286,768699,1,1,,103178476,31593,Active,,,34.6,IC50,Trypanocidal activity against epimastigote stage of Trypanosoma cruzi Y after 72 hrs by MTT assay,Confirmatory,23851115.0,
1287,774787,1,1,,103178476,31593,Active,,,1.5730000000000002,IC50,Antiprotozoal activity against Trypanosoma cruzi assessed as parasite growth inhibition,Confirmatory,23968432.0,
1288,776295,1,1,,103178476,31593,Active,,,,,Antimicrobial activity against Trypanosoma cruzi RA amastigotes infected in African green monkey Vero cells assessed as growth inhibition at 1 ug/ml after 72 hrs by Giemsa staining-based light microscopy,Other,24090917.0,
1289,776316,2,1,,103178476,31593,Active,,,1.75,ED50,Antiparasitic activity against Trypanosoma cruzi amastigotes after 3 days by fluorescence assay,Confirmatory,24090919.0,
1290,779137,1,1,,103178476,31593,Unspecified,,,,,Prodrug conversion assessed as Trypanosoma brucei brucei recombinant his-tagged nitroreductase-mediated NADH oxidization by spectrophotometric analysis,Other,24012457.0,
1291,779143,1,1,,103178476,31593,Active,,,1.85,IC50,Antimicrobial activity against Trypanosoma cruzi Tulahuen C4 amastigotes infected in rat L6 cells after 96 hrs by beta-galactosidase reporter gene assay,Confirmatory,24012457.0,
1292,1053175,2,1,,178125564,31593,Inactive,,,,,A screen for compounds that inhibit growth of Escherichia coli,Other,,
1293,1053197,1,1,,56323658,31593,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
1294,1054891,1,1,,103178476,31593,Unspecified,,,192.1,IC50,Trypanocidal activity against intracellular amastigote stage of Trypanosoma cruzi CL-B5 infected in mouse NCTC-929 cells assessed as reduction of parasite load after 7 days by resazurin dye-based fluorometric analysis,Confirmatory,24151871.0,
1295,1054899,1,1,,103178476,31593,Unspecified,,,194.0,CC50,Cytotoxicity against mouse NCTC-929 cells assessed as reduction of cell viability after 24 hrs by resazurin dye-based fluorometric analysis,Confirmatory,24151871.0,
1296,1054900,1,3,,103178476,31593,Unspecified,,,300.0,CC50,Cytotoxicity against mouse J774 cells assessed as reduction of cell viability after 24 hrs by resazurin dye-based fluorometric analysis,Confirmatory,24151871.0,
1297,1054901,1,1,,103178476,31593,Unspecified,,,54.7,IC50,Trypanocidal activity against extracellular epimastigote stage of Trypanosoma cruzi CL-B5 assessed as reduction of parasite load after 72 hrs by resazurin dye-based fluorometric analysis,Confirmatory,24151871.0,
1298,1055144,1,1,,103178476,31593,Unspecified,,,,,"Hepatotoxicity in BALB/c mouse infected with bloodstream trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 assessed as interstitial hemorrhage at 5 mg/kg/day, ip administered for 5 days measured 150 days post-infection by light microscopic analysis",Other,24158012.0,
1299,1055165,1,1,,103178476,31593,Unspecified,,,,,"Hepatotoxicity in BALB/c mouse infected with bloodstream trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 assessed as presence of necrotic cells in portal space at 5 mg/kg/day, ip administered for 5 days measured 150 days post-infection by light microscopic analysis",Other,24158012.0,
1300,1055166,1,1,,103178476,31593,Unspecified,,,,,"Hepatotoxicity in BALB/c mouse infected with bloodstream trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 assessed as hepatic destruction in portal space at 5 mg/kg/day, ip administered for 5 days measured 150 days post-infection by light microscopic analysis",Other,24158012.0,
1301,1055167,1,1,,103178476,31593,Unspecified,,,,,"Hepatotoxicity in BALB/c mouse infected with bloodstream trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 assessed as centrilobular destruction of hepatic vein at 5 mg/kg/day, ip administered for 5 days measured 150 days post-infection by light microscopic analysis",Other,24158012.0,
1302,1055168,1,1,,103178476,31593,Unspecified,,,,,"Hepatotoxicity in BALB/c mouse infected with bloodstream trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 assessed as lymphocytic infiltration in portal tracts at 5 mg/kg/day, ip administered for 5 days measured 150 days post-infection by light microscopic analysis",Other,24158012.0,
1303,1055169,1,1,,103178476,31593,Unspecified,,,,,"Hepatotoxicity in BALB/c mouse infected with bloodstream trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 assessed as vessels with thickened walls at 5 mg/kg/day, ip administered for 5 days measured 150 days post-infection by light microscopic analysis",Other,24158012.0,
1304,1055170,1,1,,103178476,31593,Unspecified,,,,,"Hepatotoxicity in BALB/c mouse infected with bloodstream trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 assessed as delocalized hepatic destruction at 5 mg/kg/day, ip administered for 5 days measured 150 days post-infection by light microscopic analysis",Other,24158012.0,
1305,1055171,1,1,,103178476,31593,Unspecified,,,,,"Hepatotoxicity in BALB/c mouse infected with bloodstream trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 assessed as granuloma with lymphocytic infiltrate at 5 mg/kg/day, ip administered for 5 days measured 150 days post-infection by light microscopic analysis",Other,24158012.0,
1306,1055177,1,2,,103178476,31593,Active,,,,,"Trypanocidal activity against bloodstream trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 infected in BALB/c mouse assessed as reduction of anti-parasitic Ig-G level in serum at 5 mg/kg/day, ip administered for 5 days measured over 40 to 120 days post-infection by ELISA",Other,24158012.0,
1307,1055178,1,1,,103178476,31593,Active,,,,,"Trypanocidal activity against bloodstream trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 infected in BALB/c mouse assessed as reduction of circulating parasite burden at 5 mg/kg, ip administered for 5 to 10 days measured 22 to 60 days post-infection by Neubauer hemocytometric analysis",Other,24158012.0,
1308,1055179,1,1,,103178476,31593,Unspecified,,,,,Trypanocidal activity against trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 infected in African green monkey Vero cells assessed as inhibition of trypomastigotes released in culture medium at IC25 relative to control,Other,24158012.0,
1309,1055180,1,1,,103178476,31593,Unspecified,,,,,Trypanocidal activity against amastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 infected in African green monkey Vero cells assessed as inhibition of amastigotes load per cell at IC25 preincubated for 12 hrs followed by compound washout measured after 10 days by Giemsa staining-based microscopic analysis relative to control,Other,24158012.0,
1310,1055181,1,1,,103178476,31593,Unspecified,,,,,Trypanocidal activity against amastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 infected in African green monkey Vero cells assessed as inhibition of parasite infection rate at IC25 preincubated for 12 hrs followed by compound washout measured after 10 days by Giemsa staining-based microscopic analysis relative to control,Other,24158012.0,
1311,1055182,1,1,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for extracellular trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3",Other,24158012.0,
1312,1055183,1,1,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for intracellular amastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3",Other,24158012.0,
1313,1055184,1,1,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for extracellular epimastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3",Other,24158012.0,
1314,1055185,1,2,,103178476,31593,Active,,,13.6,IC50,Cytotoxicity against African green monkey Vero cells after 72 hrs by flow cytometric analysis,Confirmatory,24158012.0,
1315,1055186,1,1,,103178476,31593,Active,,,22.6,IC50,Trypanocidal activity against extracellular trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 after 24 hrs by Neubauer hemocytometric analysis,Confirmatory,24158012.0,
1316,1055187,1,1,,103178476,31593,Active,,,23.0,IC50,Trypanocidal activity against intracellular amastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 infected in African green monkey Vero cells after 72 hrs by Giemsa staining assay,Confirmatory,24158012.0,
1317,1055188,1,1,,103178476,31593,Active,,,16.0,IC50,Trypanocidal activity against extracellular epimastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 after 72 hrs by Neubauer hemocytometric analysis,Confirmatory,24158012.0,
1318,1061026,2,1,,103178476,31593,Active,,,1.44,ED50,Antimicrobial activity against Trypanosoma cruzi CL amastigotes infected in african green monkey Vero cells measured on day 3 by fluorescence assay,Confirmatory,24300918.0,
1319,1061028,2,1,,103178476,31593,Active,,,2.77,ED50,Antimicrobial activity against Trypanosoma cruzi,Confirmatory,24300918.0,
1320,1062786,1,1,,103178476,31593,Inactive,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 6 infected in Swiss mouse assessed as mouse survival at 100 mg/kg, po qd administered on day 8 post-infection for 20 days followed by 10 days non-treatment period followed by three cycles of immunosuppression measured on day 58 post-infection by microscopic analysis",Other,24304150.0,
1321,1062787,1,1,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 6 infected in Swiss mouse assessed as mouse survival at 100 mg/kg, po qd administered on day 8 post-infection measured on same day by microscopic analysis",Other,24304150.0,
1322,1062981,1,1,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of CC50 for mouse L929 cells to IC50 for Trypanosoma cruzi Tulahuen amastigotes",Other,24321832.0,
1323,1062982,1,3,,103178476,31593,Unspecified,,,1000.0,CC50,Cytotoxicity against mouse L929 cells after 96 hrs by Alamar blue assay,Confirmatory,24321832.0,
1324,1062983,1,1,,103178476,31593,Active,,,3.8,IC50,Trypanocidal activity against Trypanosoma cruzi Tulahuen amastigotes infected in mouse L929 cells assessed as parasite growth inhibition after 7 days by beta-galactosidase assay,Confirmatory,24321832.0,
1325,1064591,1,3,,103178476,31593,Unspecified,,,614.7,CC50,Cytotoxicity against monkey LLC-MK2 cells after 48 hrs by MTT assay,Confirmatory,24398381.0,
1326,1064593,1,1,,103178476,31593,Active,,,34.5,EC50,Antiparasitic activity against trypomastigote form of Trypanosoma cruzi Y infected in LLCMK2 cells assessed as parasite lysis after 24 hrs by Pizzi-Brener method,Confirmatory,24398381.0,
1327,1064594,1,1,,103178476,31593,Active,,,6.5,IC50,Antiparasitic activity against epimastigote form of Trypanosoma cruzi Y after 96 hrs by hemocytometry,Confirmatory,24398381.0,
1328,1065109,1,1,,103178476,31593,Active,,,,,Trypanocidal activity against Trypanosoma cruzi CA-I/72 infected in BESM cells assessed as parasite re-emergence at 6.6 uM treated for 20 days measured after 37 days,Other,24900788.0,
1329,1065110,1,1,,103178476,31593,Active,,,,,Trypanocidal activity against Trypanosoma cruzi CA-I/72 infected in BESM cells assessed as parasite re-emergence at 6.6 uM measured over 20 days of drug treatment,Other,24900788.0,
1330,1065847,1,1,,103178476,31593,Unspecified,,,,,Trypanocidal activity against Trypanosoma cruzi Y infected in BALB/c mouse assessed as mouse survival at 100 mg/kg treated from day 2 to day 9 post-infection,Other,24299463.0,
1331,1065866,1,1,,103178476,31593,Active,,,15.9,IC50,Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes after 5 days by resazurin dye-based assay,Confirmatory,24299463.0,
1332,1065867,1,1,,103178476,31593,Active,,,,,Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes assessed as growth inhibition at 32 uM after 5 days by Neubauer chamber counting analysis relative to control,Other,24299463.0,
1333,1067348,1,1,,103178476,31593,Unspecified,,,50.0,IC50,Antimicrobial activity against promastigote stage of Leishmania amazonensis IFLA/BR/67/PH-8 clinical isolate after 72 hrs by Neubauer chamber analysis,Confirmatory,24529307.0,
1334,1067349,3,1,,103178476,31593,Active,,,18.62,IC50,Antimicrobial activity against Trichomonas vaginalis GT3 incubated for 48 hrs followed by compound washout measured after 48 hrs,Confirmatory,24529307.0,
1335,1067350,3,1,,103178476,31593,Active,,,22.58,IC50,Antimicrobial activity against Giardia intestinalis IMSS:0696:1 incubated for 48 hrs followed by compound washout measured after 48 hrs,Confirmatory,24529307.0,
1336,1067357,1,2,,103178476,31593,Active,,,14.0,CC50,Cytotoxicity against African green monkey Vero cells assessed as cell viability after 48 hrs by SRB assay,Confirmatory,24529307.0,
1337,1067358,1,1,,103178476,31593,Active,,,34.38,IC50,Antimicrobial activity against epimastigote stage of Trypanosoma cruzi MHOM/MX/1994/Ninoa clinical isolate after 72 hrs by Neubauer chamber analysis,Confirmatory,24529307.0,
1338,1070002,1,1,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of LC50 for mouse NCTC-929 cells to IC50 for amastigote stage of Trypanosoma cruzi CL Brener infected in mouse NCTC-929 cells",Other,24461296.0,
1339,1070003,1,3,,103178476,31593,Active,,,0.8,IC50,Antimicrobial activity against amastigote stage of Trypanosoma cruzi CL Brener infected in mouse NCTC-929 cells assessed as growth inhibition after 7 days by beta-galactosidase reporter gene assay,Confirmatory,24461296.0,
1340,1070004,1,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against amastigote stage of Trypanosoma cruzi CL Brener infected in mouse NCTC-929 cells assessed as growth inhibition at 0.5 uM after 7 days by beta-galactosidase reporter gene assay,Other,24461296.0,
1341,1070005,1,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against amastigote stage of Trypanosoma cruzi CL Brener infected in mouse NCTC-929 cells assessed as growth inhibition at 1 uM after 7 days by beta-galactosidase reporter gene assay,Other,24461296.0,
1342,1070006,1,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against amastigote stage of Trypanosoma cruzi CL Brener infected in mouse NCTC-929 cells assessed as growth inhibition at 2 uM after 7 days by beta-galactosidase reporter gene assay,Other,24461296.0,
1343,1070007,1,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against amastigote stage of Trypanosoma cruzi CL Brener infected in mouse NCTC-929 cells assessed as growth inhibition at 4 uM after 7 days by beta-galactosidase reporter gene assay,Other,24461296.0,
1344,1070008,1,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against amastigote stage of Trypanosoma cruzi CL Brener infected in mouse NCTC-929 cells assessed as growth inhibition at 8 uM after 7 days by beta-galactosidase reporter gene assay,Other,24461296.0,
1345,1070009,1,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against amastigote stage of Trypanosoma cruzi CL Brener infected in mouse NCTC-929 cells assessed as growth inhibition at 16 uM after 7 days by beta-galactosidase reporter gene assay,Other,24461296.0,
1346,1070010,1,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against amastigote stage of Trypanosoma cruzi CL Brener infected in mouse NCTC-929 cells assessed as growth inhibition at 32 uM after 7 days by beta-galactosidase reporter gene assay,Other,24461296.0,
1347,1070011,1,1,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of LC50 for mouse NCTC-929 cells to IC50 for epimastigote stage of Trypanosoma cruzi CL Brener",Other,24461296.0,
1348,1070012,1,1,,103178476,31593,Unspecified,,,256.0,LC50,Cytotoxicity against mouse NCTC-929 cells after 48 hrs by resazurin staining-based fluorescence assay,Confirmatory,24461296.0,
1349,1070013,1,1,,103178476,31593,Unspecified,,,,,Cytotoxicity against mouse NCTC-929 cells at 256 uM after 48 hrs by resazurin staining-based fluorescence assay,Other,24461296.0,
1350,1070014,1,3,,103178476,31593,Active,,,27.12,IC50,Antimicrobial activity against epimastigote stage of Trypanosoma cruzi CL Brener assessed as growth inhibition after 72 hrs by beta-galactosidase reporter gene assay,Confirmatory,24461296.0,
1351,1070015,1,3,,103178476,31593,Unspecified,,,,,Antimicrobial activity against epimastigote stage of Trypanosoma cruzi CL Brener assessed as growth inhibition at 256 uM after 72 hrs by beta-galactosidase reporter gene assay,Other,24461296.0,
1352,1072681,1,1,,103178476,31593,Unspecified,,,,CC50,Cytotoxicity against BALB/c mouse splenocytes assessed as cell viability after 24 hrs by [3H]thymidine incorporation assay,Confirmatory,24561675.0,
1353,1072682,1,1,,103178476,31593,Active,,,6.2,CC50,Antitrypanosomal activity against Trypanosoma cruzi Y metacyclic trypomastigotes isolated from infected LLC-MK2 cells assessed as parasite viability after 24 hrs by neubauer chamber analysis,Confirmatory,24561675.0,
1354,1072683,1,1,,103178476,31593,Active,,,48.8,IC50,Antitrypanosomal activity against Trypanosoma cruzi Dm28c epimastigotes assessed as inhibition of parasite proliferation after 5 days by hemocytometer analysis,Confirmatory,24561675.0,
1355,1074372,1,1,,103178476,31593,Unspecified,,,,,"Trypanocidal activity against metacyclic trypomastigote stage of Trypanosoma cruzi infected in BALB/c albino mouse acute chagas disease model assessed as inhibition of parasitemia at 25 mg/kg, ip administered on day 7 to 12 post-infection measured every 2 days until day 40 by ELISA relative to control",Other,24410674.0,
1356,1074373,1,1,,103178476,31593,Active,,,,,"Trypanocidal activity against metacyclic trypomastigote stage of Trypanosoma cruzi infected in BALB/c albino mouse acute chagas disease model assessed as reduction of parasite burden at 25 mg/kg, ip administered on day 7 to 12 post-infection measured on day 14 by ELISA",Other,24410674.0,
1357,1074375,1,1,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against trypomastigote stage of Trypanosoma cruzi IRHOD/CO/2008/SN3 assessed as reduction of trypomastigote number per mililiter of culture medium at IC25 preincubated for 12 hrs followed by compound washout measured every 48 hrs for 10 days by Neubauer hemocytometric chamber analysis relative to control,Other,24410674.0,
1358,1074376,1,1,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi IRHOD/CO/2008/SN3 infected in African green monkey Vero cells assessed as reduction of amastigote number per cell at IC25 preincubated for 12 hrs followed by compound washout measured every 48 hrs for 10 days by Neubauer hemocytometric chamber analysis relative to control,Other,24410674.0,
1359,1074377,1,1,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi IRHOD/CO/2008/SN3 infected in African green monkey Vero cells assessed as decrease in infection rate at IC25 preincubated for 12 hrs followed by compound washout measured every 48 hrs for 10 days by Neubauer hemocytometric chamber analysis relative to control,Other,24410674.0,
1360,1074378,1,1,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for amastigote stage of Trypanosoma cruzi IRHOD/CO/2008/SN3 infected in African green monkey Vero cells",Other,24410674.0,
1361,1074379,1,1,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for epimastigote stage of Trypanosoma cruzi IRHOD/CO/2008/SN3",Other,24410674.0,
1362,1074380,1,2,,103178476,31593,Active,,,13.6,IC50,Cytotoxicity against African green monkey Vero cells assessed as cell viability after 72 hrs by propidium iodide/fluorescein diacetate staining-based flow cytometric analysis,Confirmatory,24410674.0,
1363,1074381,1,1,,103178476,31593,Active,,,23.3,IC50,Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi IRHOD/CO/2008/SN3 infected in African green monkey Vero cells assessed as parasite growth inhibition after 72 hrs by Giemsa staining-based microscopic analysis,Confirmatory,24410674.0,
1364,1074382,1,1,,103178476,31593,Active,,,15.9,IC50,Antitrypanosomal activity against epimastigote stage of Trypanosoma cruzi IRHOD/CO/2008/SN3 assessed as parasite growth inhibition after 72 hrs by Neubauer hemocytometric chamber analysis,Confirmatory,24410674.0,
1365,1074906,1,2,,103178476,31593,Active,,,,,Antitrypanosomal activity against Trypanosoma cruzi (IRHOD/CO/2008/SN3) epimastigotes assessed as plasma membrane with scalloped appearance with undulations and discontinuities at IC25 after 96 hrs by transmission electron microscopic analysis,Other,24448422.0,
1366,1074908,1,2,,103178476,31593,Active,,,,,Antitrypanosomal activity against Trypanosoma cruzi (IRHOD/CO/2008/SN3) epimastigotes assessed as disruption of cytoskeleton with disorganization of microtubule structure at IC25 after 96 hrs by transmission electron microscopic analysis,Other,24448422.0,
1367,1074918,1,2,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi (IRHOD/CO/2008/SN3) infected in BALB/c mouse assessed as reduction in parasite specific antibodies level at 1 mg/kg/day, ip treated from day 5 to day 10 post-infection measured from day 30 to day 120 post-infection by ELISA",Other,24448422.0,
1368,1074920,1,2,,103178476,31593,Unspecified,,,,,"Toxicity in BALB/c mouse assessed as survival at 1 mg/kg/day, ip relative to control",Other,24448422.0,
1369,1074921,1,2,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi (IRHOD/CO/2008/SN3) infected in BALB/c mouse assessed as reduction in parasitemia at 1 mg/kg/day, ip treated from day 5 to day 10 post-infection measured on day 30 post-infection relative to control",Other,24448422.0,
1370,1074922,1,2,,103178476,31593,Active,,,,,"Antitrypanosomal activity against Trypanosoma cruzi (IRHOD/CO/2008/SN3) infected in BALB/c mouse assessed as reduction in parasitemia at 1 mg/kg/day, ip treated from day 5 to day 10 post-infection measured on day 14 post-infection",Other,24448422.0,
1371,1074923,1,2,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi (IRHOD/CO/2008/SN3) infected in African green monkey Vero cells assessed as reduction in number of trypomastigotes at IC25 treated for 12 hrs followed by compound-washout measured after 10 days by microscopic analysis relative to control,Other,24448422.0,
1372,1074924,1,2,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi (IRHOD/CO/2008/SN3) infected in African green monkey Vero cells assessed as reduction in infection rate at IC25 treated for 12 hrs followed by compound-washout measured after 10 days by microscopic analysis relative to control,Other,24448422.0,
1373,1074925,1,2,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma cruzi (IRHOD/CO/2008/SN3) infected in African green monkey Vero cells assessed as reduction in number of amastigotes at IC25 treated for 12 hrs followed by compound-washout measured after 10 days by microscopic analysis relative to control,Other,24448422.0,
1374,1074926,1,2,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi (IRHOD/CO/2008/SN3) trypomastigotes",Other,24448422.0,
1375,1074927,1,2,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi (IRHOD/CO/2008/SN3) epimastigotes",Other,24448422.0,
1376,1074928,1,2,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi (IRHOD/CO/2008/SN3) amastigotes",Other,24448422.0,
1377,1074929,1,2,,103178476,31593,Active,,,13.6,IC50,Cytotoxicity against African green monkey Vero cells assessed as cell viability after 72 hrs by propidium iodide staining-based flow cytometric analysis,Confirmatory,24448422.0,
1378,1074930,1,2,,103178476,31593,Active,,,16.4,IC50,Antitrypanosomal activity against Trypanosoma cruzi (IRHOD/CO/2008/SN3) trypomastigotes infected in Balb/c albino mouse after 24 hrs by Neubauer chamber counting analysis,Confirmatory,24448422.0,
1379,1074931,1,2,,103178476,31593,Active,,,23.3,IC50,Antitrypanosomal activity against Trypanosoma cruzi (IRHOD/CO/2008/SN3) amastigotes infected in African green monkey Vero cells after 72 hrs by Giemsa staining-based microscopic analysis,Confirmatory,24448422.0,
1380,1074932,1,2,,103178476,31593,Active,,,15.9,IC50,Antitrypanosomal activity against Trypanosoma cruzi (IRHOD/CO/2008/SN3) epimastigotes after 72 hrs by Neubauer chamber counting analysis,Confirmatory,24448422.0,
1381,1077475,1,2,,103178476,31593,Active,,,1.7,IC50,Antiparasitic activity against trypomastigote forms of Trypanosoma cruzi Tulahuen infected in L6 cells after 96 hrs by beta-galactosidase reporter assay,Confirmatory,,
1382,1079931,1,1,,103178476,31593,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
1383,1079932,1,1,,103178476,31593,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
1384,1079933,1,1,,103178476,31593,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
1385,1079934,1,1,,103178476,31593,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
1386,1079935,1,1,,103178476,31593,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
1387,1079936,1,1,,103178476,31593,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
1388,1079937,1,1,,103178476,31593,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
1389,1079938,1,1,,103178476,31593,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
1390,1079939,1,1,,103178476,31593,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
1391,1079940,1,1,,103178476,31593,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
1392,1079941,1,1,,103178476,31593,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
1393,1079942,1,1,,103178476,31593,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
1394,1079943,1,1,,103178476,31593,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
1395,1079944,1,1,,103178476,31593,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
1396,1079945,1,1,,103178476,31593,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
1397,1079946,1,1,,103178476,31593,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
1398,1079947,1,1,,103178476,31593,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
1399,1079948,1,1,,103178476,31593,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
1400,1079949,1,1,,103178476,31593,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
1401,1094680,1,2,,103178476,31593,Active,,,42.7,IC50,Antitrypanosomal activity against epimastigote forms of Trypanosoma cruzi Y after 72 hr,Confirmatory,,
1402,1105655,5,1,,103178476,31593,Unspecified,,,,,Cytotoxicity against Mus musculus BALB/c (mouse) splenocytes assessed as decrease in [3H]-thymidine incorporation after 24 hr by beta-radiation counting analysis,Other,,
1403,1105657,1,2,,103178476,31593,Active,,,5.0,IC50,Antitypanosomal activity against benznidazole-resistant trypomastigote stage of Trypanosoma cruzi Y assessed as parasite growth inhibition after 24 hr by hemacytometric analysis,Confirmatory,,
1404,1105658,1,2,,103178476,31593,Active,,,6.6,IC50,Antitypanosomal activity against benznidazole-resistant epimastigote stage of Trypanosoma cruzi Y assessed as parasite growth inhibition after 11 days by hemacytometric analysis,Confirmatory,,
1405,1114420,1,2,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against trypomastigote form of Trypanosoma cruzi INC5 after 24 hr by Neubauer counting method,Other,,
1406,1114421,1,2,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against trypomastigote form of Trypanosoma cruzi NINOA after 24 hr by Neubauer counting method,Other,,
1407,1117298,1,2,,170466539,31593,Inactive,,,17.7828,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
1408,1117304,1,2,,170466539,31593,Unspecified,,,,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
1409,1117305,1,2,,170466539,31593,Unspecified,,,,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
1410,1117310,1,1,,170466539,31593,Inactive,,,17.7828,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
1411,1117312,1,1,,170466539,31593,Inactive,,,,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
1412,1117314,1,1,,170466539,31593,Inactive,,,,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
1413,1117326,1,1,,170466539,31593,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
1414,1117329,1,1,,170466539,31593,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
1415,1117336,1,1,,170466539,31593,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
1416,1117340,1,1,,170466539,31593,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
1417,1117341,1,1,,170466539,31593,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
1418,1117342,1,1,,170466539,31593,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
1419,1117343,1,1,,170466539,31593,Inactive,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
1420,1117346,1,1,,170466539,31593,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
1421,1119198,1,1,,103178476,31593,Active,,,7.4,ID50,Antitrypanosomal activity against epimastigote stage of Trypanosoma cruzi Tulahuen 2 after 5 days relative to untreated control,Confirmatory,,
1422,1119253,1,1,,103178476,31593,Active,,,10.0,IC50,Antiparasitic activity against Trypanosoma cruzi strain CL Brener epimastigotes assessed as growth inhibition after 72 hrs by neubauer chamber analysis,Confirmatory,,
1423,1119254,1,1,,103178476,31593,Unspecified,,,,,Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation at 5 ug/ml after 48 hrs by MTT assay,Other,,
1424,1119519,1,1,,103178476,31593,Active,,,12.5,IC50,Antitrypanosomal activity against epimastigote stage of Trypanosoma cruzi Dm28c infected in African green monkey Vero cells after 72 hrs relative to untreated control,Confirmatory,,
1425,1119520,1,1,,103178476,31593,Unspecified,,,309.1,CC50,Cytotoxicity against African green monkey Vero cells after 72 hrs by resazurin assay,Confirmatory,,
1426,1119521,1,1,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for epimastigote stage of Trypanosoma cruzi Dm28c",Other,,
1427,1119525,1,1,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi Dm28c infected in African green monkey Vero cells assessed as growth inhibition at 1 uM incubated 8 hrs post infection measured after 24 hrs relative to control,Other,,
1428,1119526,1,1,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi Dm28c infected in African green monkey Vero cells assessed as growth inhibition at 15 uM incubated 8 hrs post infection measured after 24 hrs relative to control,Other,,
1429,1119527,1,1,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi Dm28c infected in African green monkey Vero cells assessed as growth inhibition at 30 uM incubated 8 hrs post infection measured after 24 hrs relative to control,Other,,
1430,1119912,1,1,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against epimastigote stage of Trypanosoma cruzi Y assessed as parasite growth inhibition at 10 ug/mL after 72 hrs by spectrophotometric analysis relative to control,Other,,
1431,1119913,1,1,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against epimastigote stage of Trypanosoma cruzi Y assessed as parasite growth inhibition at 20 ug/mL after 72 hrs by spectrophotometric analysis relative to control,Other,,
1432,1119914,1,1,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against epimastigote stage of Trypanosoma cruzi Y assessed as parasite growth inhibition at 50 ug/mL after 72 hrs by spectrophotometric analysis relative to control,Other,,
1433,1120587,1,1,,103178476,31593,Active,,,0.8859999999999999,IC50,Antiprotozoal activity against Trypanosoma cruzi Tulahuen C2C4,Confirmatory,,
1434,1120588,1,1,,103178476,31593,Inconclusive,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma cruzi Tulahuen C2C4",Other,,
1435,1124783,1,1,,103178476,31593,Unspecified,,,2126.16,IC50,Cytotoxicity against human HepG2 cells by MTT assay,Confirmatory,24630563.0,
1436,1124784,1,1,,103178476,31593,Unspecified,,,207.57,IC50,Antimicrobial activity against procyclic stage of Trypanosoma brucei 427 after 24 hrs by MTT assay,Confirmatory,24630563.0,
1437,1124785,1,1,,103178476,31593,Unspecified,,,,,"Safety index, ratio of IC50 for human HepG2 cells to IC50 for procyclic stage of Trypanosoma brucei 427",Other,24630563.0,
1438,1124786,1,1,,103178476,31593,Unspecified,,,149.58,IC50,Antimicrobial activity against epimastigote stage of Trypanosoma brucei 29-13 after 24 hrs by MTT assay,Confirmatory,24630563.0,
1439,1124787,1,1,,103178476,31593,Unspecified,,,,,"Safety index, ratio of IC50 for human HepG2 cells to IC50 for epimastigote stage of Trypanosoma brucei 29-13",Other,24630563.0,
1440,1124788,1,1,,103178476,31593,Active,,,34.0,IC50,Antimicrobial activity against epimastigote stage of Trypanosoma cruzi Y after 72 hrs by MTT assay,Confirmatory,24630563.0,
1441,1124789,1,1,,103178476,31593,Unspecified,,,,,"Safety index, ratio of IC50 for human HepG2 cells to IC50 for epimastigote stage of Trypanosoma cruzi Y",Other,24630563.0,
1442,1126158,1,1,,103178476,31593,Active,,,1.73,IC50,Antitrypanosomal activity against trypomastigote forms of Trypanosoma cruzi Tulahuen C4,Confirmatory,24673206.0,
1443,1128397,1,1,,103178476,31593,Active,,,4.8,IC50,Antitrypanosomal activity against amastigote stage of lacZ expressing Trypanosoma cruzi Tulahuen after 72 hrs,Confirmatory,24533839.0,
1444,1140922,1,1,,103178476,31593,Active,,,7.0,IC50,Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 epimastigotes assessed as growth inhibition after 5 days,Confirmatory,24749923.0,
1445,1140925,1,1,,103178476,31593,Active,,,3.3,IC50,Antitrypanosomal activity against Trypanosoma cruzi Sylvio X-10 amastigotes infected in African green monkey Vero cells assessed as eradication of amastigotes after 72 hrs by Giemsa staining-based assay,Confirmatory,24749923.0,
1446,1140926,1,1,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi Sylvio X-10 amastigotes",Other,24749923.0,
1447,1140993,1,1,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi CL Brener infected in BALB/c mouse assessed as peak of maximum parasitemia at 192 umol/kg/day, po for 14 days administered in saline and tween 80 measured up to 60 days relative to control",Other,24749923.0,
1448,1140998,1,1,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma cruzi CL Brener infected in BALB/c mouse assessed as mouse survival at 192 umol/kg/day, po for 14 days administered in saline and tween 80 measured up to 60 days relative to control",Other,24749923.0,
1449,1154398,1,1,,103178476,31593,Active,,,11.3,IC50,Antitrypanosomal activity against trypomastigote stage of Trypanosoma cruzi Y assessed as living parasites level after 24 hrs by Neubauer chamber analysis,Confirmatory,24871307.0,
1450,1154399,1,1,,103178476,31593,Active,,,14.0,IC50,Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi Y in BALB/c mouse peritoneal macrophages assessed as reduction of number of intracellular parasites per 100 cells after 4 days by hematoxylin/eosin staining-based optical microscopic analysis,Confirmatory,24871307.0,
1451,1154400,1,1,,103178476,31593,Unspecified,,,20.0,LC50,Cytotoxicity against BALB/c mouse peritoneal macrophages after 72 hrs by AlamarBlue assay,Confirmatory,24871307.0,
1452,1154402,1,1,,103178476,31593,Active,,,,,Antitrypanosomal activity against trypomastigote stage of Trypanosoma cruzi Y infected in BALB/c mouse peritoneal macrophages assessed as inhibition of host cell invasion at 10 uM after 2 hrs by hematoxylin/eosin staining-based optical microscopic analysis,Other,24871307.0,
1453,1154403,1,1,,103178476,31593,Unspecified,,,,,"Antitrypanosomal activity against blood stage trypomastigote form of Trypanosoma cruzi Y infected in BALB/c mouse assessed as reduction of blood parasitemia at 100 mg/kg, po qd administered for 5 days relative to control",Other,24871307.0,
1454,1155753,1,1,,103178476,31593,Active,,,1.5,IC50,Trypanocidal activity against Trypanosoma cruzi Tulahuen C2C4 amastigotes infected in rat L6 cells after 4 days,Confirmatory,24929292.0,
1455,1155754,1,1,,103178476,31593,Inconclusive,,,,IC50,Induction of NO release assessed as nitrite level,Confirmatory,24929292.0,
1456,1155759,1,1,,103178476,31593,Active,,,28.1,IC50,Cytotoxicity against human HepG2 cells after 24 hrs by XTT assay,Confirmatory,24929292.0,
1457,1155760,1,1,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for human HepG2 cells to IC50 for Trypanosoma cruzi Tulahuen C2C4",Other,24929292.0,
1458,1156603,1,1,,103178476,31593,Unspecified,,,150.0,IC50,Cytotoxicity against rat L6 cells after 3 days by Alamar blue assay,Confirmatory,24956553.0,
1459,1156604,1,1,,103178476,31593,Active,,,1.87,IC50,Antiparasitic activity against Trypanosoma cruzi Tulahen LacZ/C4 amastigotes after 4 days by beta-galactosidase reporter gene assay,Confirmatory,24956553.0,
1460,1156605,1,1,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma cruzi Tulahen LacZ/C4 amastigotes",Other,24956553.0,
1461,1156606,1,1,,103178476,31593,Inconclusive,,,,IC50,Antiparasitic activity against Leishmania amazonensis infected in CD-1 mouse macrophages after 72 hrs by spectrophotometric analysis,Confirmatory,24956553.0,
1462,1156608,1,1,,103178476,31593,Inconclusive,,,,IC50,Antiparasitic activity against Trypanosoma brucei rhodesiense STIB900 trypomastigotes after 3 days by Alamar blue assay,Confirmatory,24956553.0,
1463,1156610,1,1,,103178476,31593,Inconclusive,,,,IC50,Antiparasitic activity against chloroquine-resistant Plasmodium falciparum K1 after 3 days by [3H]-hypoxanthine incorporation assay,Confirmatory,24956553.0,
1464,1159509,1,1,,170466539,31593,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
1465,1159515,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
1466,1159516,1,1,,170466539,31593,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
1467,1159517,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
1468,1159518,1,1,,170466539,31593,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
1469,1159519,1,1,,170466539,31593,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
1470,1159520,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1471,1159521,1,1,,170466539,31593,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1472,1159523,1,1,,170466539,31593,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
1473,1159524,1,1,,56320744,31593,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
1474,1159525,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
1475,1159526,1,1,,170466539,31593,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
1476,1159527,1,1,,170466539,31593,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
1477,1159528,1,1,,170466539,31593,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
1478,1159529,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
1479,1159531,1,1,,170466539,31593,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
1480,1159551,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
1481,1159552,1,1,,170466539,31593,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1482,1159553,2,1,,170466539,31593,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1483,1159555,1,1,,170466539,31593,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
1484,1159583,2,1,,178125564,31593,Inactive,,,,,High throughput screen for small molecule inhibitors of a hypoxia-regulated fluorescent biosensor in Mycobacterium tuberculosis,Other,,
1485,1159606,1,1,,56320744,31593,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
1486,1159614,1,2,,170466539,31593,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
1487,1163253,1,1,,103178476,31593,Active,,,2.56,IC50,Trypanocidal activity against nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 infected in human MRC5 SV2 cells assessed as parasite growth inhibition after 168 hrs by beta-galactosidase assay,Confirmatory,25199582.0,
1488,1164929,1,1,,103178476,31593,Unspecified,,,,,Trypanocidal activity against epimastigote forms of Trypanosoma cruzi Punta Lobos after 24 hrs,Other,25238291.0,
1489,1164930,1,1,,103178476,31593,Unspecified,,,,,Trypanocidal activity against epimastigote forms of Trypanosoma cruzi Queretaro after 24 hrs,Other,25238291.0,
1490,1164931,1,1,,103178476,31593,Unspecified,,,,,Induction of apoptosis in human monocytes assessed as viable cells using Annexin V/propidium iodide by flow cytometry (Rvb = 97.53 %),Other,25238291.0,
1491,1164932,1,1,,103178476,31593,Unspecified,,,,,Induction of apoptosis in human monocytes assessed as early apoptotic cells using Annexin V/propidium iodide by flow cytometry (Rvb = 2.18 %),Other,25238291.0,
1492,1164933,1,1,,103178476,31593,Unspecified,,,,,Induction of apoptosis in human monocytes assessed as late apoptotic cells using Annexin V/propidium iodide by flow cytometry (Rvb = 0.27 %),Other,25238291.0,
1493,1164934,1,1,,103178476,31593,Unspecified,,,,,Induction of apoptosis in human monocytes assessed as necrotic cells using Annexin V/propidium iodide by flow cytometry (Rvb = 0.02 %),Other,25238291.0,
1494,1164935,1,1,,103178476,31593,Unspecified,,,,,Induction of apoptosis in human platelets assessed as viable cells after 10 mins using Annexin V/propidium iodide by flow cytometry (Rvb = 89.61 %),Other,25238291.0,
1495,1164936,1,1,,103178476,31593,Unspecified,,,,,Induction of apoptosis in human platelets assessed as early apoptotic cells after 10 mins using Annexin V/propidium iodide by flow cytometry (Rvb = 10.30 %),Other,25238291.0,
1496,1164937,1,1,,103178476,31593,Unspecified,,,,,Induction of apoptosis in human platelets assessed as late apoptotic cells after 10 mins using Annexin V/propidium iodide by flow cytometry (Rvb = 0.02 %),Other,25238291.0,
1497,1164938,1,1,,103178476,31593,Unspecified,,,,,Induction of apoptosis in human platelets assessed as necrotic cells after 10 mins using Annexin V/propidium iodide by flow cytometry (Rvb = 0.07 %),Other,25238291.0,
1498,1164939,1,1,,103178476,31593,Unspecified,,,,,Activation of human platelets assessed as CD62P expression at 3.9 ug/ml by flow cytometry relative to control,Other,25238291.0,
1499,1165090,1,1,,103178476,31593,Active,,,2.13,IC50,Antiparasitic activity against trypomastigote forms of Trypanosoma cruzi Tulahuen C2C4 infected in rat L6 cells assessed as inhibition of growth after 96 hrs by inverted microscopy,Confirmatory,25240098.0,
1500,1165095,1,1,,103178476,31593,Active,,,21.8,IC50,Trypanocidal activity against bloodstream forms of Trypanosoma brucei brucei Lister 427 clone 221a overexpressing type I nitroreductase assessed as inhibition of proliferation after 3 days by resazurin assay in absence of tetracycline,Confirmatory,25240098.0,
1501,1165096,1,1,,103178476,31593,Active,,,2.2,IC50,Trypanocidal activity against bloodstream forms of Trypanosoma brucei brucei Lister 427 clone 221a overexpressing type I nitroreductase assessed as inhibition of proliferation after 3 days by resazurin assay in presence of tetracycline,Confirmatory,25240098.0,
1502,1165097,1,1,,103178476,31593,Unspecified,,,,,Ratio of IC50 for bloodstream forms of Trypanosoma brucei brucei Lister 427 clone 221a overexpressing type I nitroreductase in absence of tetracycline to IC50 for bloodstream forms of Trypanosoma brucei brucei Lister 427 clone 221a overexpressing type I nitroreductase in presence of tetracycline,Other,25240098.0,
1503,1169288,1,1,,103178476,31593,Active,,,2.9,IC50,Antitrypanosomal activity against LacZ expressing Trypanosoma cruzi Tuluhaen C2C4 amastigotes,Confirmatory,25314007.0,
1504,1171005,1,1,,103178476,31593,Inactive,,,,,Effect on lipid composition in Trypanosoma cruzi CAI/72 amastigotes infected in mouse C2C12 cells at 5 uM incubated for 24 hrs by GC-MS method,Other,25393646.0,
1505,1174777,1,1,,103178476,31593,Active,,,15.9,IC50,Trypanocidal activity against epimastigote Trypanosoma cruzi IRHOD/CO/2008/SN3,Confirmatory,25462275.0,
1506,1174778,1,1,,103178476,31593,Active,,,23.3,IC50,Trypanocidal activity against intracellular amastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 in african green monkey Vero cells,Confirmatory,25462275.0,
1507,1174779,1,2,,103178476,31593,Active,,,16.4,IC50,Antiparasitic activity against trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 infected in BALB/c mouse acute chagas disease model assessed as parasite reduction in blood,Confirmatory,25462275.0,
1508,1174780,1,1,,103178476,31593,Active,,,13.6,IC50,Cytotoxicity against african green monkey Vero cells after 72 hrs,Confirmatory,25462275.0,
1509,1174781,1,1,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for epimastigote Trypanosoma cruzi IRHOD/CO/2008/SN3",Other,25462275.0,
1510,1174782,1,1,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for intracellular amastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3",Other,25462275.0,
1511,1174783,1,1,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3",Other,25462275.0,
1512,1174796,1,2,,103178476,31593,Unspecified,,,,,"Antiparasitic activity against trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 infected in BALB/c mouse acute chagas disease model assessed as parasite reduction in blood at 5 mg/kg, ip measured on day 40 post infection",Other,25462275.0,
1513,1174798,1,1,,103178476,31593,Unspecified,,,,,"Antiparasitic activity against trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 infected in BALB/c mouse acute chagas disease model assessed as parasitemia reactivation at 5 mg/kg, ip after 60 days immunosuppressed with cyclophosphamide monohydrate measured up to day 120 post infection (Rvb = 80.3%)",Other,25462275.0,
1514,1176976,1,1,,103178476,31593,Active,,,0.409,IC50,Antitrypanosomal activity against Trypanosoma cruzi assessed as growth inhibition,Confirmatory,25547934.0,
1515,1177051,1,1,,103178476,31593,Active,,,2.13,IC50,Antiprotozoan activity against Trypanosoma cruzi Tulahuen C4 amastigotes,Confirmatory,25563890.0,
1516,1177592,1,1,,103178476,31593,Active,,,1.73,IC50,Antiparasitic activity against Trypanosoma cruzi Tulahuen C4,Confirmatory,25080196.0,
1517,1181597,1,1,,103178476,31593,Unspecified,,,,IC50,Antimicrobial activity against trypomastigote form of Trypanosoma cruzi Tulahuen C2C4 infected in rat L6 cells after 96 hrs by microscopic analysis,Confirmatory,24978605.0,
1518,1184288,1,1,,103178476,31593,Active,,,20.7,EC50,Antitrypanosomal activity against intracellular Trypanosoma cruzi infected in human U2OS cells after 48 hrs by confocal microscopy,Confirmatory,25036797.0,
1519,1184289,1,1,,103178476,31593,Unspecified,,,50.0,CC50,Cytotoxicity against human U2OS cells infected with intracellular Trypanosoma cruzi,Confirmatory,25036797.0,
1520,1184290,1,1,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for human U2OS cells to IC50 for intracellular Trypanosoma cruzi",Other,25036797.0,
1521,1184292,1,1,,103178476,31593,Active,,,,,Antitrypanosomal activity against intracellular Trypanosoma cruzi infected in human U2OS cells assessed as reduction in parasite count at 400 uM after 48 hrs by confocal microscopy,Other,25036797.0,
1522,1184293,1,1,,103178476,31593,Inactive,,,,,Antitrypanosomal activity against intracellular Trypanosoma cruzi infected in human U2OS cells assessed as reduction in parasite count at 12.5 uM after 48 hrs by confocal microscopy,Other,25036797.0,
1523,1188733,1,1,,103178476,31593,Inconclusive,,,,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by,Confirmatory,25147146.0,
1524,1188734,1,1,,103178476,31593,Active,,,6.2,IC50,Antitrypanosomal activity against trypomastigote forms of Trypanosoma cruzi Y infected in LLC-MK2 cells assessed as reduction in viable parasites after 24 hrs by Neubauer chamber counting method,Confirmatory,25147146.0,
1525,1188735,1,1,,103178476,31593,Active,,,6.6,IC50,Trypanocidal activity against epimastigote forms of Trypanosoma cruzi Y assessed as reduction in viable parasites after 11 days by Neubauer chamber counting method,Confirmatory,25147146.0,
1526,1191151,1,1,,103178476,31593,Active,,,3.4,EC50,Antitrypanosomal activity against trypomastigote stage of Trypanosoma cruzi Y infected in monkey LLC-MK2 cells after 24 hrs by Pizzi-Brener method,Confirmatory,25461316.0,
1527,1191152,1,1,,103178476,31593,Active,,,8.1,IC50,Antitrypanosomal activity against epimastigote stage of Trypanosoma cruzi Y after 96 hrs by hemocytometry,Confirmatory,25461316.0,
1528,1191155,1,1,,103178476,31593,Active,,,26.1,IC50,Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi,Confirmatory,25461316.0,
1529,1196782,1,1,,103178476,31593,Unspecified,,,,,Inhibition of recombinant full-length Trypanosoma cruzi CYP51 assessed as molar ratio of inhibitor to enzyme which causes 2 fold decrease in enzyme activity in 5 mins by HPLC analysis,Other,25580906.0,
1530,1196783,1,1,,103178476,31593,Unspecified,,,,,Inhibition of recombinant full-length Trypanosoma cruzi CYP51 assessed as molar ratio of inhibitor to enzyme which causes 2 fold decrease in enzyme activity in 1 hr by HPLC analysis,Other,25580906.0,
1531,1196784,1,1,,103178476,31593,Unspecified,,,,,"Antichagasic activity against trypomastigote stage of Trypanosoma cruzi Brazil infected in Balb/c mouse assessed as reduction of parasite index at 15 mg/kg/day, ip measured after 10 days by luciferase reporter gene assay relative to control",Other,25580906.0,
1532,1196788,1,1,,103178476,31593,Unspecified,,,,,"Antichagasic activity against trypomastigote stage of Trypanosoma cruzi Brazil infected in Balb/c mouse assessed as parasite index at 15 mg/kg/day, ip measured after 5 days by luciferase reporter gene assay",Other,25580906.0,
1533,1196789,1,1,,103178476,31593,Unspecified,,,,,"Toxicity in Balb/c mouse at 15 mg/kg/day, ip measured after 5 to 10 days",Other,25580906.0,
1534,1196799,1,1,,103178476,31593,Active,,,2.18,IC50,Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi Tulahuen C4 infected in rat L6 cells assessed as parasite growth inhibition after 96 hrs by colorimetric analysis,Confirmatory,25580906.0,
1535,1196803,1,1,,103178476,31593,Unspecified,,,,,Activity of his-tagged recombinant Trypanosoma brucei type-1 nitroreductase assessed as oxidized NADH level per mg of protein after 5 mins by absorption spectrum analysis,Other,25580906.0,
1536,1196804,1,1,,103178476,31593,Unspecified,,,,,Activity of his-tagged recombinant Trypanosoma cruzi type-1 nitroreductase assessed as oxidized NADH level per mg of protein after 5 mins by absorption spectrum analysis,Other,25580906.0,
1537,1196810,1,1,,103178476,31593,Inconclusive,,,,Kd,Binding affinity to recombinant full-length Trypanosoma cruzi CYP51 by UV-spectrophotometric analysis,Confirmatory,25580906.0,
1538,1198533,1,1,,103178476,31593,Active,,,,,"Trypanocidal activity against GFP expressing Trypanosoma cruzi Y C57BL/6J mouse acute model of trypanosomal infection assessed as reduction in parasitemia at 100 mg/kg/day, ip measured at 10,14 and 20 days post infection",Other,25707014.0,
1539,1198535,1,1,,103178476,31593,Active,,,,,"Trypanocidal activity against GFP expressing Trypanosoma cruzi Y C57BL/6J mouse acute model of trypanosomal infection assessed as reduction in cardiac amastigote nests counts at 100 mg/kg/day, ip measured at 10,14 and 20 days post infection by HE staining based conventional microscopy",Other,25707014.0,
1540,1198733,1,1,,103178476,31593,Unspecified,,,,,Cytotoxicity against human U937 cells assessed as cell viability after 72 hrs by MTT assay,Other,25725376.0,
1541,1198737,1,1,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi Tulahuen infected in human U937 cells assessed as parasite growth inhibition at 20 ug/mL after 72 hrs by beta-galactosidase reporter gene assay relative to control,Other,25725376.0,
1542,1198739,1,1,,103178476,31593,Unspecified,,,,,Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi Tulahuen infected in human U937 cells assessed as parasite growth inhibition after 72 hrs by beta-galactosidase reporter gene assay,Other,25725376.0,
1543,1199919,1,1,,103178476,31593,Active,,,1.7,IC50,Antiprotozoal activity against intracellular amastigote stage of Trypanosoma cruzi Tulahuen C4 by colorimetric assay,Confirmatory,25642604.0,
1544,1202488,1,1,,103178476,31593,Unspecified,,,54.7,IC50,Trypanosomicidal activity against epimastigote stage of Trypanosoma cruzi CL-B5 after 72 hrs by beta-galactosidase reporter gene assay,Confirmatory,25884114.0,
1545,1202549,1,1,,103178476,31593,Unspecified,,,780.0,LC50,Antimicrobial activity against bloodstream trypomastigote stage of Trypanosoma cruzi NINOA after 24 hrs by Brener method,Confirmatory,25899334.0,
1546,1202550,1,1,,103178476,31593,Unspecified,,,690.0,LC50,Antimicrobial activity against bloodstream trypomastigote stage of Trypanosoma cruzi INC-5 after 24 hrs by Brener method,Confirmatory,25899334.0,
1547,1202551,1,1,,103178476,31593,Inconclusive,,,,LC50,Antimicrobial activity against Leishmania mexicana MHOM/BZ/61/M379 after 24 hrs by haemocytometry,Confirmatory,25899334.0,
1548,1202572,1,1,,103178476,31593,Unspecified,,,,IC50,Anti-trypanosomal activity against Trypanosoma cruzi Y epimastigote forms assessed as inhibition of parasite growth after 72 hrs by microplate reader based assay,Confirmatory,25899337.0,
1549,1202573,1,1,,103178476,31593,Unspecified,,,,IC50,Anti-trypanosomal activity against Trypanosoma cruzi Silvio X10 cl1 epimastigote forms assessed as inhibition of parasite growth after 72 hrs by microplate reader based assay,Confirmatory,25899337.0,
1550,1202574,1,1,,103178476,31593,Unspecified,,,,IC50,Anti-trypanosomal activity against Trypanosoma cruzi Bug 2149 cl10 epimastigote forms assessed as inhibition of parasite growth after 72 hrs by microplate reader based assay,Confirmatory,25899337.0,
1551,1202575,1,1,,103178476,31593,Unspecified,,,200.0,IC50,Cytotoxicity against human LL24 cells assessed as inhibition of cell growth after 24 hrs by MTT assay,Confirmatory,25899337.0,
1552,1202576,1,1,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for human LL24 cells to IC50 for Trypanosoma cruzi Y epimastigote forms",Other,25899337.0,
1553,1202577,1,1,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for human LL24 cells to IC50 for Trypanosoma cruzi Silvio X10 cl1 epimastigote forms",Other,25899337.0,
1554,1202578,1,1,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for human LL24 cells to IC50 for Trypanosoma cruzi Bug 2149 cl10",Other,25899337.0,
1555,1224834,3,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
1556,1224835,1,1,,170466539,31593,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
1557,1224836,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1558,1224837,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1559,1224838,1,1,,170466539,31593,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1560,1224839,1,1,,170466539,31593,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1561,1224840,3,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
1562,1224841,3,1,,170466539,31593,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1563,1224842,3,1,,170466539,31593,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1564,1224843,1,1,,170466539,31593,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1565,1224844,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
1566,1224845,1,1,,170466539,31593,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
1567,1224846,1,1,,170466539,31593,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
1568,1224847,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
1569,1224848,3,1,,170466539,31593,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1570,1224849,3,1,,170466539,31593,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1571,1224857,2,1,,170466539,31593,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
1572,1224859,2,1,,170466539,31593,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1573,1224865,1,2,,56320744,31593,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
1574,1224867,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
1575,1224868,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
1576,1224869,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
1577,1224870,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
1578,1224871,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
1579,1224872,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
1580,1224873,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
1581,1224874,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
1582,1224875,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
1583,1224876,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
1584,1224877,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
1585,1224878,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
1586,1224879,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
1587,1224880,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
1588,1224881,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
1589,1224882,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
1590,1224883,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
1591,1224884,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
1592,1224885,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
1593,1224886,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
1594,1224887,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
1595,1224888,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
1596,1224889,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
1597,1224890,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
1598,1224892,1,1,,170466539,31593,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1599,1224893,1,1,,170466539,31593,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1600,1224894,1,1,,170466539,31593,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
1601,1224895,1,1,,170466539,31593,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1602,1224896,1,1,,170466539,31593,Inconclusive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
1603,1228663,1,1,,103178476,31593,Unspecified,,,441.0,IC50,Antitrypanosomal activity against trypomastigote stage of Trypanosoma cruzi Y assessed as inhibition of cell viability after 24 hrs by MTT assay,Confirmatory,25924111.0,
1604,1228665,1,1,,103178476,31593,Unspecified,,,477.0,IC50,Cytotoxicity against rhesus monkey LLC-MK2 cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,25924111.0,
1605,1228672,1,1,,103178476,31593,Inconclusive,,,,IC50,Antileishmanial activity against promastigote stage of Leishmania infantum MHOM/BR/1972/LD assessed as reduction of cell viability after 48 hrs by MTT assay,Confirmatory,25924111.0,
1606,1233721,1,1,,103178476,31593,Active,,,1.2,EC50,Antiparasite activity against Trypanosoma cruzi Tulahuen expressing beta-galactosidase assessed as growth inhibition incubated for 96 hrs by CPRG dye based assay,Confirmatory,26087257.0,
1607,1234671,1,1,,103178476,31593,Active,,,18.8,IC50,Antiparasitic activity against Trypanosoma cruzi strain CL Brener epimastigotes after 12 days by ELISA reader,Confirmatory,26072173.0,
1608,1234672,1,1,,103178476,31593,Inactive,,,,,Antiparasitic activity against Trypanosoma cruzi strain CL Brener epimastigotes at 300 uM after 12 days by ELISA reader,Other,26072173.0,
1609,1236978,1,1,,103178476,31593,Active,,,6.8,IC50,Antitrypanosomal activity against trypomastigotes stage of Trypanosoma cruzi infected in human HT1080 cells assessed as inhibition of parasite growth after 24 hrs by microscopic analysis,Confirmatory,26037321.0,
1610,1236979,1,1,,103178476,31593,Active,,,,,Induction of reactive oxygen species formation in human HT1080 cells at 10 to 50 M by fluorometric analysis,Other,26037321.0,
1611,1236980,1,1,,103178476,31593,Unspecified,,,100.0,LD50,Cytotoxicity against Swiss mouse 3T3 cells assessed as cell death after 24 hrs by lactate dehydrogenase assay,Confirmatory,26037321.0,
1612,1238019,1,1,,103178476,31593,Inconclusive,,,,EC50,Anti-leishmanial activity against Leishmania amazonensis MPRO/BR/1972/M1841-LV-79 promastigotes assessed as parasite growth inhibition incubated for 72 hrs by MTT assay,Confirmatory,26055530.0,
1613,1238020,1,1,,103178476,31593,Inconclusive,,,,,"Selectivity index, ratio of EC50 for BALB/c mouse peritoneal macrophages to EC50 for Leishmania amazonensis MPRO/BR/1972/M1841-LV-79 promastigotes",Other,26055530.0,
1614,1238021,1,1,,103178476,31593,Inconclusive,,,,EC50,Anti-leishmanial activity against Leishmania amazonensis MPRO/BR/1972/M1841-LV-79 amastigotes infected in BALB/c mouse peritoneal macrophages assessed as reduction in the infection index incubated for 24 hrs by Giemsa staining method,Confirmatory,26055530.0,
1615,1238022,1,1,,103178476,31593,Inconclusive,,,,,"Selectivity index, ratio of EC50 for BALB/c mouse peritoneal macrophages to EC50 for Leishmania amazonensis MPRO/BR/1972/M1841-LV-79 amastigotes",Other,26055530.0,
1616,1238023,1,1,,103178476,31593,Inconclusive,,,,EC50,Anti-leishmanial activity against Leishmania infantum MHOM/BR/72 promastigotes assessed as parasite growth inhibition incubated for 72 hrs by MTT assay,Confirmatory,26055530.0,
1617,1238024,1,1,,103178476,31593,Inconclusive,,,,,"Selectivity index, ratio of EC50 for BALB/c mouse peritoneal macrophages to EC50 for Leishmania infantum MHOM/BR/72 promastigotes",Other,26055530.0,
1618,1238025,1,1,,103178476,31593,Inconclusive,,,,EC50,Anti-leishmanial activity against Leishmania infantum MHOM/BR/72 amastigotes infected in BALB/c mouse peritoneal macrophages assessed as reduction in the infection index incubated for 24 hrs by Giemsa staining method,Confirmatory,26055530.0,
1619,1238026,1,1,,103178476,31593,Inconclusive,,,,,"Selectivity index, ratio of EC50 for BALB/c mouse peritoneal macrophages to EC50 for Leishmania infantum MHOM/BR/72 amastigotes",Other,26055530.0,
1620,1238027,1,1,,103178476,31593,Active,,,4.07,EC50,Anti-trypanosomal activity against Trypanosoma cruzi Y epimastigotes assessed as parasite growth inhibition incubated for 72 hrs by MTT assay,Confirmatory,26055530.0,
1621,1238028,1,1,,103178476,31593,Inconclusive,,,,,"Selectivity index, ratio of EC50 for BALB/c mouse peritoneal macrophages to EC50 for Trypanosoma cruzi Y epimastigotes",Other,26055530.0,
1622,1238029,1,1,,103178476,31593,Inconclusive,,,,EC50,Cytotoxicity against BALB/c mouse peritoneal macrophages incubated for 24 hrs by MTT assay,Confirmatory,26055530.0,
1623,1240904,1,1,,103178476,31593,Active,,,1.7,IC50,Antitrypanosomal activity against trypomastigote forms of Trypanosoma cruzi Tulahuen C4 expressing LacZ gene infected in rat L6 cells after 96 hrs by inverted microscope analysis,Confirmatory,26237241.0,
1624,1240905,1,1,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for trypomastigote forms of Trypanosoma cruzi Tulahuen C4",Other,26237241.0,
1625,1240908,1,1,,103178476,31593,Unspecified,,,384.0,IC50,Cytotoxicity against rat L6 cells after 72 hrs by alamar blue assay,Confirmatory,26237241.0,
1626,1244462,1,1,,103178476,31593,Unspecified,,,687.7,LC50,Cytotoxicity against human U937 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,26218652.0,
1627,1244469,1,1,,103178476,31593,Unspecified,,,,,Trypanocidal activity against intracellular amastigotes of Trypanosoma cruzi Tulahuen infected in human U937 cells assessed as reduction of viability of intracellular amastigotes by measuring beta-galactosidase activity at 20 ug/ml after 72 hrs by spectrophotometry analysis,Other,26218652.0,
1628,1244472,1,1,,103178476,31593,Unspecified,,,,,Trypanocidal activity against intracellular amastigotes of Trypanosoma cruzi Tulahuen infected in human U937 cells assessed as reduction of viability of intracellular amastigotes by measuring beta-galactosidase activity after 72 hrs by spectrophotometry analysis,Other,26218652.0,
1629,1244474,1,1,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of LC50 for human U937 cells to EC50 for intracellular amastigotes of Trypanosoma cruzi Tulahuen",Other,26218652.0,
1630,1244575,1,1,,103178476,31593,Active,,,48.8,IC50,Antiparasitic activity against epimastigotes of Trypanosoma cruzi Dm28c assessed as reduction of parasite count after 5 days,Confirmatory,26231082.0,
1631,1244576,1,1,,103178476,31593,Active,,,6.2,CC50,Antiparasitic activity against trypomastigotes of Trypanosoma cruzi Y assessed as reduction of parasite count after 24 hrs,Confirmatory,26231082.0,
1632,1244577,1,1,,103178476,31593,Unspecified,,,,,Cytotoxicity against BALB/c mouse splenocytes assessed as maximum non-toxic concentration by measuring [3H]-thymidine incorporation after 24 hrs by liquid scintillation counting,Other,26231082.0,
1633,1244578,1,1,,103178476,31593,Active,,,3.8,IC50,Antitrypanosomal activity against amastigote and trypomastigote forms of Trypanosoma cruzi Tulahuen expressing beta-galactosidase gene infected in mouse L-929 cells assessed as inhibition of parasite growth after 7 days by colorimetric betagalactosidase assay,Confirmatory,26231082.0,
1634,1244579,1,1,,103178476,31593,Unspecified,,,2381.0,CC50,Cytotoxicity against mouse L929 cells assessed as cell viability after 96 hrs by alamarBlue assay,Confirmatory,26231082.0,
1635,1244580,1,1,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of CC50 for mouse L929 cells to IC50 for amastigote and trypomastigote forms of Trypanosoma cruzi Tulahuen",Other,26231082.0,
1636,1244585,1,1,,103178476,31593,Unspecified,,,,,Antiparasitic activity against trypomastigotes of Trypanosoma cruzi Y assessed as induction of parasite death at 5 uM after 24 hrs using propidium iodide staining after 24 hrs by flow cytometry analysis,Other,26231082.0,
1637,1244586,1,1,,103178476,31593,Unspecified,,,,,Antiparasitic activity against trypomastigotes of Trypanosoma cruzi Y assessed as induction of parasite death at 25 uM after 24 hrs using propidium iodide staining after 24 hrs by flow cytometry analysis,Other,26231082.0,
1638,1245580,1,1,,103178476,31593,Active,,,2.153,IC50,Antiparasitic activity against amastigote stage of Trypanosoma cruzi Tulahuen C4 infected in rat L6 cells assessed as parasite growth inhibition after 96 hrs by beta-galactosidase reporter gene assay,Confirmatory,26344593.0,
1639,1245589,1,1,,103178476,31593,Unspecified,,,,,Prodrug conversion assessed as Trypanosoma brucei recombinant His-tagged type-1 nitroreductase-mediated drug metabolism by measuring NADH oxidation after 5 mins by spectrophotometric analysis,Other,26344593.0,
1640,1245590,1,1,,103178476,31593,Unspecified,,,,,Prodrug conversion assessed as Trypanosoma cruzi recombinant type-1 nitroreductase-mediated drug metabolism by measuring NADH oxidation after 5 mins by spectrophotometric analysis,Other,26344593.0,
1641,1245595,1,1,,103178476,31593,Active,,,,,"Antichagasic activity against trypomastigote stage of Trypanosoma cruzi Brazil infected in Balb/c mouse assessed as reduction in parasite load at 13 mg/kg/day, ip measured after 5 days by luciferase reporter gene assay",Other,26344593.0,
1642,1245596,1,1,,103178476,31593,Unspecified,,,,,"Toxicity in Balb/c mouse at 13 mg/kg/day, ip",Other,26344593.0,
1643,1254020,1,1,,103178476,31593,Active,,,34.0,IC50,Antiparasitic activity against trypomastigote form of Trypanosoma cruzi Tulahuen-lacZ infected in LLC-MK2 ATCC cells assessed as parasite viability incubated for 4 days at 37 degC by chlorophenol beta-D-galactopyranose substrate based trypanocidal assay,Confirmatory,26476667.0,
1644,1254024,1,1,,103178476,31593,Active,,,,,Antiparasitic activity against trypomastigote form of Trypanosoma cruzi Y strain assessed as parasite viability at 62.5 to 500 uM incubated for 24 hrs,Other,26476667.0,
1645,1254025,1,1,,103178476,31593,Active,,,16.0,IC50,Antiparasitic activity against amastigote form of Trypanosoma cruzi Y strain infected in bone marrow macrophage cells assessed as amastigote viability incubated for 4 days by rapid panoptic stain based microscopy method,Confirmatory,26476667.0,
1646,1254435,1,1,,103178476,31593,Active,,,10.6,IC50,Antiparasitic activity against bloodstream trypomastigote stage of Trypanosoma cruzi Y assessed as parasite viability after 24 hrs by Neubauer chamber analysis,Confirmatory,26549870.0,
1647,1254436,1,1,,103178476,31593,Unspecified,,,100.0,CC50,Cytotoxicity against mouse J774 cells assessed as cell viability after 72 hrs by Alamar Blue assay,Confirmatory,26549870.0,
1648,1254437,1,1,,103178476,31593,Unspecified,,,,,"Selectivity index, ratio of CC50 for human J774 cells to IC50 for bloodstream trypomastigote stage of Trypanosoma cruzi Y",Other,26549870.0,
1649,1254439,1,1,,103178476,31593,Active,,,,,Antiparasitic activity against amastigote stage of Trypanosoma cruzi Y in BALB/c mouse macrophages assessed as decrease in number of infected cells at 50 uM incubated for 6 hrs by Giemsa staining-based optical microscopic analysis,Other,26549870.0,
1650,1254440,1,1,,103178476,31593,Active,,,,,Antiparasitic activity against amastigote stage of Trypanosoma cruzi Y in BALB/c mouse macrophages assessed as decrease in number of intracellular amastigotes at 50 uM incubated for 6 hrs by Giemsa staining-based optical microscopic analysis,Other,26549870.0,
1651,1254441,1,1,,103178476,31593,Active,,,13.9,IC50,Antiparasitic activity against amastigote stage of Trypanosoma cruzi Y in BALB/c mouse macrophages assessed as decrease in number of intracellular amastigotes incubated for 6 hrs by Giemsa staining-based optical microscopic analysis,Confirmatory,26549870.0,
1652,1254442,1,1,,103178476,31593,Unspecified,,,,,"Antiparasitic activity against bloodstream trypomastigote stage of Trypanosoma cruzi Y infected in BALB/c mouse assessed as reduction of parasitemia at 100 mg/kg, po qd administered for 5 days measured on day 10 post infection relative to vehicle-treated control",Other,26549870.0,
1653,1254443,1,1,,103178476,31593,Unspecified,,,,,"Antiparasitic activity against bloodstream trypomastigote stage of Trypanosoma cruzi Y infected in BALB/c mouse assessed as reduction of parasitemia at 100 mg/kg, po qd administered for 5 days measured on day 12 post infection relative to vehicle-treated control",Other,26549870.0,
1654,1254444,1,1,,103178476,31593,Active,,,,,"Antiparasitic activity against bloodstream trypomastigote stage of Trypanosoma cruzi Y infected in BALB/c mouse assessed as increase in survival rate by measuring mortality at 100 mg/kg, po qd administered for 5 days measured until 30 days",Other,26549870.0,
1655,1254447,1,1,,103178476,31593,Unspecified,,,,,"Toxicity in BALB/c mouse infected with bloodstream trypomastigote stage of Trypanosoma cruzi Y assessed as body weight loss at 100 mg/kg, po qd administered for 5 days",Other,26549870.0,
1656,1254670,1,1,,103178476,31593,Active,,,2.325,IC50,Antitrypanosomal activity against trypomastigote form of Trypanosoma cruzi Tulahuen C2C4 infected in rat L6 cells assessed as growth inhibition after 96 hrs by beta-galactosidase reporter gene assay,Confirmatory,,
1657,1254916,1,1,,103178476,31593,Active,,,2.153,IC50,Antichagasic activity against amastigote forms of Trypanosoma cruzi Tulahuen C4 assessed as inhibition of growth,Confirmatory,26363868.0,
1658,1254921,1,1,,103178476,31593,Unspecified,,,,,Activity of histidine tagged recombinant Trypanosoma brucei brucei type 1 nitroreductase assessed as NADH oxidation at 100 uM by spectrophotometry method,Other,26363868.0,
1659,1254922,1,1,,103178476,31593,Unspecified,,,,,Activity of histidine tagged recombinant Trypanosoma cruzi type 1 nitroreductase assessed as NADH oxidation at 100 uM by spectrophotometry method,Other,26363868.0,
1660,1254936,1,1,,103178476,31593,Unspecified,,,,,"Antichagasic activity against firefly luciferase expressing trypamastigote forms of transgenic Trypanosoma cruzi Y infected in Balb/c mouse assessed as reduction in parasite level at 15 mg/kg/day, ip dosed for 10 days by luciferase reporter gene assay",Other,26363868.0,
1661,1259241,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
1662,1259242,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
1663,1259243,1,1,,170466539,31593,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
1664,1259244,1,1,,170466539,31593,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
1665,1259247,1,1,,170466539,31593,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
1666,1259248,1,1,,170466539,31593,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
1667,1259309,1,1,,178125564,31593,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted,Other,,
1668,1259311,1,1,,178125564,31593,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220,Other,,
1669,1259313,1,1,,56320744,31593,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
1670,1259318,1,1,,56323658,31593,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
1671,1259336,1,3,,340126056,31593,Inactive,,,,,Small molecule activity in anthelmintic screen (C. elegans growth),Screening,,
1672,1259344,1,1,,144205917,31593,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
1673,1259355,1,1,,144205917,31593,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
1674,1259356,1,1,,144205917,31593,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
1675,1259364,1,1,,170466539,31593,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
1676,1259365,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
1677,1259366,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1678,1259367,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1679,1259368,1,1,,170466539,31593,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1680,1259369,1,1,,170466539,31593,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1681,1259377,1,1,,170466539,31593,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1682,1259378,1,1,,170466539,31593,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1683,1259379,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1684,1259380,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1685,1259381,1,1,,170466539,31593,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
1686,1259382,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1687,1259383,1,1,,170466539,31593,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
1688,1259384,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
1689,1259385,1,1,,170466539,31593,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1690,1259386,1,1,,170466539,31593,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1691,1259387,1,1,,170466539,31593,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
1692,1259388,1,1,,170466539,31593,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
1693,1259390,1,1,,170466539,31593,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1694,1259391,1,1,,170466539,31593,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
1695,1259392,1,1,,170466539,31593,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1696,1259393,1,1,,170466539,31593,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
1697,1259394,1,1,,170466539,31593,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1698,1259395,1,1,,170466539,31593,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1699,1259396,1,1,,170466539,31593,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1700,1259400,1,1,,170466539,31593,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
1701,1259401,1,1,,170466539,31593,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1702,1259402,1,1,,170466539,31593,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1703,1259403,1,1,,170466539,31593,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1704,1259404,1,1,,170466539,31593,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1705,1259407,1,1,,363900150,31593,Active,,,,,CCRIS mutagenicity studies,Other,,
1706,1259408,1,1,,363897052,31593,Active,,,,,GENE-TOX mutagenicity studies,Other,,
1707,1259411,1,1,,363900150,31593,Active,,,,,CCRIS carcinogenicity studies,Other,,
1708,1259415,1,1,,56323658,31593,Inactive,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
1709,1259416,1,2,,124360168,31593,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1710,1259416,1,2,,340081213,31593,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1711,1259421,1,1,,124360168,31593,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1712,1259421,1,1,,340081213,31593,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
